Telescoping prosthetic valve with retention element

Information

  • Patent Grant
  • 11497601
  • Patent Number
    11,497,601
  • Date Filed
    Friday, February 28, 2020
    4 years ago
  • Date Issued
    Tuesday, November 15, 2022
    a year ago
Abstract
An implantable device is disclosed. The device includes a leaflet frame subcomponent and an anchor frame subcomponent that are configured to be delivered in a series configuration and subsequently nested or telescoped in-situ.
Description
FIELD

The present disclosure relates generally to prosthetic valves and more specifically to flexible leaflet-type prosthetic valve devices, systems and methods.


BACKGROUND

Bioprosthetic valves have been developed that attempt to mimic the function and performance of a native valve. Bioprosthetic valves may be formed from synthetic materials, natural tissue such as biological tissue, or a combination of synthetic materials and natural tissue.


Though many conventional designs require delivery to a target region within a patient's anatomy via open-heart surgical techniques, alternative approaches such as transcatheter techniques offer a number of advantages. Among other examples, a transcatheter prosthetic valve that is delivered endovascularly via a catheter can help to minimize patient trauma as compared with an open-heart, surgical procedure. Open-heart surgery involves extensive trauma to the patient, with attendant morbidity and extended recovery. On the other hand, a valve delivered to the recipient site via a catheter avoids the trauma of open-heart surgery and may be performed on patients too ill or feeble to survive the open-heart surgery.


However, challenges exist with accessing treatment regions within the anatomy, properly positioning the bioprosthesis for deployment, and depending on the particular anatomy being repaired or augmented, modifications of the surrounding anatomy may arise as a consequence of the presence of the bioprosthesis. In some instances, such consequential modifications to the surrounding anatomy may negatively impact a patient's health.


While multiple embodiments are disclosed, still other embodiments will become apparent to those skilled in the art from the following detailed description, which shows and describes illustrative examples. Accordingly, the drawings and detailed description are to be regarded as illustrative in nature and not restrictive.


SUMMARY

Various aspects relate to prosthetic valves transitional between a delivery configuration and a deployed, nested configuration in-situ.


Various aspects relate to a prosthetic valve including a leaflet frame subcomponent including a one-way valve, the leaflet frame subcomponent having a leaflet frame subcomponent inflow end and a leaflet frame subcomponent outflow end; an anchor frame subcomponent having an anchor frame subcomponent inflow end and an anchor frame subcomponent outflow end; a connecting sheath coupling the leaflet frame subcomponent to the anchor frame subcomponent; and a retention element coupled to the connecting sheath, the retention element being configured to retain the prosthetic valve in the deployed, nested configuration, wherein in the delivery configuration the leaflet frame subcomponent and the anchor frame subcomponent are longitudinally offset relative to one another with the connecting sheath being unfolded and uneverted and in the nested configuration the leaflet frame subcomponent is nested with the anchor frame subcomponent and the connecting sheath is folded and everted so as to lie between the leaflet frame subcomponent and the anchor frame subcomponent, such that the retention element extends from the leaflet frame subcomponent inflow end to the anchor frame subcomponent inflow end.


Various aspects also relate to a prosthetic valve configured to be retrieved, or a method of retrieving a prosthetic valve, in which an anchor frame subcomponent of the prosthetic valve has a predetermined flexibility such that the anchor frame subcomponent may be everted into an anchor frame subcomponent lumen such that the anchor frame subcomponent is operable to peel away from a tissue annulus and be drawn out of the anchor frame subcomponent lumen such that the prosthetic valve may be removed from the tissue annulus. In some implementations, a portion of the anchor frame subcomponent may pivot and compress about a location adjacent to an anchor frame subcomponent inflow end (e.g., at a flared portion), such that the anchor frame subcomponent may pivot or fold inwardly into the anchor frame subcomponent lumen and be drawn out of the anchor frame subcomponent lumen having been everted.


According to one example (“Example 1”), a prosthetic valve transitionable between a delivery configuration and a deployed, nested configuration in-situ, includes a leaflet frame subcomponent, an anchor frame subcomponent, a connecting sheath coupling the leaflet frame and anchor frame subcomponents, and a retention element coupled to the connecting sheath, wherein when the prosthetic valve is in the deployed, nested configuration, the connecting sheath is everted and the leaflet frame subcomponent is at least partially nested within an anchor frame subcomponent lumen, the retention element has translated within the anchor frame subcomponent lumen toward an anchor frame subcomponent inflow end, and the retention element is biased outwardly against the anchor frame subcomponent with an outward bias such that the retention element extends from a leaflet frame subcomponent inflow end to an anchor frame subcomponent inflow end.


Optionally, the leaflet frame subcomponent defines a tubular shape and has a leaflet frame subcomponent wall extending from the leaflet frame subcomponent inflow end and a leaflet frame subcomponent outflow end and the leaflet frame subcomponent defining a leaflet frame subcomponent lumen, the leaflet frame subcomponent including a one-way valve.


Optionally, the anchor frame subcomponent defines a tubular shape and has the anchor frame subcomponent inflow end and an anchor frame subcomponent outflow end, and the anchor frame subcomponent defines an anchor frame subcomponent lumen.


Optionally, the connecting sheath defines a tubular shape and has a connecting sheath inflow end coupled to the anchor frame subcomponent outflow end and a connecting sheath outflow end coupled to the leaflet frame subcomponent inflow end coupling the leaflet frame subcomponent to the anchor frame subcomponent, and the connecting sheath has a connecting sheath inner surface that defines a connecting sheath lumen.


Optionally, the retention element has a retention element first end and a retention element second end, the retention element second end being coupled to the connecting sheath outflow end.


Optionally, when the prosthetic valve is in the delivery configuration, the leaflet frame subcomponent and the anchor frame subcomponent are longitudinally offset from one another such that the leaflet frame subcomponent inflow end is situated distal of the anchor frame subcomponent outflow end, wherein the retention element resides within the connecting sheath lumen and extends away from the leaflet frame subcomponent inflow end and substantially parallel with a longitudinal axis of the leaflet frame subcomponent and adjacent to the connecting sheath.


Optionally, when the prosthetic valve is in the deployed, nested configuration, the anchor frame subcomponent inflow end flares or tapers radially outward.


According to another example (“Example 2”) further to Example 1, wherein the prosthetic valve is transitionable between the delivery configuration and the deployed, nested configuration via an expanded pre-deployed, un-nested configuration.


According to another example (“Example 3”) further to Example 2, the retention element is pivotable about the retention element second end upon translation of the retention element translated within the anchor frame subcomponent lumen towards the anchor frame subcomponent inflow end, such that the retention element extends from the leaflet frame subcomponent inflow end to the anchor frame subcomponent inflow end.


According to another example (“Example 4”) further to any one of Examples 1 to 3, the leaflet frame subcomponent includes a leaflet frame defining a leaflet frame wall, one or more leaflets, and leaflet frame cover, the leaflet frame is generally tubular shaped defining a leaflet frame inflow end and a leaflet frame outflow end with a leaflet frame lumen therethrough.


According to another example (“Example 5”) further to Example 4, the leaflet frame wall of the leaflet frame is at least partially covered with the leaflet frame cover configured to restrict fluid from passing through the covered portion of the leaflet frame wall.


According to another example (“Example 6”) further to Example 4 or 5, the one or more leaflets are operable to open to allow flow from the leaflet frame subcomponent inflow end and to pass through the leaflet frame subcomponent outflow end in antegrade flow conditions, and are operable to close to restrict flow from flowing from the leaflet frame subcomponent outflow end through the leaflet frame subcomponent inflow end in retrograde flow conditions.


According to another example (“Example 7”) further to any one of Examples 4 to 6, the retention element second end is not directly coupled to the leaflet frame at the leaflet frame subcomponent inflow end, there being a portion of the connecting sheath therebetween.


According to another example (“Example 8”) further to any one of Examples 4 to 7, the leaflets comprise a composite material including a porous synthetic fluoropolymer membrane defining pores and an elastomer or elastomeric material filling the pores, and optionally TFE-PMVE copolymer comprising from about 27 to about 32 weight percent perfluoromethyl vinyl ether and respectively from about 73 to about 68 weight percent tetrafluoroethylene on at least a portion of the composite material, and optionally, wherein the elastomer or elastomeric material comprises a TFE-PMVE copolymer, and optionally wherein the porous synthetic fluoropolymer membrane is ePTFE.


According to another example (“Example 9”) further to any one of the preceding Examples, the anchor frame subcomponent includes an anchor frame and an anchor frame cover, the anchor frame defines a generally tubular shape extending between the anchor frame subcomponent inflow end and the anchor frame subcomponent outflow end, an anchor frame inner surface and an anchor frame outer surface defining an anchor frame wall, the anchor frame is at least partially covered with the anchor frame cover to restrict fluid from passing through the anchor frame wall.


According to another example (“Example 10”) further to Example 9, the prosthetic valve is in the deployed, nested configuration, the anchor frame defines a flared portion at the anchor frame subcomponent inflow end that flares or tapers radially outward.


According to another example (“Example 11”) further to Example 9 or 10, when Example 9 or 10 is further to any one of Examples 4 to 8, the connecting sheath is contiguous with the anchor frame cover and the leaflet frame cover.


According to another example (“Example 12”) further to any one of Examples 9 to 11, when any one of Examples 9 to 11 is further to any one of Examples 4 to 8, the retention element is coupled to the connecting sheath between, but not directly coupled to, the leaflet frame or the anchor frame such that the retention element is operable to maintain the nested configuration of the anchor frame subcomponent and the leaflet frame subcomponent.


According to another example (“Example 13”) further to any preceding Example, the prosthetic valve has a smaller diameter in the delivery configuration than in the deployed, nested configuration.


According to another example (“Example 14”) further to any preceding Example, the anchor frame subcomponent has an anchor frame subcomponent inner surface, wherein, in the deployed, nested configuration, the anchor frame subcomponent inner surface has a diameter at least slightly larger than a leaflet frame subcomponent outer surface of the leaflet frame subcomponent and the leaflet frame subcomponent is nested within the anchor frame subcomponent.


According to another example (“Example 15”) further to Example 2 or further to any one of Examples 3 to 14 further to Example 2, the connecting sheath is a thin-walled flexible tubular member having a connecting sheath inner surface that defines a connecting sheath lumen in fluid communication with the anchor frame subcomponent lumen and the leaflet frame subcomponent lumen, and wherein the connecting sheath is operable to fold and evert when the leaflet frame subcomponent is advanced from the pre-deployed, un-nested configuration to the deployed, nested configuration so as to lie between the leaflet frame subcomponent and the anchor frame subcomponent.


According to another example (“Example 16”) further to any preceding Example, the connecting sheath comprises flow enabling features in a wall of the connecting sheath, the wall extending between the connecting sheath inflow end and the connecting sheath outflow end, wherein the flow enabling features are operable to allow antegrade fluid flow through the connecting sheath wall and restrict retrograde flow through the connecting sheath wall when the leaflet frame subassembly is not in the deployed, nested configuration.


According to another example (“Example 17”) further to any one of Examples 1 to 15, the connecting sheath comprises an inner film layer and an outer film layer, the inner film layer and the outer film layer being coupled together at least at the leaflet frame subcomponent inflow end and the anchor frame subcomponent outflow end, the inner film layer defining at least one inner aperture therethrough adjacent the anchor frame subcomponent outflow end and the outer film layer defines at least one outer aperture therethrough adjacent the leaflet frame subcomponent, the inner film layer and the outer film layer being not coupled at least between one of the inner apertures and one of the outer apertures so as to define a flow space therebetween operable to permit antegrade blood flow and restrict retrograde flow therethrough when the leaflet frame subcomponent is not in the deployed, nested configuration in the anchor frame subcomponent, and is operable to restrict antegrade and retrograde flow when the leaflet frame subcomponent is in the deployed, nested configuration within the anchor frame subcomponent.


According to another example (“Example 18”) further to any one of Examples 1 to 15, the connecting sheath comprises an inner film layer and an outer film layer, the inner film layer and the outer film layer being coupled together at least at the anchor frame subcomponent outflow end, the inner film layer defining at least one inner aperture therethrough adjacent the anchor frame subcomponent outflow end, the inner film layer and the outer film layer being not coupled at least downstream of the inner apertures so as to define a flow space therebetween operable to permit antegrade blood flow with the inner film layer separating from the outer film layer at the inner aperture and so as to restrict retrograde flow therethrough with the inner film layer coming together and covering the inner aperture when the leaflet frame subcomponent is not in the deployed, nested configuration in the anchor frame subcomponent, and is operable to restrict antegrade and retrograde flow when the leaflet frame subcomponent is in the deployed, nested configuration within the anchor frame subcomponent.


According to another example (“Example 19”) further to any preceding Example, when the prosthetic valve is in the deployed, nested configuration, the retention element is configured to cover an inflow annular groove formed between the anchor frame subcomponent, the everted connecting sheath, and the leaflet frame subcomponent.


According to another example (“Example 20”) further to any preceding Example, the retention element further includes a non-permeable cover and wherein, when the prosthetic valve is in the deployed, nested configuration, an inflow annular groove is defined by the anchor frame subcomponent, the connecting sheath, and the leaflet frame subcomponent at an inflow end of the prosthetic valve, and wherein the retention element, including the non-permeable cover, is operable to cover and restrict fluid flow into an inflow annular groove.


According to another example (“Example 21”) further to Example 2 or further to any one of Examples 3 to 20 further to Example 2, the retention element is an elongated element that is operable to extend generally parallel to a central, longitudinal axis X of the prosthetic valve when in the pre-deployed configuration, and operable to extend at an angle to the central, longitudinal axis X when in the deployed configuration.


According to another example (“Example 22”) further to any preceding Example, the retention element is operable to translate through the anchor frame subcomponent during transition of the prosthetic valve between the delivery configuration and the deployed, nested configuration and the connecting sheath is operable to fold and evert within the anchor frame subcomponent lumen and lie between the leaflet frame subcomponent and the anchor frame subcomponent during transition of the prosthetic valve between the delivery configuration and the deployed, nested configuration.


According to another example (“Example 23”) further to any preceding Example, the retention element comprises a continuous sinuous element configured to have an outward spring bias toward a planar star-shaped configuration defining elongated elements bending about apices, the elongated elements have an elongated element first end and an elongated element second end, when in the star-shaped configuration the elongated elements extend radially with the elongated element first ends and respective apices defining an inner circumference at a retention element first end and the elongated element second ends and respective apices defining an outer circumference at a retention element second end, the sinuous element is operable to be elastically restrained to a tubular configuration wherein the elongated elements are rotated about the apices at the elongated element first ends such that the elongated element second ends are rotated toward each other to define a tubular or conical configuration, with the sinuous element defining a first tubular diameter wherein the elongated elements extend laterally to the central, longitudinal axis X and along the connecting sheath and lateral with the anchor frame subcomponent and leaflet frame subcomponent.


According to another example (“Example 24”) further to Example 23 further to Example 20, the non-permeable cover extends from the apices at the elongated element first ends of the elongated elements to the apices at the elongated element second ends, wherein when the prosthetic valve is in the deployed, nested configuration, the non-permeable cover extends from the leaflet frame subcomponent inflow end to the anchor frame subcomponent inflow end covering the inflow annular groove formed between the anchor frame subcomponent, the connecting sheath and the leaflet frame subcomponent.


According to another example (“Example 25”) further to Example 23 or 24, further comprising a tether element coupled to the retention element, operable to be pulled by an operator to affect advancement of the retention element through the anchor frame subcomponent, the retention element second end of the retention element being held in a compressed state by a predetermined amount of tension on the tether element, wherein the tension of the tether element may be released and thus release the elongated element second end of the retention element so as to allow expansion and deployment of the retention element.


According to another example (“Example 26”) further to any preceding Example, the retention element is biased towards a planar position and operable to retain the relative position of the leaflet frame subcomponent and the anchor frame subcomponent by virtue of the outward bias.


According to another example (“Example 27”) further to any preceding Example, one or more apices at the retention element second end of the retention element may abut and slide along the connecting sheath inner surface and subsequently the anchor frame subcomponent inner surface while expanding under the outward bias until the apices at the retention element second end are fully expanded about the anchor frame subcomponent inflow end, wherein the outward bias produces sufficient force to advance the retention element through the connecting sheath and the anchor frame subcomponent inner surface toward the anchor frame subcomponent inflow end while pulling the leaflet frame subcomponent into the anchor frame subcomponent.


According to another example (“Example 28”) further to any preceding Example, a length of the anchor frame subcomponent varies along its circumference wherein the anchor frame subcomponent outflow end has a tapered geometry operable such that, when the prosthetic valve is placed in a mitral valve annulus, the anchor frame subcomponent outflow end may extend further into a left ventricle adjacent to a posterior side of the left ventricle and extends less into a LVOT on an anterior side of the left ventricle.


According to another example (“Example 29”) further to any preceding Example, a hoop strength of the anchor frame subcomponent is variable along a length and/or a circumference of the anchor frame subcomponent and is predetermined to have a greater stiffness at a smaller tapered portion of an anchor frame subcomponent anterior portion of the anchor frame subcomponent outflow end, to substantially match a stiffness of an aortomitral junction, whereas the stiffness may be relatively less at a longer prosthetic valve posterior portion adjacent a posterior side of the left ventricle.


According to another example (“Example 30”) further to any preceding Example, the anchor frame subcomponent has a predetermined flexibility such that the anchor frame subcomponent may be everted into the anchor frame subcomponent lumen such that the anchor frame subcomponent is operable to peel away from a tissue annulus and be drawn out of the anchor frame subcomponent lumen such that the prosthetic valve may be removed from the tissue annulus.


According to another example (“Example 31”) further to any preceding Example, the anchor frame subcomponent includes one or more tissue engagement features that project away from an anchor frame outer surface of the anchor frame subcomponent and are operable to engage a tissue annulus.


According to another example (“Example 32”) further to any preceding Example, the prosthetic valve further comprises an outflow annular groove cover extending from the anchor frame subcomponent outflow end and the leaflet frame subcomponent outflow end.


According to another example (“Example 33”) further to Example 32, the outflow annular groove cover is configured to be blood permeable under physiologic conditions prior to the prosthetic valve being transitioned to the deployed, nested configuration.


According to another example (“Example 34”) further to Examples 32 or 33, the outflow annular groove cover is configured to be less permeable to blood under physiologic conditions when the prosthetic valve is in the deployed, nested configuration than when the prosthetic valve is not in the deployed, nested configuration.


Disclosed herein are also methods of replacing a native valve of a patient's anatomy. According to one example (“Example 35”), the method includes providing a prosthetic valve including, an anchor frame subcomponent; a leaflet frame subcomponent nestable within the anchor frame subcomponent; a connecting sheath coupled to the leaflet frame subcomponent and the anchor frame subcomponent, the anchor frame subcomponent comprising an anchor frame subcomponent inflow end and anchor frame subcomponent outflow end; and a retention element coupled to the connecting sheath adjacent the leaflet frame subcomponent inflow end. The prosthetic valve is advanced in a delivery configuration to a treatment site within a patient's anatomy, wherein in the delivery configuration the leaflet frame subcomponent and the anchor frame subcomponent are longitudinally offset from one another such that a leaflet frame subcomponent inflow end of the leaflet frame subcomponent is situated distal of an anchor frame subcomponent inflow end. The anchor frame subcomponent is deployed within a tissue annulus. The leaflet frame subcomponent is nested within the anchor frame subcomponent by changing a relative position between the leaflet frame subcomponent and the anchor frame subcomponent. The retention element is deployed to extend from the leaflet frame subcomponent inflow end to the anchor frame subcomponent inflow end.


According to another example (“Example 36”) further to Example 35, the method further comprises deploying the prosthetic valve at the treatment site.


According to another example (“Example 37”) further to Examples 35 or 36, the leaflet frame subcomponent is nested within the anchor frame subcomponent after the prosthetic valve is deployed at the treatment site.


According to another example (“Example 38”) further to any one of Example 35 to 37, the prosthetic valve is advanced to the treatment site via a catheter.


According to another example (“Example 39”) further to any one of Examples 35 to 38, nesting the leaflet frame subcomponent within the anchor frame subcomponent includes drawing the leaflet frame subcomponent proximally relative to the anchor frame subcomponent.


According to another example (“Example 40”) further to any one of Examples 35 to 39, the method further comprises securing the prosthetic valve to a valve orifice of the native valve such that the prosthetic valve is operable to transition between an open position wherein fluid flow is permitted, and a closed position wherein fluid flow is obstructed.


According to another example (“Example 41”) further to any one of Examples 35 to 40, deploying the anchor frame within a tissue annulus includes releasing constraining elements to expand the anchor frame to a larger diameter of the tissue annulus.


According to another example (“Example 42”) further to any one of Examples 35 to 39 and 41, deploying the anchor frame within a tissue annulus includes tightening the constraining elements to recompress the anchor frame to a smaller diameter to allow for repositioning of the prosthetic valve.


According to another example (“Example 43”) further to any one of Examples 35 to 42, deploying the anchor frame within a tissue annulus includes tightening the constraining elements to recompress the anchor frame to a smaller diameter to allow for repositioning of the prosthetic valve.


Further disclosed herein is a method of treating a failing or dysfunctional native heart valve with a prosthetic valve. According to one example (“Example 44”), the method includes replacing the native valve with a prosthetic valve in accordance with any of claims 1 to 34.


The foregoing Examples are just that, and should not be read to limit or otherwise narrow the scope of any of the inventive concepts otherwise provided by the instant disclosure. While multiple examples are disclosed, still other embodiments will become apparent to those skilled in the art from the following detailed description, which shows and describes illustrative examples. Accordingly, the drawings and detailed description are to be regarded as illustrative in nature rather than restrictive in nature.





BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings are included to provide a further understanding of the disclosure and are incorporated in and constitute a part of this specification, illustrate embodiments, and together with the description serve to explain the principles of the disclosure.



FIG. 1A is a side view of a prosthetic valve in a compressed pre-deployed configuration, according to some embodiments;


FIG. 1B1 is a side view of the prosthetic valve of FIG. 1A in an expanded pre-deployed configuration;


FIG. 1B2 is a side view of a prosthetic valve in an expanded pre-deployed configuration, according to some embodiments


FIG. 1B3 is a side view of a prosthetic valve in an expanded pre-deployed configuration, according to some embodiments;


FIG. 1C1 a side cross-sectional view along cut line 1C2 of the prosthetic valve of FIG. 1B1 in an expanded pre-deployed configuration;


FIG. 1C2 is a side cross-sectional view along cut line 1C2 of the prosthetic valve of FIG. 1B1 in a deployed configuration as shown in FIG. 7C;



FIG. 1D is an axial view of the prosthetic valve of FIG. 1A in a deployed configuration;



FIG. 1E is a perspective view of a leaflet frame and an anchor frame of the prosthetic valve of FIG. 1A in a deployed configuration;



FIG. 2A is a side view of a leaflet frame subcomponent in the expanded configuration of a prosthetic valve, according to some embodiments;



FIG. 2B is an axial view of the leaflet frame subcomponent of FIG. 2A, according to some embodiments;



FIG. 3A is a side view of an anchor frame subcomponent in the expanded configuration of a prosthetic valve, according to some embodiments;



FIG. 3B is an axial view of the anchor frame subcomponent of FIG. 3A;



FIG. 4 is a side view of a prosthetic valve in a compressed pre-deployed configuration mounted on a delivery catheter, according to some embodiments;



FIG. 5A is a side view of the prosthetic valve with flow enabling features in an open configuration, according to some embodiments;



FIG. 5B is a side view of the prosthetic valve with the flow enabling features of FIG. 5A in a closed configuration;



FIG. 5C is a side view of a connecting sheath coupled to a leaflet frame subcomponent and an anchor frame subcomponent including flow enabling features, according to some embodiments;



FIG. 5D is an exploded view of the connecting sheath of FIG. 5C;



FIG. 5E is a side view of a connecting sheath coupled to a leaflet frame subcomponent and an anchor frame subcomponent including flow enabling features, according to some embodiments;



FIG. 6A is a cross-sectional view of a simplified representation of the prosthetic valve being constrained onto a delivery catheter and placed within a tissue annulus, in accordance with an embodiment;


FIG. 6B1 is a simplified representation cross-sectional view of the prosthetic valve being partially deployed from a delivery catheter within a tissue annulus showing antegrade flow, in accordance with the embodiment of FIG. 6A;


FIG. 6B2 is a simplified representation cross-sectional view of the prosthetic valve partially deployed within a tissue annulus showing retrograde flow, in accordance with the embodiment of FIG. 6A;


FIG. 6C1 is a simplified representation cross-sectional view of the prosthetic valve deployed within a native valve orifice showing antegrade flow, in accordance with the embodiment of FIG. 6A


FIG. 6C2 is a simplified representation cross-sectional view of the prosthetic valve deployed within a native valve orifice showing retrograde flow, in accordance with the embodiment of FIG. 6A



FIG. 6D is a simplified representation cross-sectional view of the prosthetic valve deployed within a native valve orifice, in accordance with the embodiment of FIG. 6A;



FIG. 7A is a side view of a retention element in a partially compressed configuration, according to some embodiments;



FIG. 7B is a top perspective view of a prosthetic valve in accordance with the embodiment of FIG. 1B1 showing the retention element of FIG. 7A in an expanded configuration, according to some embodiments;



FIG. 7C is a side perspective view of the prosthetic valve of FIG. 7B showing the retention element of FIG. 7A in an expanded configuration;


FIG. 7D1 is a side cross-sectional view along cut line 7D2 of the prosthetic valve of FIG. 7D3 in a deployed configuration, such as shown in FIG. 7C by way of example;


FIG. 7D2 is a side cross-sectional view along cut line 7D2 of the prosthetic valve of FIG. 7D3 in an expanded pre-deployed configuration;


FIG. 7D3 is a side view of an embodiment of a prosthetic valve in an expanded pre-deployed configuration;



FIG. 8A is partial cross-sectional view of a prosthetic valve deployed in an anatomy with a larger aortomitral angle with an anchor frame having a constant length along a circumference, according to some embodiments;



FIG. 8B is partial cross-sectional view of a prosthetic valve deployed in anatomy with a smaller aortomitral angle with an anchor frame having a constant length along a circumference, according to some embodiments;



FIG. 8C is partial cross-sectional view of a prosthetic valve deployed in anatomy with a smaller aortomitral angle with an anchor frame having a variable length along a circumference, according to some embodiments



FIG. 9A is a highly simplified side partial cross-sectional representation of a prosthetic valve in a deployed configuration with a retrieval means illustrating an exemplary prosthetic valve retrieval procedure, according to some embodiments;



FIG. 9B is a highly simplified side partial cross-sectional representation of the prosthetic valve of FIG. 9A in a partially compressed configuration with a retrieval means illustrating an exemplary prosthetic valve retrieval procedure, according to some embodiments;


FIG. 9C1 is a highly simplified side partial cross-sectional representation of the prosthetic valve in a partially compressed partially deconstructed configuration with the anchor frame everting upon itself, illustrating an exemplary prosthetic valve retrieval procedure, according to some embodiments;


FIG. 9C2 is a highly simplified side partial cross-sectional representation of the prosthetic valve of FIG. 9A in a partially compressed partially deconstructed configuration with the anchor frame pivoting and compressing to an everted configuration, illustrating an exemplary prosthetic valve retrieval procedure, according to some embodiments; and



FIG. 9D is a highly simplified side partial cross-sectional representation of the prosthetic valve of FIG. 9A in a compressed deconstructed configuration within a retrieval sheath illustrating an exemplary prosthetic valve retrieval procedure, according to some embodiments;



FIG. 10A is a cross-sectional view of a heart illustrating an exemplary medical device delivery procedure, according to some embodiments;



FIG. 10B is a partial cross-sectional view of a prosthetic valve being positioned into a mitral valve tissue annulus illustrating an exemplary delivery procedure, according to some embodiments;



FIG. 10C is a partial cross-sectional view of a prosthetic valve being partially deployed into a mitral valve tissue annulus illustrating an exemplary delivery procedure, according to some embodiments;



FIG. 10D is a partial cross-sectional view of a prosthetic valve being partially deployed into a mitral valve tissue annulus illustrating an exemplary delivery procedure, according to some embodiments;



FIG. 10E is a partial cross-sectional view of a prosthetic valve being partially deployed into a mitral valve tissue annulus illustrating an exemplary delivery procedure, according to some embodiments;



FIG. 10F is a partial cross-sectional view of a prosthetic valve being partially deployed into a mitral valve tissue annulus illustrating an exemplary delivery procedure, according to some embodiments;



FIG. 10G is a partial cross-sectional view of a prosthetic valve being partially deployed into a mitral valve tissue annulus illustrating an exemplary delivery procedure, according to some embodiments;



FIG. 10H is a partial cross-sectional view of a prosthetic valve being partially deployed into a mitral valve tissue annulus illustrating an exemplary delivery procedure, according to some embodiments;



FIG. 10I is a partial cross-sectional view of a prosthetic valve being partially deployed into a mitral valve tissue annulus illustrating an exemplary delivery procedure, according to some embodiments;



FIG. 10J is a partial cross-sectional view of a prosthetic valve being partially deployed into a mitral valve tissue annulus illustrating an exemplary delivery procedure, according to some embodiments;



FIG. 10K is a partial cross-sectional view of a prosthetic valve being deployed into a mitral valve tissue annulus illustrating an exemplary delivery procedure, according to some embodiments;



FIG. 10L is a partial cross-sectional view of a prosthetic valve being deployed into a mitral valve tissue annulus illustrating an exemplary delivery procedure, according to some embodiments; and



FIG. 10M is a partial cross-sectional view of a prosthetic valve having been deployed into a mitral valve tissue annulus illustrating an exemplary delivery procedure, according to some embodiments.





DETAILED DESCRIPTION
Definitions and Terminology

This disclosure is not meant to be read in a restrictive manner. For example, the terminology used in the application should be read broadly in the context of the meaning those in the field would attribute such terminology.


Persons skilled in the art will readily appreciate that various aspects of the present disclosure can be realized by any number of methods and apparatus configured to perform the intended functions. Stated differently, other methods and apparatus can be incorporated herein to perform the intended functions. It should also be noted that the accompanying drawing figures referred to herein are not necessarily drawn to scale, but may be exaggerated to illustrate various aspects of the present disclosure, and in that regard, the drawing figures should not be construed as limiting.


Certain relative terminology is used to indicate the relative position of components and features. For example, words such as “top”, “bottom”, “upper,” “lower,” “left,” “right,” “horizontal,” “vertical,” “upward,” and “downward” are used in a relational sense (e.g., how components or features are positioned relative to one another) and not in an absolute sense unless context dictates otherwise. Similarly, throughout this disclosure, where a process or method is shown or described, the method may be performed in any order or simultaneously, unless it is clear from the context that the method depends on certain actions being performed first.


With respect to terminology of inexactitude, the terms “about” and “approximately” may be used, in certain instances, to refer to a measurement that includes the stated measurement and that also includes any measurements that are reasonably close to the stated measurement. Measurements that are reasonably close to the stated measurement deviate from the stated measurement by a reasonably small amount as understood and readily ascertained by individuals having ordinary skill in the relevant arts. Such deviations may be attributable to measurement error, differences in measurement and/or manufacturing equipment calibration, human error in reading and/or setting measurements, minor adjustments made to optimize performance and/or structural parameters in view of differences in measurements associated with other components, particular implementation scenarios, imprecise adjustment and/or manipulation of objects by a person or machine, and/or the like, for example.


As used herein, “couple” means join, connect, attach, adhere, affix, or bond, whether directly or indirectly, and whether permanently or temporarily.


The term “membrane” as used herein refers to a sheet of material comprising a single composition, such as, but not limited to, expanded fluoropolymer.


The term “composite material” as used herein refers to a material including two or more material components with one or more different material properties from the other. In some examples, a composite material includes at least a first material component in the form of a membrane and a second material component in the form of a polymer that is combined with the membrane (e.g., by coating and/or imbibing processes).


The term “laminate” as used herein refers to multiple layers of membrane, composite material, or other materials, such as, but not limited to a polymer, such as, but not limited to an elastomer, elastomeric or non-elastomeric material, and combinations thereof.


As used herein, the term “elastomer” refers to a polymer or a mixture of polymers that has the ability to be stretched to at least 1.3 times its original length and to retract rapidly to approximately its original length when released.


The term “elastomeric material” as used herein refers to a polymer or a mixture of polymers that displays stretch and recovery properties similar to an elastomer, although not necessarily to the same degree of stretch and/or recovery.


The term “non-elastomeric material” refers to a polymer or a mixture of polymers that displays stretch and recovery properties not similar to either an elastomer or elastomeric material, that is, considered not an elastomer or elastomeric material as is generally known.


The term “film” as used herein generically refers to one or more of the membrane, composite material, or laminate.


The term “biocompatible material” as used herein generically refers to any material with biocompatible characteristics including synthetic materials, such as, but not limited to, a biocompatible polymer, or a biological material, such as, but not limited to, bovine pericardium. Biocompatible material may comprise a first film and a second film as described herein for various embodiments.


The terms “native valve orifice” and “tissue orifice” as used herein refer to an anatomical structure into which a prosthetic valve can be placed. Such anatomical structure includes, but is not limited to, a location wherein a cardiac valve may or may not have been surgically removed. It is understood that other anatomical structures that can receive a prosthetic valve include, but are not limited to, veins, arteries, ducts and shunts. It is further understood that a valve tissue orifice or implant site may also refer to a location in a synthetic or biological conduit that may receive a valve.


The term “frame” as used herein generically refers to any structure or support used to directly or indirectly support leaflets for use in a prosthetic valve. It will be understood that, where appropriate, that the term frame may be used interchangeably with support structure. In accordance with some embodiments, the leaflets may be supported by the wall of a solid-walled conduit, the solid-walled conduit being understood to be a frame or support structure.


Description of Various Embodiments

As will be described further below, in various examples, the prosthetic valve provides a leaflet frame subcomponent that does not directly couple with a tissue annulus and essentially floats within an anchor frame subcomponent coupled together by a connecting sheath and supported by a retention element. In various examples, the leaflet frame subcomponent, anchor frame subcomponent, and the connecting sheath are all tubular members, although non-tubular configurations for one or more of the foregoing are contemplated. It is understood that “tubular” as used herein includes tubes having a constant diameter along the length of the tube, and tubes having a variable diameter along the length of the tube, such as, but not limited to, a taper and an irregular circumference. For example, a tubular member may have a variable diameter along its length in at least one configuration of the tubular member. For example, a tubular member may have a generally constant diameter in a delivery configuration, and a variable diameter in a deployed or pre-deployed configuration. The anchor frame subcomponent may conform to the shape of the tissue annulus whereas the leaflet frame subcomponent does not necessarily conform to the shape of the tissue annulus. The leaflet frame subcomponent may remain a right circular hollow cylinder or at a preferred geometrical configuration so as to present the leaflets with a geometrically stable platform ensuring proper leaflet function, including opening and closing dynamics and coaptation in the case of flexible leaflets.


In various embodiments, the retention element is operable to retain relative positioning of the leaflet frame subcomponent within the anchor frame subcomponent. The retention element is operable to translate within the lumen of the anchor frame subcomponent to adjacent the anchor frame subcomponent inflow end. The retention element hinges about the retention element second end from a compressed configuration to a deployed configuration such that the retention element is positioned substantially perpendicular to the longitudinal axis of the leaflet frame subcomponent with the retention element first end adjacent to the anchor frame subcomponent inflow end and the retention element second end adjacent to the leaflet frame subcomponent inflow end.


In various embodiments, the retention element further includes a non-permeable cover that is operable to cover an inflow annular groove defined by the anchor frame subcomponent and the connecting sheath at an inflow end of the prosthetic valve. In the retention element deployed configuration the retention element extends between the leaflet frame subcomponent inflow end and the anchor frame subcomponent inflow end with the retention element including the cover operable to cover and restrict fluid flow into the inflow annular groove.


In various embodiments, the anchor frame subcomponent has a variable length about a circumference such that the anchor frame subcomponent outflow end defines a tapered profile. The tapered profile is configured such that the outflow end of the anchor frame subcomponent minimizes obstructing the left ventricular outflow track (LVOT). For example, wherein the prosthetic valve is used to replace a mitral valve, a shorter portion of the anchor frame subcomponent may be orientated to face the interventricular septum (the anterior portion of the tissue annulus) whereas the longer portion of the anchor frame subcomponent may lay adjacent the posterior wall of the left ventricle.


In various embodiments, the anchor frame subcomponent is provided with an outwardly flared inflow end that is conformal to an inflow end of a tissue annulus, such as that of the mitral valve tissue annulus at the left atrium. The outwardly flared anchor frame subcomponent inflow end and/or in combination with the retention element, facilitates, among other things, the securing of the prosthetic valve against axial forces from atrial pressure when the leaflets are open.


In various embodiments, the prosthetic valve may be retrieved after deployment within the tissue annulus. The leaflet frame subcomponent is provided with a retrieval tether coupled to the leaflet frame subcomponent inflow end that is operable to compress the leaflet frame subcomponent to a smaller diameter and to pull the leaflet frame subcomponent into a retrieval sheath. The anchor frame subcomponent is operable to evert under the force of the retrieval tether pulling the leaflet frame subcomponent so as to compress and pull the anchor frame subcomponent into the retrieval sheath subsequent to the leaflet frame subcomponent. The anchor frame subcomponent may be provided tissue anchor elements configured to allow for repositioning and removal of the anchor frame from the tissue annulus with minimal trauma, discussed in greater detail herein.


Although it is appreciated that the examples of the prosthetic valve may be suitable for either surgical or transcatheter applications, examples provided herein are presented as for transcatheter applications to avoid the repetition if surgical examples are also presented. Therefore, the inventive concepts are applicable for both surgical and transcatheter applications and not limited to only transcatheter applications.


Various embodiments illustrated and described herein are directed to a prosthetic valve 1000. The prosthetic valve 1000 is transitionable between a delivery, compressed, un-nested configuration and a deployed, expanded, nested configuration in-situ. FIG. 1A is a side view of the prosthetic valve 1000 in the pre-deployed un-nested configuration showing a leaflet frame subcomponent 1200, an anchor frame subcomponent 1100, a connecting sheath 1300 therebetween in coaxial serial alignment with and connecting the leaflet frame subcomponent 1200 to the anchor frame subcomponent 1100, further including a retention element 1400 coupled to the connecting sheath 1300 adjacent the leaflet frame subcomponent 1200. FIG. 1B1 is a side view of the prosthetic valve 1000 in an expanded pre-deployed configuration showing the leaflet frame subcomponent 1200 and the anchor frame subcomponent 1100 having been expanded to larger diameters relative to the pre-expanded configuration of FIG. 1A.


The view of FIG. 1B1 would be as if the prosthetic valve 1000, as shown in FIG. 1A, was unconstrained from a constrained pre-nested configuration, such as when the prosthetic valve is placed over a delivery catheter 1504 prior to constraining onto the delivery catheter by a containing element 1716, as shown in FIG. 4. The connecting sheath 1300 defines a tapered configuration extending from the leaflet frame subcomponent 1200 and the anchor frame subcomponent 1100. The retention element 1400 may be either constrained by a restraining element, discussed below, or allowed to take the shape of the tapered configuration of the connecting sheath 1300. The leaflet frame subcomponent 1200 and the anchor frame subcomponent 1100 are configured to be nestable. FIG. 1C1 a simplified side cross-sectional view along cut line 1C2 of the prosthetic valve 1000 of FIG. 1B1 in an expanded pre-deployed configuration. FIG. 1C2 is a simplified side cross-sectional view along cut line 1C2 of the prosthetic valve 1000 of FIG. 1B1 in a deployed configuration as shown in FIG. 7C showing the leaflet frame subcomponent 1200 translated into the anchor frame subcomponent 1100 in nested alignment, with the connecting sheath 1300 having been everted and positioned therebetween. The retention element 1400 having been translated through the anchor frame subcomponent 1100 and deployed to extend from the leaflet frame subcomponent 1200 to the anchor frame subcomponent 1100. The leaflet frame subcomponent 1200 and an anchor frame subcomponent 1100 can be nested in-situ as will be described below.


The leaflet frame subcomponent 1200 and the anchor frame subcomponent 1100 are generally tubular shaped and operable to have a smaller delivery configuration diameter and a larger deployed configuration diameter, facilitated by balloon expansion and/or self-expansion deployment means. The connecting sheath 1300 is a flexible tubular membrane coupled about its circumference to the leaflet frame subcomponent 1200 at the leaflet frame subcomponent inflow end 1202 and to the anchor frame subcomponent 1100 at the anchor frame subcomponent outflow end 1104 operable to couple the leaflet frame subcomponent 1200 to the anchor frame subcomponent 1100. The connecting sheath 1300 is thin and flexible, and operable to fold or elastically contract to a smaller diameter in a delivery configuration. The retention element 1400 is coupled to the connecting sheath 1300 adjacent to the leaflet frame subcomponent inflow end 1202. The retention element 1400 is a flexible spring-like element that is operable to stow into a low radial profile in a delivery configuration and is operable to extend away from the leaflet frame subcomponent inflow end 1202 toward the anchor frame subcomponent inflow end 1102 under spring bias when in a deployed position. Engagement of the retention element 1400 with the anchor frame subcomponent inflow end 1102 assists in maintaining the relative position of the leaflet frame subcomponent 1200 within an anchor frame subcomponent lumen 1140.


In various embodiments, the leaflet frame subcomponent 1200 is nestable within the anchor frame subcomponent 1100. In particular, as shown, the anchor frame subcomponent 1100 and the leaflet frame subcomponent 1200 are sized and shaped in a manner that provides for the leaflet frame subcomponent 1200 being coaxially disposable or receivable at least partially within the anchor frame subcomponent 1100. Thus, in various examples, the anchor frame subcomponent 1100 is configured such that a portion of (or alternatively all of) the leaflet frame subcomponent 1200 can be received by or otherwise positioned within a space defined by the anchor frame subcomponent 1100. In some examples, the leaflet frame subcomponent 1200 is sized such that a diameter of the exterior surface of the leaflet frame subcomponent 1200 is less than a diameter of the interior surface of the anchor frame subcomponent 1100. In some examples, a diameter of the exterior surface of the leaflet frame subcomponent 1200 is in a range of between seventy five percent (75%) and ninety percent (90%) of a diameter of the interior surface of the anchor frame subcomponent 1100. In some examples, a diameter of the exterior surface of the leaflet frame subcomponent 1200 is seventy five percent (75%) or less than a diameter of the interior surface of the anchor frame subcomponent 1100. In various examples, such configurations also provide that the leaflet frame subcomponent 1200 can be received within the anchor frame subcomponent 1100. In various examples, such configurations provide that the anchor frame subcomponent 1100 can deform, such as, but not limited to being out of round or generally oval-shaped, to accommodate or otherwise conform to the native valve orifice without causing a deformation of the leaflet frame subcomponent 1200. The prosthetic valve 1000 provides a leaflet frame subcomponent 1200 that essentially floats within the anchor frame subcomponent 1100 and does not directly couple with a native valve orifice. The anchor frame subcomponent 1100 may conform to the shape of the native valve orifice whereas the leaflet frame subcomponent 1200 does not conform to the shape of the native valve orifice. The leaflet frame subcomponent 1200 remains a right circular hollow cylinder or at a preferred geometrical configuration so as to present the leaflets 1230 with a geometrically stable platform ensuring proper leaflet function, including opening and closing dynamics and, for flexible leaflets, coaptation. It is appreciated that these benefits associated with the leaflet frame subcomponent 1200 not needing to conform to the native valve orifice may be realized in either transcatheter or surgical placement of the prosthetic valve 1000.


In various embodiments, as discussed in greater detail below, the prosthetic valve 1000 is configured such that the anchor frame subcomponent 1100 and the leaflet frame subcomponent 1200 can be nested in-situ after the anchor frame subcomponent 1100 and the leaflet frame subcomponent 1200 are deployed to a treatment site in a patient's anatomy. That is, in various embodiments, the prosthetic valve 1000 can be delivered to a treatment region within a patient's anatomy with the anchor frame subcomponent 1100 and the leaflet frame subcomponent 1200 longitudinally offset relative to one another and subsequently nested with one another at the treatment site. In various embodiments, the prosthetic valve 1000 is loaded onto a delivery catheter with the anchor frame subcomponent 1100 and the leaflet frame subcomponent 1200 longitudinally offset relative to one another which presents a lower profile or diameter than if the prosthetic valve 1000 were to be loaded onto the delivery catheter in the nested configuration. A lower delivery profile of a transcatheter delivered prosthetic valve has well recognized advantages, including easier advancement though vessels.


It is appreciated that these benefits associated with the leaflet frame subcomponent 1200 not being nested into the anchor frame subcomponent 1100 during implantation may also be realized in surgical placement of the prosthetic valve 1000. By way of example, but not limited thereto, the anchor frame subcomponent 1100 may be more easily sutured into the native valve orifice without the leaflet frame subcomponent 1200 being within the anchor frame subcomponent 1100 and in close proximity to the suturing procedure lessening the chance of needle damage to the leaflets.


Leaflet Frame Subcomponent



FIG. 1D is an axial view of the prosthetic valve 1000 from the inflow end in the deployed configuration showing a leaflet frame subcomponent 1200, an anchor frame subcomponent 1100, and the connecting sheath 1300 therebetween (the retention element 1400 is shown without a cover in accordance with an embodiment and for clarity of visualizing the other components). FIG. 1E is a perspective view of the leaflet frame 1220 and anchor frame 1120, without other components for clarity, in the deployed configuration. The leaflet frame subcomponent 1200 provides the prosthetic valve 1000 with the functionality of a one-way valve 1030. It is understood and appreciated that one-way valves 1030 are well known in the art and may be used herein. It is appreciated that mechanical valves, biological valves, and biological and synthetic leaflet valves may be used as the one-way valve 1030 of the leaflet frame subcomponent 1200. It is also appreciated that, for transcatheter applications, the leaflet frame subcomponent 1200 is required to have a smaller-diameter compressed configuration and a larger-diameter expanded configuration, and that the one-way valve component must be able to accommodate that functionality.


Referring for FIGS. 1A-1E, in accordance with embodiments, the leaflet frame subcomponent 1200 includes a leaflet frame 1220, one or more leaflets 1230, and leaflet frame cover 1232. The leaflet frame subcomponent 1200 is generally tubular shaped defining a leaflet frame subcomponent inflow end 1202 and a leaflet frame subcomponent outflow end 1204 with a leaflet frame subcomponent lumen 1240 therethrough.


The leaflet frame 1220 provides structural support for the leaflets 1230. The leaflet frame 1220 is operable to have a smaller delivery configuration diameter and a larger deployed configuration diameter, facilitated by balloon expansion and/or self-expansion deployment means. As is known in the art, by way of example, a structure defining apertures, such as, but not limited to, a wire form or perforated wall tube that allows for the leaflet frame to have various diameters, such as a stent, is suitable for the particular purpose.


The leaflet frame subcomponent 1200 is configured to be received within at least a portion of the anchor frame subcomponent 1100, as shown in FIGS. 1C2, 1D and 10M, and as will be described in more detail below. It will be appreciated that nonlimiting examples of the leaflet frame subcomponent 1200 can be provided with a diameter (e.g., a diameter of an interior or exterior surface of the leaflet frame subcomponent 1200) in a range of between twenty (20) millimeters and thirty (30) millimeters, depending on a patient's anatomy.



FIG. 2A is a side view of the leaflet frame 1220 without leaflets 1230 nor leaflet frame cover 1232 shown for clarity. FIG. 2B is an axial view of the leaflet frame 1220 showing a plurality of leaflets 1230 therein. The leaflet frame wall 1205 of the leaflet frame 1220 may be at least partially covered with a leaflet frame cover 1232, such as an impermeable film or fabric, suitable for a particular purpose, such as to restrict fluid from passing through the leaflet frame wall 1205 of the leaflet frame 1220. For illustrative purposes, the following examples are suitable especially for a transcatheter application, but are also suitable for a surgical application.


Referring to FIG. 2A, the leaflet frame 1220 is a generally tubular member having a leaflet frame inflow end 1222 corresponding to a leaflet frame subcomponent inflow end 1202, a leaflet frame outflow end 1224 corresponding to a leaflet frame subcomponent outflow end 1204, a leaflet frame inner surface 1206 and a leaflet frame outer surface 1208 defining a leaflet frame wall 1205, wherein the leaflet frame inner surface 1206 defining a leaflet frame subcomponent lumen 1210 therethrough. The leaflet frame subcomponent lumen 1210 is a generally cylindrical void defined between the leaflet frame inflow end 1222 and the leaflet frame outflow end 1224, and the leaflet frame inner surface 1206.


The leaflet frame 1220 defines a tubular framework defining apertures or voids 1216. For example, as shown, the leaflet frame 1220 includes a plurality of frame members 1212 that are interconnected and arranged in one or more patterns. In various examples, the frame members 1112 are connected to one another at various joints 1214. In some examples, these joints 1214 operate as flex points so as to provide a preferential flexing location for the leaflet frame subcomponent 1200, such as to flex when compressed to a smaller delivery diameter such as required for transcatheter delivery. In some examples, a flex point or joint 1214 comprises a site on the leaflet frame 1220 that undergoes a high degree of bending. In some examples, the flex points or joints 1214 may comprise a geometry, structural modification or material modification, among others, that biases the leaflet frame 1220 to bend at the joint 1214 when compressed or expanded between a larger diameter and a smaller diameter.


In some examples, one or more closed cell apertures or voids 1216 are defined between the joints 1214 and the interconnected frame members 1212 of the leaflet frame subcomponent 1200. In some examples, these apertures or voids 1216 extend from the leaflet frame outer surface 1208 to the leaflet frame inner surface 1206 of the leaflet frame wall 1205 of the leaflet frame 1220. As illustrated in the embodiments of FIG. 2A, one or more of the apertures or voids 1216 define a diamond shape when the leaflet frame subcomponent 1200 is in a deployed configuration. Upon compression to a smaller diameter (e.g., a delivery diameter), one or more of the joints 1214 and the frame members 1212 deform such that the apertures or voids 1216 generally define an elongated diamond shape (e.g., as shown generally in FIG. 1A). Upon expanding the leaflet frame subcomponent 1200 to a larger diameter during deployment at a treatment site, the apertures or voids 1216 expand to define the generally wider diamond shape.


It should be appreciated that while the frame members 1212 illustrated and described herein are interconnected and define apertures or voids 1216 having generally a diamond shape, the interconnected frame members 1212 may be arranged in a number of alternative patterns without departing from the spirit or scope of the disclosure. That is, a number of alternative patterns are envisioned where the arrangement of frame members 1212 is configured in such a manner as to provide for a leaflet frame subcomponent 1200 that can be compressed to a smaller diameter for transcatheter delivery and subsequently expanded (or allowed to expand) to a larger diameter at a treatment site during deployment of the prosthetic valve 1000. Accordingly, the disclosure should not be limited to arrangements of the frame members 1212 that define diamond-shaped apertures or voids 1216. For example, a framework of the leaflet frame 1220 can define any number of features, repeatable or otherwise, such as geometric shapes and/or linear or meandering series of sinusoids. Geometric shapes can comprise any shape that facilitates circumferential compressibility and expandability.


In various embodiments, the leaflet frame 1220 may comprise or otherwise be formed from a cut tube, or any other element suitable for the particular purpose of the leaflet frame 1220 as described herein. In some examples, the leaflet frame 1220 may be etched, cut, laser cut, or stamped into a tube or a sheet of material, with the sheet then formed into a tubular structure. Alternatively, an elongated material, such as a wire, bendable strip, or a series thereof, can be bent or braided and formed into a substantially tubular structure wherein the wall of the tube comprises an open framework that is compressible to a smaller diameter and expandable to a larger diameter as illustrated and described herein.


The leaflet frame 1220 may comprise, such as, but not limited to, any elastically deformable metallic or polymeric biocompatible material, in accordance with embodiments. The leaflet frame 1220 may comprise a shape-memory material, such as nitinol, a nickel-titanium alloy. Other materials suitable for the leaflet frame 1220 include, but are not limited to, other titanium alloys, stainless steel, cobalt-nickel alloy, polypropylene, acetyl homopolymer, acetyl copolymer, other alloys or polymers, or any other biocompatible material having adequate physical and mechanical properties to function as a leaflet frame subcomponent 1200 as described herein.


In various examples, as the leaflet frame 1220 is elastically deformable so as to be self-expanding under spring loads, as those of skill will appreciate. In some examples, the leaflet frame 1220 is plastically deformable so as to be mechanically expanded such as with a balloon, as those of skill will appreciate. In yet some other examples, the leaflet frame 1220 is plastically deformable as well as elastically deformable. That is, in some examples, the leaflet frame 1220 includes one or more elastically deformable components or features and one or more plastically deformable components or features. Thus, it should be appreciated that the examples of the leaflet frame 1220 presented herein are not to be limited to a specific design or mode of expansion.


In accordance with some embodiments, the leaflet frame 1220 comprises a shape memory material operable to flex under load and retain its original shape when the load is removed, thus allowing the leaflet frame subcomponent 1200 to self-expand from a compressed shape to a predetermined shape. The leaflet frame subcomponent 1200 and the anchor frame subcomponent 1100 may comprise the same or different materials. In accordance with an embodiment, the leaflet frame 1220 is plastically deformable to be expanded by a balloon. In another embodiment the leaflet frame 1220 is elastically deformable so as to be self-expanding.


In various embodiments, the leaflet frame subcomponent 1200 supports or otherwise includes a one-way valve 1030. In some examples, the one-way valve 1030 includes one or more leaflets 1230 as shown in FIGS. 1D and 2B. A variety of mechanical valve, biological leaflet, and synthetic leaflet designs are known in the medical technology arts, any of which may be incorporated into the leaflet frame subcomponent 1200 of the present disclosure. Examples of suitable leaflet constructs and methods of attachment to leaflet frame subcomponents are illustrated and described in U.S. patent application Ser. Nos. 13/833,650, 14/973,589, and 14/622,599, the contents of each of which are incorporated herein by reference. Further examples of suitable leaflet material are presented below.


In the embodiments of FIGS. 1D and 2B, the leaflet frame subcomponent 1200 further comprises one or more flexible leaflets 1230 coupled to the leaflet frame 1220 that are operable to open to allow flow from the leaflet frame subcomponent inflow end 1202 and to pass through the leaflet frame subcomponent outflow end 1204, as shown in FIGS. 1B1-1B3, also referred to as the forward flow direction, and are operable to close to restrict flow from flowing from the leaflet frame subcomponent outflow end 1204 through the leaflet frame subcomponent inflow end 1202, also referred to as the retrograde flow direction.


In some examples, the one-way valve 1030 or leaflets 1230 are coupled to the leaflet frame inner surface 1206 of the leaflet frame 1220. In other examples, a film that comprises a leaflet material is coupled to the leaflet frame outer surface 1208 and extends through a leaflet window defined by the leaflet frame 1220. Such a configuration minimizes a potential for the leaflet 1230 to peel or delaminate, as compared to configurations where the leaflets 1230 are coupled to a leaflet frame inner surface 1206 of the leaflet frame 1220. In some examples, one or more portions of the leaflets 1230 are wrapped about one or more portions of the leaflet frame subcomponent 1200.


The leaflet frame subcomponent 1200 further comprises a leaflet frame cover 1232 that is operable to prevent the flow of fluid through the wall of the leaflet frame 1220 such that the fluid can only flow through a lumen defined by the open leaflets 1230. FIGS. 1B1-1B3 provide embodiments wherein the voids 1216 of the leaflet frame 1220 are covered by the leaflet frame cover 1232 so as to block flow through the portion of the leaflet frame 1220 that is upstream of the attachment of leaflets 1230 to the leaflet frame 1220. In accordance with an example, the leaflet frame cover 1232 may be an impermeable film, sheet or membrane material that is wrapped around and coupled to the leaflet frame outer surface 1208. The leaflet frame cover 1232 may comprise any suitable material known in the art. By way of example, the leaflet frame cover 1232 may be a film, fabric, among others.


The leaflet frame cover 1232 may be a sheet-like material that is biologically compatible and configured to couple to the leaflet frame 1220. In various examples, the biocompatible material is a film that is not of a biological source and that is sufficiently flexible and strong for the particular purpose, such as a biocompatible polymer. In an embodiment, the film comprises a biocompatible polymer (e.g., ePTFE). In some examples, the film is a composite of two or more materials. The film may comprise one or more of a membrane, composite material of two or more components, or laminate of more than one layer of material. In various examples, the construction of and materials used in the film are such that the leaflet frame cover 1232 is impermeable to fluid flow.


Anchor Frame Subcomponent


In accordance with an embodiment, the anchor frame subcomponent 1100 includes an anchor frame 1120 and an anchor frame cover 1132 as shown in FIGS. 1B1-1B3. FIG. 3A is a side view of the anchor frame 1120. FIG. 3B is an axial view of the anchor frame 1120. The anchor frame wall 1105 of the anchor frame 1120 may be at least partially covered, such as with a film or fabric, not shown for clarity, suitable for a particular purpose, such as to restrict fluid from passing through the anchor frame wall 1105 of the anchor frame 1120, or to encourage tissue ingrowth of the anchor frame subcomponent 1100 with the implant site. The anchor frame cover 1132 may be coupled to the inner surface, outer surface, or both inner surface and outer surface of the anchor frame 1120. For illustrative purposes, the following examples are suitable especially for a transcatheter application, but are also suitable for a surgical application.



FIGS. 3A and 3B are side and axial views, respectively, of the anchor frame 1120 without the anchor frame cover 1132 for clarity, in accordance with an embodiment. The anchor frame 1120 is a generally tubular member having an anchor frame inflow end 1122 corresponding to an anchor frame subcomponent inflow end 1102, an anchor frame outflow end 1124 corresponding to an anchor frame subcomponent outflow end 1104, an anchor frame inner surface 1106 and an anchor frame outer surface 1108 defining an anchor frame wall 1105, wherein the anchor frame inner surface 1106 defining an anchor frame subcomponent lumen 1110 therethrough. The anchor frame subcomponent lumen 1110 is a generally cylindrical void defined between the anchor frame subcomponent inflow end 1102 and the anchor frame subcomponent outflow end 1104, and the anchor frame inner surface 1106 of the anchor frame subcomponent 1100. However, in-situ, the anchor frame subcomponent lumen 1110 may adopt an irregular cross section, depending on the geometry of the tissue orifice into which it is placed and the conformity of the anchor frame subcomponent 1100 to the tissue annulus at the implant site.


In various examples, the anchor frame 1120 is configured to couple to a native valve orifice. Accordingly, in various examples, a diameter of the anchor frame 1120 (e.g., a diameter of the anchor frame outer surface 1108, and essentially the diameter of the anchor frame subcomponent outer surface 1109, shown in FIG. 1D, of the anchor frame subcomponent 1100) is sized in accordance with patient anatomy. It will be appreciated that nonlimiting examples of an anchor frame subcomponent 1100 can be provided with a diameter (e.g., a diameter of an exterior surface of the anchor frame subcomponent 1100) in a range of between twenty five (25) millimeters and fifty (50) millimeters, depending on a patient's anatomy. However, anchor frames 1120 having diameters (e.g., a diameter of an anchor frame outer surface 1106 of the anchor frame 1120) in excess of fifty (50) millimeters are also envisioned and fall within the scope of the present disclosure, depending on patient anatomy. Note that the anchor frame subcomponent inner surface 1107, shown in FIG. 1D, of the anchor frame subcomponent 1100 has a diameter at least slightly larger than the leaflet frame outer surface 1208 of the leaflet frame subcomponent 1200 such that the leaflet frame subcomponent 1200 may telescopically nest within the anchor frame subcomponent 1100.


In another embodiment the anchor frame 1120 is elastically deformable so as to be self-expanding. In accordance with some embodiments, the anchor frame 1120 comprises a shape memory material operable to flex under load and retain its original shape when the load is removed, thus allowing the anchor frame subcomponent 1100 to self-expand from a compressed shape to a predetermined larger shape. The anchor frame 1120 may comprise the same or different materials as the leaflet frame 1220. In accordance with an embodiment, the anchor frame 1120 is plastically deformable, such that it may be mechanically expanded such as by a balloon.


In some embodiments, the anchor frame 1120 defines a tubular mesh having a framework defining apertures or voids 1116 as shown in FIG. 3A. For example, as shown, the anchor frame 1120 includes a plurality of frame members 1112 that are interconnected and arranged in one or more patterns. In some examples, these patterns repeat one or more times. In some such examples, the frame members 1112 are arranged and interconnected such that the anchor frame 1120 includes a plurality of patterned rows. In various examples, the frame members 1112 are connected to one another at various joints 1114. In some examples, these joints 1114 operate as flex points so as to provide a preferential flexing location for the anchor frame 1120 to flex when compressed to a smaller delivery diameter and when forces from the surrounding anatomy act to compress the anchor frame 1120 during normal operation after delivery and deployment of the prosthetic valve 1000. In some examples, a flex point or joint 1114 comprises a site on the anchor frame 1120 that undergoes a high degree of bending. In some examples, the joints 1114 may comprise a geometry, structural modification or material modification, among others, that biases the anchor frame 1120 to bend at the flex point or joint 1114 when compressed.


In some embodiments, one or more closed cell apertures or voids 1116 are defined between the joints 1114 and the interconnected frame members 1112 of the anchor frame 1120. In some examples, these apertures or voids 1116 extend from the anchor frame outer surface 1108 to the anchor frame subcomponent inner surface 1107 of the anchor frame 1120. As illustrated in the embodiments of FIGS. 3A and 3B, one or more of the apertures or voids 1116 define a diamond shape when the anchor frame 1120 is in a deployed configuration. Upon compression to a smaller diameter (e.g., a delivery diameter), one or more of the joints 1114 and the frame members 1112 deform such that the apertures or voids 1116 generally define an elongated diamond shape (e.g., as shown generally in FIG. 1A). Upon expanding the anchor frame 1120 to a larger diameter during deployment at a treatment site, the apertures or voids 1116 expand to define the generally wider diamond shape.


It should be appreciated that while the frame members 1112 illustrated and described herein are interconnected and define apertures or voids 1116 having generally a diamond shape, the interconnected frame members 1112 may be arranged in a number of alternative patterns. For example, a framework of the anchor frame 1120 can define any number of features, repeatable or otherwise, such as geometric shapes and/or linear or meandering series of sinusoids. Geometric shapes can comprise any shape that facilitates circumferential compressibility and expandability of the anchor frame 1120. That is, a number of alternative patterns are envisioned where the arrangement of frame members 1112 is configured in such a manner as to provide for an anchor frame 1120 that can be compressed to a smaller diameter for transcatheter delivery and subsequently expanded (or allowed to expand) to a larger diameter at a treatment site during deployment of the prosthetic valve 1000. Accordingly, the disclosure should not be read as being limited to arrangements of the frame members 1112 that define diamond-shaped apertures or voids 1116.


In various embodiments, the anchor frame 1120 may comprise or otherwise be formed from a cut tube, or any other element suitable for the particular purpose of the anchor frame 1120 as described herein. In some examples, the anchor frame 1120 may be etched, cut, laser cut, or stamped into a tube or a sheet of material, with the sheet then formed into a tubular structure. Alternatively, an elongated material, such as a wire, bendable strip, or a series thereof, can be bent or braided and formed into a tubular structure wherein the wall of the tube comprises an open framework that is compressible to a smaller diameter in a generally uniform and circumferential manner and expandable to a larger diameter as illustrated and described herein.


The anchor frame 1120 can comprise any metallic or polymeric biocompatible material. For example, the anchor frame 1120 can comprise a material, such as, but not limited to nitinol, cobalt-nickel alloy, stainless steel, or polypropylene, acetyl homopolymer, acetyl copolymer, ePTFE, other alloys or polymers, or any other biocompatible material having adequate physical and mechanical properties to function as described herein.


In various examples, the anchor frame 1120 is elastically deformable so as to be self-expanding under spring loads, as those of skill will appreciate. In some examples, the anchor frame 1120 is plastically deformable so as to be mechanically expanded such as with a balloon, as those of skill will appreciate. In yet some other examples, the anchor frame 1120 is plastically deformable as well as elastically deformable. That is, in some examples, the anchor frame 1120 includes one or more elastically deformable components or features and one or more plastically deformable components or features. Thus, it should be appreciated that the examples of the anchor frame 1120 presented herein are not to be limited to a specific design or mode of expansion.


In various embodiments, the anchor frame subcomponent 1100 is configured to provide positive engagement with an implant site to firmly anchor the prosthetic valve 1000 to the site. Such positive engagement with the implant site may be facilitated by one or more of the following, but not limited thereto: expansion spring bias of the anchor frame 1120; hoop strength of the expanded anchor frame 1120, tissue engagement features, and the geometric shape, contour and/or texture of the anchor frame subcomponent outer surface 1109.


For instance, in various examples, the anchor frame subcomponent 1100 includes one or more tissue engagement features 1118 that are configured to engage one or more regions of tissue at the tissue orifice surrounding the prosthetic valve 1000. In various examples, the tissue engagement features 1118 comprise one or more barbs or tissue anchors. The tissue engagement features 1118 will be discussed in detail later.


In some embodiments, the anchor frame 1120 defines a flange or a flared portion 1130 at the anchor frame subcomponent inflow end 1102 that flares or tapers radially outward when in the deployed configuration. For example, as shown in at least FIGS. 1B1, 1B2, 1B3, 2A, 5A-5C, 5E, and 10B-10M, the anchor frame subcomponent inflow end 1102 is flared or otherwise tapered radially outward when in the deployed configuration. That is, as shown, the anchor frame subcomponent inflow end 1102 has a larger deployed diameter than does the anchor frame subcomponent outflow end 1104. In various examples, as discussed in greater detail below, such a configuration operates to minimize migration risks and helps facilitate abutment of the anchor frame subcomponent 1100 with native tissue annulus at the implant site.


In some embodiments, the anchor frame subcomponent 1100 further comprises a flange element 1150 separate from, adjacent to, and coaxial with the anchor frame inflow end 1122 of the anchor frame 1120. FIG. 1B2 is a side view of the prosthetic valve 1000 in an expanded pre-deployed configuration showing the leaflet frame subcomponent 1200 and the anchor frame subcomponent 1100 having been expanded to larger diameters so as to show the details of the flange element 1150 as compared with an integral flange or flared portion 1130 of the anchor frame inflow end 1122 of anchor frame 1120 of the embodiment of FIG. 1B1. The flange element 1150 defines a flange or a flared portion 1130 of the anchor frame subcomponent 1100 that also defines the anchor frame subcomponent inflow end 1102 that flares or tapers radially outward when in the deployed configuration. The flange element 1150 is a generally tubular member of substantially the same construction as the anchor frame 1120. The flange element 1150 has a flange element inflow end 1152, a flange element outflow end 1154, a flange element inner surface 1156, and a flange element outer surface 1158 defining a flange element wall 1155 defining flange voids 1157. The flange element inner surface 1156 defines a portion of the anchor frame subcomponent lumen 1110 therethrough. In-situ, the flange element 1150 may adopt an irregular cross section, depending on the geometry of the tissue orifice into which it is placed and the conformity of the flange element 1150 to the tissue annulus at the implant site.


The flange element 1150 is coupled to the anchor frame inflow end 1122 by the anchor frame cover 1132 which is described below. The flange element 1150 defines a flange element inflow end 1152 and a flange element outflow end 1154. The flange element 1150 is located adjacent to, coaxial with, and axially spaced apart from the anchor frame 1120, with the flange element outflow end 1154 adjacent to but separate from the anchor frame inflow end 1122.


FIG. 1B2 shows the flange element 1150 flaring outward in a trumpet shape having a concave curvature to the flange element outer surface 1158. FIG. 1B3 shows another embodiment of the flange element 1150 wherein the flange element outer surface 1158 defines a convex curvature. The shape of the anatomy into which the anchor frame subcomponent 1100 is placed will determine the best choice of shape for the flange element 1150 of FIGS. 1B2-1B3 or the flared portion 1130 of the anchor frame subcomponent 1100 of FIG. 1B1. The flared portion 1130 of the anchor frame subcomponent 1100 of FIG. 1B1 may also define the convex curvature of the embodiment of FIG. 1B3 suitable for a particular anatomy into which is it placed.


The anchor frame subcomponent 1100 further comprises an anchor frame cover 1132 that is operable to prevent the flow of fluid through the anchor frame wall 1105 of the anchor frame 1120. The anchor frame cover 1132 may also be operable to provide a favorable surface for tissue abutment at the tissue annulus, and further, may be operable to facilitate tissue ingrowth which may be advantageous for fixation of the prosthetic valve 1000 to the tissue annulus, facilitate a favorable biological response of the blood (e.g., to prevent a thrombotic response), and/or facilitate sealing of the prosthetic valve 1000 with the tissue orifice to minimize para-valvular leakage. FIG. 1B provides an embodiment wherein all of the voids 1116 of the anchor frame 1120 are covered by the anchor frame cover 1132 so as to block flow through the anchor frame wall 1105. In accordance with an example, the anchor frame cover 1132 may be an impermeable film, sheet or membrane material that is wrapped around and coupled to the anchor frame outer surface 1108. The anchor frame cover 1132 may comprise any suitable material known in the art. By way of example, the anchor frame cover 1132 may be a film, fabric, among others.


The anchor frame cover 1132 may be a sheet-like material that is biologically compatible and configured to couple to the anchor frame 1120. In various examples, the biocompatible material is a film that is not of a biological source and that is sufficiently flexible and strong for the particular purpose, such as a biocompatible polymer. In an embodiment, the film comprises a biocompatible polymer (e.g., ePTFE). In some examples, the film is a composite of two or more materials. The film may comprise one or more of a membrane, composite material, or laminate. In various examples, the construction of and materials used in the film are such that the anchor frame cover 1132 is impermeable to fluid flow. In various examples, the construction of and materials used in the film are such that the anchor frame cover 1132 promotes cellular ingrowth, adhesion, and/or attachment. That is, in various examples, the anchor frame cover 1132 is constructed in a manner that promotes the ingrowth of tissue into one or more portions of the anchor frame cover 1132. It will be appreciated that cellular ingrowth may further increase sealing of the prosthetic valve with the tissue orifice and helps minimize para-valvular leakage, that is, leakage between the prosthetic valve and the tissue into which it is coupled.


Connecting Sheath


In accordance with embodiments of the prosthetic valve 1000, the anchor frame subcomponent 1100 and the leaflet frame subcomponent 1200 are coupled together by the connecting sheath 1300. Referring to FIGS. 1A-1C2, the connecting sheath 1300 is coupled to the anchor frame subcomponent outflow end 1104 of the anchor frame subcomponent 1100 at a connecting sheath inflow end 1322 and is coupled to the leaflet frame subcomponent inflow end 1202 at a connecting sheath outflow end 1324. The connecting sheath 1300 is a thin-walled flexible tubular member that defines a connecting sheath lumen 1340 in fluid communication with the anchor frame subcomponent lumen 1140 and the leaflet frame subcomponent lumen 1240 when in the pre-deployed configuration. When the leaflet frame subcomponent 1200 is nested into the anchor frame subcomponent 1100 the connecting sheath 1300 is operable to fold and evert so as to lie between the leaflet frame subcomponent 1200 and the anchor frame subcomponent 1100. The connecting sheath 1300 may comprise any suitable material known in the art. By way of example, the connecting sheath 1300 may be a film, fabric, membrane, among others, that is flexible and impermeable to fluid flow.


Referring to FIG. 4, showing a side view of the prosthetic valve 1000 in a pre-deployed configuration on a delivery catheter 1504 of a delivery device 1500, in some examples, the connecting sheath 1300 is disposed within and/or about the anchor frame subcomponent 1100 and the leaflet frame subcomponent 1200. In some examples, the connecting sheath 1300 is a contiguous film that at least extends between and operates to couple the anchor frame subcomponent 1100 and the leaflet frame subcomponent 1200 to one another. In some examples, the connecting sheath 1300 extends not only between but also over or within either or both of the anchor frame subcomponent 1100 and the leaflet frame subcomponent 1200. In some examples, the connecting sheath 1300 is a contiguous film with that of the anchor frame cover 1132 and/or the leaflet frame cover 1232 that at least extends between and operates to couple the anchor frame subcomponent 1100 and the leaflet frame subcomponent 1200 to one another. In some examples, the connecting sheath 1300 is formed from a generally tubular material and at least partially covers one or more of the anchor frame subcomponent 1100 and the leaflet frame subcomponent 1200. In some examples, the connecting sheath 1300 is formed by wrapping a film over and around a cylindrical mandrel that defines a variable diameter to match the respective inner diameter of each of the leaflet frame 1220 and anchor frame 1120 with a tapered portion therebetween to transition from the smaller diameter of the leaflet frame 1220 to the larger diameter of the anchor frame 1120. Either or both of the anchor frame 1120 and the leaflet frame 1220 are slid over the film and bonded thereto to the inner surface of the frames. In some examples, the connecting sheath 1300 is formed by wrapping the film over and around either or both of the anchor frame 1120 and the leaflet frame 1220 and bonded thereto to the outer surface of the frames.


The connecting sheath 1300 is generally any sheet-like material that is biologically compatible and configured to couple to the anchor frame subcomponent 1100 and the leaflet frame subcomponent 1200. In various examples, the biocompatible material is a film that is not of a biological source and that is sufficiently flexible and strong for the particular purpose, such as a biocompatible polymer. In an embodiment, the film comprises a biocompatible polymer (e.g., ePTFE). In some examples, the film is a composite of two or more materials. The film may comprise one or more of a membrane, composite material, or laminate. In various examples, the construction of and materials used in the film are such that the connecting sheath 1300 is impermeable to fluid flow.


In various examples, the connecting sheath 1300 is a tubular member having a connecting sheath wall 1305 that is impervious to fluid flow and controls the flow of fluid only through the connecting sheath lumen 1340 particularly during deployment of the prosthetic valve 1000 into the tissue orifice, as shown in FIGS. 6B1-6C2, and acts as an impermeable seal between the leaflet frame subcomponent 1200 and the anchor frame subcomponent 1100 when in the deployed nested configuration as shown in FIG. 6D. As will be discussed further below, during deployment of the prosthetic valve 1000, with the anchor frame subcomponent 1100 deployed within the tissue annulus and the leaflet frame subcomponent 1200 still mounted on the delivery catheter 1504, as shown in FIGS. 6B1-6C2, blood flow may be occluded until which time the leaflet frame subcomponent 1200 is released from the delivery catheter 1504 and/or after the leaflet frame subcomponent 1200 is deployed within the anchor frame subcomponent 1100 and the delivery catheter 1308 removed from the leaflet frame subcomponent 1200.


In various examples, the connecting sheath 1300 is operable to allow antegrade fluid flow, (i.e., blood perfusion) through the connecting sheath wall 1305 during deployment of the prosthetic valve 1000 into the tissue orifice. For example, and with reference to FIGS. 5A-5C and 5E, a prosthetic valve 2000 includes one or more flow enabling features 2350 formed in the connecting sheath 1300 extending between the anchor frame subcomponent 1100 and the leaflet frame subcomponent 1200. FIG. 5A is a side view of the prosthetic valve 2000 with the flow enabling features 2350 in an open configuration where antegrade flow (denoted by arrow “A”) is permitted. FIG. 5B is a side view of the prosthetic valve 2000 with the flow enabling features 2350 in a closed configuration where retrograde (denoted by arrow “R”) flow is obstructed. In some examples, the one or more flow enabling feature 2350 include one or more perforations or apertures. The flow enabling features 2350 are operable to enable antegrade flow and prevent retrograde flow through the flow enabling features 2350 prior to the anchor frame subcomponent 2100 and the leaflet frame subcomponent 2200 being nested together and in a fully deployed configuration. Further, the flow enabling features 2350 are configured to be fully closed and sealed when the leaflet frame subcomponent 2200 is nested into the anchor frame subcomponent 1100 and in a fully deployed configuration.


In some examples, the one or more flow enabling features 2350 additionally or alternatively include one or more mechanisms that facilitate unidirectional flow. For instance, in some examples, the flow enabling features are configured as one-way valves. In some examples, one-way valves include an aperture or perforation and a flap or element of material that overlays and is larger than the aperture or perforation so as to cover and seal the aperture or perforation under retrograde flow pressure. In some examples, the one-way valve is oriented to permit antegrade flow through the prosthetic valve, while minimizing or preventing retrograde flow through the prosthetic valve.



FIGS. 5A-5E are side views as if the prosthetic valve 1000, as shown in FIG. 4, was unconstrained from a constrained pre-nested configuration in order to more clearly show the particular elements. As shown in FIGS. 5A-5B, an example of flow enabling features 2350 include an aperture 2352 and a flap 2354 that operate to enable antegrade flow through the prosthetic valve 2000 prior to the anchor frame subcomponent 2100 and the leaflet frame subcomponent 2200 being nested together (i.e., while the anchor frame subcomponent 2100 and the leaflet frame subcomponent 2200 are longitudinally offset as illustrated and described herein). The flap 1354 is oversized relative to the aperture 2352 to cover the aperture 2352 under retrograde flow pressure and restrict or minimize retrograde flow through the aperture 2352, while during antegrade flow the flap 1354 lifts away from the aperture 2352 permitting antegrade flow through the aperture 2352. Further, the flap 1354 is configured to cover and seal the aperture 2352 when the leaflet frame subcomponent 2200 is nested into the anchor frame subcomponent 1100 and in a fully deployed configuration.


In some embodiments as will be described below, the connecting sheath 1300 comprises two layers of film, an inner film layer 1304 and an outer film layer 1306 (as shown in FIG. 5C-5D) with both layers coupled to either the inner or outer surface of the anchor frame 1120 and leaflet frame 1220, or the inner film layer 1304 bonded to the inner surfaces of the anchor frame 1120 and leaflet frame 1220 and the outer film layer 1306 coupled to the outer surfaces of the anchor frame 1120 and leaflet frame 1220.



FIG. 5C is a side view of another embodiment of the connecting sheath 1300 as shown coupled to the leaflet frame subcomponent 1200 and anchor frame subcomponent 1100. FIG. 5D is an exploded view of the connecting sheath 1300. In accordance with this embodiment, the connecting sheath 1300 is a double layer of film, an inner film layer 1304 that is a conical tubular member that defines an inner layer of the connecting sheath 1300 and an outer film layer 1306 that is a conical tubular member that is slightly larger than the inner film layer 1304 that defines an outer layer of the connecting sheath 1300 when in the partially deployed configuration shown in FIG. 5C. The inner film layer 1304 and the outer film layer 1306 are coupled together at least at the leaflet frame subcomponent inflow end 1202 of the leaflet frame subcomponent 1200 and the anchor frame subcomponent outflow end 1104 of the anchor frame subcomponent 1100. The inner film layer 1304 defines at least one inner film aperture 1312 therethrough adjacent the anchor frame subcomponent 1100 and the outer film layer 1306 defines at least one outer film aperture 1310 therethrough adjacent the leaflet frame subcomponent 1200. A respective inner film aperture 1312 is offset in the radial direction from a respective outer film aperture 1310 to facilitate operation as provided below. The inner film layer 1304 and the outer film layer 1306 are not coupled at least between one of the inner film apertures 1312 and one of the outer film apertures 1310 so as to define a flow space 1320 therebetween such that the outer film layer 1306 lifts away from the inner film apertures 1312 to enable antegrade flow through the inner film apertures 1312 and the outer film apertures 1310 prior to the anchor frame subcomponent 2100 and the leaflet frame subcomponent 2200 being nested (i.e., while the anchor frame subcomponent 2100 and the leaflet frame subcomponent 2200 are longitudinally offset as illustrated and described herein). The inner film layer 1304 and the outer film layer 1306 come together to close the flow space and to cover and seal the inner film apertures 1312 and outer film apertures 1310 under retrograde flow pressure and restrict or minimize retrograde flow through the inner film apertures 1312 and outer film apertures 1310. Further, the inner film layer 1304 and the outer film layer 1306 are configured to cover and seal the inner film apertures 1312 and outer film apertures 1310 when the leaflet frame subcomponent 2200 is nested into the anchor frame subcomponent 1100 and in a fully deployed configuration.


In the above embodiment, the inner film layer 1304 and the outer film layer 1306 are coupled together at least at the leaflet frame subcomponent inflow end 1202 of the leaflet frame subcomponent 1200 and the anchor frame subcomponent outflow end 1104 of the anchor frame subcomponent 1100. It is appreciated that in accordance with an embodiment, the outer film layer 1306 may not be coupled together at or adjacent to the anchor frame subcomponent outflow end 1104 and still function to cover the inner film aperture 1312 during retrograde flow conditions. A provided in the above embodiment related to the flap 2354, the outer film layer 1306 may function as does the flap 2354; that is to occlude the inner film aperture 1312 during retrograde flow conditions.



FIG. 5E is a side view of an embodiment of the connecting sheath 1300 as shown coupled to the leaflet frame subcomponent 1200 and anchor frame subcomponent 1100. In accordance with this embodiment, the connecting sheath 1300 is a double layer of film, an inner film layer 1304 that is a conical tubular member that defines an inner layer of the connecting sheath 1300 and an outer film layer 1306 that is a conical tubular member that is slightly larger but shorter than the inner film layer 1304 that defines an outer layer of the connecting sheath 1300 when in the partially deployed configuration shown in FIG. 5C. The inner film layer 1304 and the outer film layer 1306 are coupled together at least at the anchor frame subcomponent outflow end 1104 of the anchor frame subcomponent 1100 but are not coupled at the leaflet frame subcomponent inflow end 1202 of the leaflet frame subcomponent 1200.


The inner film layer 1304 defines at least one inner film aperture 1312 therethrough adjacent the anchor frame subcomponent 1100 and the outer film layer 1306 is configured to cover the at least one inner film aperture 1312. Under antegrade flow conditions, the outer film layer 1306 lifts away from the inner film layer 1304 and uncovers the at least one inner film aperture 1312 so as to define a flow space 1320 therebetween such that the outer film layer 1306 lifts away from the inner film apertures 1312 to enable antegrade flow through the inner film apertures 1312 prior to the anchor frame subcomponent 2100 and the leaflet frame subcomponent 2200 being nested (i.e., while the anchor frame subcomponent 2100 and the leaflet frame subcomponent 2200 are longitudinally offset as illustrated and described herein). The inner film layer 1304 and the outer film layer 1306 come together to close the flow space and to cover and seal the inner film apertures 1312 under retrograde flow pressure and restrict or minimize retrograde flow through the inner film apertures 1312. Further, the inner film layer 1304 and the outer film layer 1306 are configured to cover and seal the inner film apertures 1312 when the leaflet frame subcomponent 2200 is nested into the anchor frame subcomponent 1100 and in a fully deployed configuration



FIG. 6A is a greatly simplified cross-sectional view of a representation of the prosthetic valve 1000 constrained onto a delivery catheter 1504 and placed within a tissue annulus 1342, in accordance with an embodiment. In accordance with the above embodiment, as shown in FIGS. 6B1 and 6B2, while the anchor frame subcomponent 1100 is being deployed within the tissue annulus 1342 and the leaflet frame subcomponent 1200 is translated and nested into the anchor frame subcomponent 1100 in the pre-deployed configuration, whereby everting or folding/rotating the connecting sheath 1300, antegrade flow pressure causes the outer film layer 1306 to move away from the inner film layer 1304 so as to define the flow space 1320 between the inner film layer 1304 and outer film layer 1306. Blood may flow in the antegrade direction into the inner film aperture 1312 and out of the outer film aperture 1310 especially during deployment of the prosthetic valve 1000 when the anchor frame subcomponent 1100 and the still mounted on the delivery catheter leaflet frame subcomponent 1200 are blocking antegrade flow and the leaflets 1230 are not yet functional. In this example, blood profusion may be maintained during substantially the entire deployment process of the prosthetic valve 1000.


Under retrograde flow pressure, blood is prevented from flowing through the flow enabling features 2350 in a retrograde direction. Retrograde flow pressure causes the outer film layer 1306 to move toward and against the inner film layer 1304 so as to close the flow space 1320 between the inner film layer 1304 and outer film layer 1306, with the inner film layer 1304 covering the outer film aperture 1310 and/or the outer film layer 1306 covering the inner film aperture 1312 due to the radial offset of the inner film aperture 1312 and the outer film aperture 1310. Blood is prevented from flowing in the retrograde direction into the outer film aperture 1310 and out of the inner film aperture 1312 especially during deployment of the prosthetic valve 1000 when the deployed anchor frame subcomponent 1100 and the still mounted on the delivery catheter leaflet frame subcomponent 1200 are blocking retrograde flow.


As shown in FIG. 6D the leaflet frame subcomponent 1200 is expanded into its final deployed configuration. The inner film layer 1304 and the outer film layer 1306 are caused to come together under antegrade and retrograde fluid pressure and/or mechanical pressure narrowing or closing the flow space 1320 and with the inner film layer 1304 covering the outer film aperture 1310 and/or the outer film layer 1306 covering the inner film aperture 1312 closing the respective outer film aperture 1310 and inner film aperture 1312 due to the radial offset of the inner film aperture 1312 and the outer film aperture 1310, preventing flow therethrough. In this example, blood profusion may be maintained during substantially the entire deployment process, and with the delivery catheter 1504 removed from the prosthetic valve 1000, the leaflets 1230 become functional.


Retention Element


Referring again to FIGS. 1A-1B3, in various embodiments, the retention element 1400 is operable to position and/or retain the leaflet frame subcomponent 1200 within the anchor frame subcomponent. In accordance with an embodiment, the retention element 1400 is operable to control the axial position of the leaflet frame subcomponent 1200 within the anchor frame subcomponent 1100. In accordance with another embodiment, the retention element 1400 is configured to cover an inflow annular groove formed between the anchor frame subcomponent 1100 and the connecting sheath 1300 which had been everted during the deployment process.


In accordance with an embodiment, the retention element 1400 defines a retention element first end 1403 and a retention element second end 1405. The retention element second end 1405 is coupled to the sheath outflow end 1316 but is not directly coupled to the leaflet frame 1220 at the leaflet frame subcomponent inflow end 1202, there being a portion of the connecting sheath 1300 therebetween. In examples of the retention element 1400, the retention element second end 1405 is coupled only to the connecting sheath 1300 adjacent the leaflet frame subcomponent inflow end 1202 allowing the retention element 1400 to hinge or pivot about the retention element second end 1405. The retention element 1400 is an elongated element that is operable to extend generally parallel to axis X of the prosthetic valve 1000, as shown in FIGS. 1B1-1B3, 6A-6C2, 10D-10F, and 10I, when in the pre-deployed configuration, and operable to extend at an angle, and in some examples, in a generally lateral direction to the axis X when in the deployed configuration, as shown in FIGS. 1C2, 1D, 6D, 7B-7C, and 10J-10K. As shown, the axis X is optionally a central, longitudinal axis of the prosthetic valve 1000. The retention element 1400 is operable to translate through the anchor frame subcomponent 1100 during the deployment process, as shown in FIGS. 6A-6C2 and 10D-10J while the connecting sheath 1300 is operable to fold and evert within the anchor frame subcomponent lumen 1140 of the anchor frame subcomponent 1100 and lie between the leaflet frame subcomponent 1200 and the anchor frame subcomponent 1100.


In accordance with an embodiment, the retention element 1400 comprises a continuous sinuous element 1702. The sinuous element 1702 is configured to have a spring bias toward a planar star-shaped configuration defining elongated elements 1412 bending about apices 1414, as shown in FIGS. 7B-7C. The elongated elements 1412 have an elongated element first end 1402 and an elongated element second end 1404. In the star-shaped configuration, the elongated elements 1412 extend radially with the elongated element first ends 1402 and respective apices 1414 defining an inner circumference 1422 at a retention element first end 1403 and the elongated element second ends 1404 and respective apices 1414 defining an outer circumference 1424 at a retention element second end 1405. The sinuous element 1702 is operable to be elastically restrained to a tubular configuration wherein the elongated elements 1412 are rotated about the apices 1414 at the elongated element first ends 1402 such that the elongated element second ends 1404 are rotated toward each other to define a tubular or conical configuration. With the sinuous element 1702 defining a first tubular diameter, the tubular diameter may be further reduced by bringing the elongated elements 1412 into closer arrangement while bending at the apices 1414; that is, the elongated elements 1412 extend laterally to the axis X and along the connecting sheath 1300 and lateral with the anchor frame subcomponent 1100 and leaflet frame subcomponent 1200 as shown in FIG. 1A.


The sinuous element 1702 may be restrained to define a small tubular diameter in the constrained pre-deployment configuration at relatively the same diameter as that of the constrained leaflet frame subcomponent 1200 and the constrained anchor frame subcomponent 1100 and extending therebetween, with the retention element 1400 within the connecting sheath lumen 1340, as shown in FIG. 1A. The connecting sheath 1300 may be folded and/or pleated to facilitate reduction to a smaller diameter. In the deployed configuration, the retention element first end 1403 of the sinuous element 1702 retains substantially the same diameter as the expanded leaflet frame subcomponent 1200, wherein the elongated element second ends 1404 flare away from the elongated element first ends 1402 to define substantially the diameter of the anchor frame subcomponent inflow end 1102, bridging the distance between the leaflet frame subcomponent inflow end 1202 and the anchor frame subcomponent inflow end 1102 and extending across an inflow annular groove 1704 defined by the anchor frame subcomponent inflow end 1102 and the connecting sheath 1300. The retention element first end 1403 is coupled to and restrained by the connecting sheath outflow end 1324. The retention element second end 1405 may be restrained by a retention means 1710 such as a lasso 1712, noose, tether element 1714, draw string, removable clip, or other restraining element whether on the prosthetic valve 1000 or on a delivery device, as shown in FIGS. 6I-6K, 7A.


The retention element 1400 is operable to retain the relative position of the leaflet frame subcomponent 1200 and the anchor frame subcomponent 1100 by virtue of the spring bias of the sinuous element 1702 resisting forces in opposition to the retention element 1400 being biased to a planar configuration. Spring bias forces may be predetermined such that fluid dynamic forces on the prosthetic valve 1000 are not sufficient to overcome the spring bias needed to bend the elongated elements 1412 to a tubular configuration which would lead to the leaflet frame subcomponent 1200 moving an unacceptable distance axially within the anchor frame subcomponent lumen 1140 and maintain a relative axial position (or at least minimize relative axial movement) between the anchor frame subcomponent 1100 and the leaflet frame subcomponent 1200.


It is understood that the retention element 1400 may be provided with a predetermined spring bias, such that the retention element 1400 is operable as a shock absorber, to allow a predetermined amount of movement of the leaflet frame subcomponent 1200 during the operation of the prosthetic valve 1000. Such predetermined amount of movement may reduce stresses within various components of the prosthetic valve 1000, such as, but not limited to, the leaflets or other valve structures.


In accordance with embodiments, a non-permeable cover 1432 is coupled to the sinuous element 1702 such that fluid is prevented from passing through the retention element 1400 when in the deployed configuration, as shown in FIGS. 7B-7C. The cover 1432 extends from the apices 1414 at the elongated element first ends 1402 of the elongated elements 1412 to the apices 1414 at the elongated element second ends 1404. In the deployed configuration, the cover 1432 extends from the leaflet frame subcomponent inflow end 1202 to the anchor frame subcomponent inflow end 1102 effectively covering the inflow annular groove 1704 formed between the anchor frame subcomponent 1100 and the connecting sheath 1300.


It is desired to cover or seal off the inflow annular groove 1704 from blood flow for various reasons. In accordance with an embodiment, covering the inflow annular groove 1704 provides a smoother flow into the leaflet frame subcomponent inflow end 1202 of the leaflet frame subcomponent 1200 compared with flow that would otherwise flow antegrade into and retrograde out of the inflow annular groove 1704. Further, covering the inflow annular groove 1704 might prevent embolus that might be formed within the inflow annular groove 1704 from being dislodged and flow through the prosthetic valve 1000.


Manual Deployment


In accordance with embodiments, the retention element 1400 is advanced through the anchor frame subcomponent 1100 while in a compressed configuration constrained to the delivery catheter 1504 by withdrawing the delivery catheter 1504 upon which the retention element 1400 is mounted. The retention element 1400 is subsequently deployed when positioned adjacent to the anchor frame subcomponent inflow end 1102. In accordance with an example, a tether element 1714 is coupled to the retention element 1400, such as at the retention element second end 1405 of the retention element 1400, such that an operator may pull the tether element 1714 to affect advancement of the retention element 1400 through the anchor frame subcomponent 1100. The retention element second end 1405 of the retention element 1400 may be held in a compressed state by a predetermined amount of tension on the tether element 1714. Tension of the tether element 1714 may be released and thus release the elongated element second end 1404 of the retention element 1400 so as to allow expansion and deployment of the retention element 1400.


In accordance with an example, the leaflet frame subcomponent 1200 is nested and deployed within the anchor frame subcomponent 1100 prior to the deployment of the retention element 1400. In another example, the retention element 1400 is deployed before the deployment of the leaflet frame subcomponent 1200 with in the anchor frame subcomponent 1100. In accordance with another example, the leaflet frame subcomponent 1200 and the retention element 1400 are deployed simultaneously.


Although various examples include one or more of the anchor frame 1120, flange or flared portion 1130, leaflet frame 1220, and/or retention element 1400 being discrete, separate components that are directly or indirectly coupled together, it should be understood that various examples also include one or more (e.g., all of) the anchor frame 1120, flange or flared portion 1130, leaflet frame 1220, and retention element 1400 being formed as an integral unit (e.g., cut or formed from a single tube of material).


Passive Deployment


In accordance with other embodiments, after deployment or expansion of the anchor frame subcomponent 1100 into the tissue annulus, the connecting sheath 1300 presents a tapered configuration having a smaller diameter at the leaflet frame subcomponent inflow end 1202 to a larger diameter at the anchor frame subcomponent outflow end 1104. The retention element 1400 may be released or deployed while still within the connecting sheath 1300, wherein the apices 1414 at the retention element second end of the retention element 1400 may abut and slide along the taper of the connecting sheath inner surface 1314 of the connecting sheath 1300, as shown in FIGS. 1C1, 1C2 and 6G, and subsequently the anchor frame subcomponent inner surface 1107 of the anchor frame subcomponent 1100 while expanding under spring bias, until the apices 1414 at the retention element second end are fully expanded about the anchor frame subcomponent inflow end 1102 of the anchor frame subcomponent 1100. The spring bias may be configured such that sufficient force is produced to advance the retention element 1400 through the taper of the connecting sheath 1300 and the anchor frame subcomponent inner surface 1107 of the anchor frame subcomponent 1100 toward the anchor frame subcomponent inflow end 1102 while pulling the leaflet frame subcomponent 1200 into the anchor frame subcomponent 1100. In accordance with embodiments, the leaflet frame subcomponent 1200 may be either retained on the delivery catheter 1504 or deployed to the expanded configuration prior to being pulled into the anchor frame subcomponent 1100. In this embodiment, release of the constrained retention element 1400 allows for a passive means for advancing the leaflet frame subcomponent 1200 into the anchor frame subcomponent 1100, that is, the operator does not need to manipulate the position of the delivery catheter 1504 during deployment of the leaflet frame subcomponent 1200.


In accordance with another embodiment, the length of the retention element 1400 is predetermined such that the apices 1414 at the retention element second end 1405 of the retention element 1400 extend within the anchor frame subcomponent 1100 while in the pre-deployed configuration. When deployed, the apices 1414 at the retention element second end 1405 may abut and slide along the anchor frame subcomponent inner surface 1107 of the anchor frame subcomponent 1100 while expanding under spring bias, until the apices 1414 at the retention element second end 1405 are fully expanded about the anchor frame subcomponent inflow end 1102. The spring bias may be configured such that sufficient force is produced to advance the retention element 1400 through the anchor frame subcomponent 1100 toward the anchor frame subcomponent inflow end 1102 while pulling the leaflet frame subcomponent 1200 into and nesting the anchor frame subcomponent 1100. In accordance with embodiments, the leaflet frame subcomponent 1200 may be either retained on the delivery catheter 1504 or deployed to the expanded configuration prior to being pulled into and nested in the anchor frame subcomponent 1100. In this embodiment, release of the constrained retention element 1400 allows for a passive means for advancing the leaflet frame subcomponent 1200 into the anchor frame subcomponent 1100, that is, the operator does not need to manipulate the position of the delivery catheter 1504 during deployment of the leaflet frame subcomponent 1200.


As will be discussed below, the delivery device may incorporate elements to facilitate the advancement and deployment of the anchor frame subcomponent 1100, the leaflet frame subcomponent 1200, and the retention element 1400. In accordance with embodiments, the advancement of the leaflet frame subcomponent 1200, and the retention element 1400 into the anchor frame subcomponent 1100 is facilitated by moving or staged withdraw of the delivery catheter. In accordance with other embodiments, the advancement of the leaflet frame subcomponent 1200 and the retention element 1400 into or through, respectively, the anchor frame subcomponent 1100 is facilitated by moving internal components of the delivery catheter 1504, such as, but not limited to the leaflet frame subcomponent 1200 riding on a trolley advanced by a pulling of a tether element 1714 or by spring bias of the retention element 1400 or an internal component of the delivery device. An embodiment of a sliding trolley may be a larger diameter tubular member operable to be slidingly received onto a smaller diameter delivery catheter 1504. The trolley may be constrained from sliding on the delivery catheter 1504 by a retention means, such as, but not limited to, a tether element 1714 or a latch.


LVOT Taper


Referring again to the anchor frame subcomponent 1100, as shown in FIGS. 1B1-1B3, the length of the anchor frame 1120 and thus the anchor frame subcomponent 1100, is predetermined for a particular purpose. In accordance with embodiments, the length of the anchor frame 1120 is predetermined based on, among other things, the anatomy of the tissue annulus into which the prosthetic valve 1000 is implanted, including, but not limited to, the shape of the annulus, the amount of tissue available to support the anchor frame subcomponent 1100, the proximity with flow paths, other tissues, and nerves, and the structural characteristics of the anchor frame subcomponent (urging engagement spring bias or plastic deformation hoop strength, fixation barbs, proper compliance, reforming/reshaping).



FIG. 8A is a cross-sectional view of the heart and the prosthetic valve 1000 deployed within a tissue annulus of a mitral valve. In accordance with embodiments, the length of the anchor frame subcomponent 1100 is the uniform along its circumference. In other embodiments, the length of the anchor frame subcomponent 1100 varies along the circumference, for example, when viewed transverse to the axis X, the anchor frame subcomponent outflow end 1104 has a tapered geometry, as shown in FIG. 8C. By way of example, discussion of the mitral valve anatomy follows with the application of the prosthetic valve 1000 being used to replace a mitral valve 1920 (obscured and deformed by the prosthetic valve 1000). Referring to FIG. 8A, the mitral valve 1920 is a one-way valve that allows blood flow from the left atrium 1902 to the left ventricle 1904. Blood leaves the left ventricle 1904 through the aortic valve 1906 and into the aorta 1910. Immediately before the aortic valve 1906, the anatomy defines the left ventricular outflow tract (LVOT) 1908, a conduit though which blood enters the aortic valve 1906. Cardiac output is directly related to the smallest diameter of the LVOT 1908 to permit the flow of blood to the aortic valve 1906. An LVOT 1908 that is reduced in diameter or restricted by tissue or an implanted device reduces cardiac output and can lead to debilitating cardiac function. Therefore, minimizing the blocking of the LVOT 1908 by the prosthetic valve 1000 is imperative.


The mitral valve 1920 and the aortic valve 1906 are adjacent each other and form an aortomitral angle 1800 relative to their transverse axes, which can vary between patients. One can see from FIG. 8A that where the aortomitral angle 1800 is much greater than 90 degrees and approaching 180 degrees, the degree of interference of the anchor frame subcomponent 1100 extending into the LVOT 1908 is less than if the aortomitral angle is closer to 90 degrees, as shown in FIG. 8B. As the aortomitral angle approaches 90 degrees, the extension of an anchor frame subcomponent anterior portion 1822 of the anchor frame subcomponent outflow end 1104 of the anchor frame subcomponent 1100 of a given constant length into the LVOT 1908 becomes greater.


In accordance with an embodiment of the prosthetic valve 1000 for mitral valve replacement, the length of the anchor frame subcomponent 1100 is determined by considering one or more of at least the following parameters: the aortomitral angle 1800, and the degree of obstruction or blockage by the prosthetic valve 1000 of the LVOT 1908, the dimensions of the tissue annulus 1930 and the amount of tissue available for engagement with the prosthetic valve 1000. In accordance with an embodiment, to minimize blockage of the LVOT 1808 for smaller aortomitral angles 1800, the length of the anchor frame subcomponent 1100 varies along its circumference, for example, when viewed transverse to the axis X, the anchor frame subcomponent outflow end 1104 has a tapered geometry. The anchor frame subcomponent outflow end 1104 is tapered such that the anchor frame subcomponent outflow end 1104 extends further into the left ventricle 1904 adjacent to a posterior side 1914 of the left ventricle 1904 and extends less into the LVOT 1908 on the anterior side 1916 of the left ventricle 1904.


As shown in FIG. 8C, the length of the anchor frame subcomponent 1100 varies along the circumference, for example, when viewed transverse to the axis X, the anchor frame subcomponent outflow end 1104 has a tapered geometry, in some embodiments. As shown, the anchor frame subcomponent 1100 can be oriented along the X-axis and the leaflet frame subcomponent 1200 can be oriented along the X1-axis which is off-set to the X-axis. FIG. 8C shows an embodiment in which “off-set” can refer to an arrangement wherein the X1-axis can be angled from the X1-axis (e.g., the X-axis and the X1-axis are non-collinear or non-parallel) such that the leaflet frame subcomponent 1200 is generally tilted with respect to the anchor frame subcomponent 1100. In one embodiment, the second longitudinal axis is disposed at a tilt angle A between 15° and 45° relative to the first longitudinal axis. In another embodiment, the leaflet frame subcomponent outflow end 1204 is generally parallel with the anchor frame subcomponent outflow end 1104, wherein the anchor frame subcomponent outflow end 1104 has a taper as characterized as having a length that varies around the circumference. In this orientation, the extension of the leaflet frame subcomponent outflow end 1204 into the LVOT is reduced as compared with a coaxial anchor frame subcomponent 1100 and leaflet frame subcomponent 1200, as shown in FIG. 8B.


It has been found that fixation of the anchor frame subcomponent 1100 may be greater on the anchor frame subcomponent anterior portion 1822 of the prosthetic valve 1000 adjacent the aortic valve 1906, that is the anterior side 1916 of the left ventricle 1904, as compared with the anchor frame subcomponent posterior portion 1932 of the prosthetic valve 1000 adjacent the posterior side 1914 of the left ventricle 1904. In such a case, the prosthetic valve 1000 may want to preferentially pivot about the anchor frame subcomponent anterior portion 1822. The taper as described above having more extension and tissue engagement with the posterior side 1914 of the left ventricle 1904, will act to further resist the movement of the anchor frame subcomponent posterior portion 1932 of the prosthetic valve 1000. Fluid pressure in the left ventricle 1904 acting on the closed leaflets of the prosthetic valve 1000 will tend to provide a camming force to further engage the anchor frame subcomponent posterior portion 1932 with the posterior side 1914 of the left atrium 1902.


Anchor Frame Variable Stiffness


In accordance with other embodiments, the hoop strength of the anchor frame subcomponent 1100 can be relatively invariable along the length and circumference of the anchor frame 1120. In accordance with other embodiments, the hoop strength of the anchor frame subcomponent 1100 can be variable along the length and/or the circumference of the anchor frame 1120. By way of example and in reference to the anatomy of the mitral valve tissue annulus 1930, the tissue at the aortomitral junction 1940 side of the tissue annulus 1930 may be stiffer than the annulus posterior side 1942 of the tissue annulus 1930. The variable stiffness of the anchor frame 1120 may be predetermined to have a greater stiffness at the smaller tapered portion of the anchor frame subcomponent anterior portion 1822 of the anchor frame subcomponent outflow end 1104 to match the stiffness of the aortomitral junction 1940, as shown in FIG. 8A, whereas the stiffness may be relatively less at the longer prosthetic valve posterior portion 1820 adjacent the posterior side 1914 of the left ventricle 1904.


Retrieval


In accordance with another embodiment, during a transcatheter procedure, the prosthetic valve 1000 is operable to be removable after deployment of the anchor frame subcomponent 1100 but before deployment of the leaflet frame subcomponent 1200 into the anchor frame subcomponent 1100. In accordance with an embodiment, the anchor frame subcomponent 1100 has a predetermined flexibility such that the anchor frame subcomponent 1100 may be everted into the anchor frame subcomponent lumen 1110. In an embodiment, the bending of the anchor frame subcomponent 1100 during eversion occurs along the length of the anchor frame 1120, such that the anchor frame subcomponent 1100 peels away from the tissue annulus 1342, as shown in FIG. 9C1. In accordance with another embodiment, a portion of the anchor frame subcomponent 1100 may pivot and compress about a location adjacent to the anchor frame subcomponent inflow end 1102, such as at the flared portion 1130, such that the anchor frame subcomponent 1100 may pivot or fold inwardly into the anchor frame subcomponent lumen 1110 and be drawn out of the anchor frame subcomponent lumen 1110 having been everted, as shown in FIG. 9C2.


In accordance with a method of retrieving the prosthetic valve 1000, a distal end of a retrieval sheath 1950 is positioned adjacent to the anchor frame subcomponent inflow end 1102 of the prosthetic valve 1000. The retrieval sheath 1950 is an elongated tubular member, such as a catheter, that defines a retrieval sheath lumen 1952 operable to receive the at least partially compressed prosthetic valve 1000. The leaflet frame subcomponent 1200 is reduced in diameter if fully deployed within the anchor frame subcomponent lumen 1110 by use of a retraction means 1956, such as a noose, tether, or the like to a diameter small enough to enter the retrieval sheath lumen 1952. The retracting means 1956 extends from the retrieval sheath lumen 1952 and is operable to pull the prosthetic valve 1000 into the retrieval sheath lumen 1952.


The leaflet frame subcomponent 1200 is reduced in diameter and pulled into the retrieval sheath lumen 1952 by the retraction means 1956, as shown in FIG. 9A. As the leaflet frame subcomponent 1200 and the connecting sheath 1300 is pulled into the retrieval sheath lumen 1952, the anchor frame subcomponent 1100 is pulled away from the tissue annulus 1930. In an embodiment, the bending of the anchor frame subcomponent 1100 during eversion occurs along the length of the anchor frame 1120, such that the anchor frame subcomponent 1100 peels away from the tissue annulus 1342, as shown in FIG. 9B1. In accordance with another embodiment, a portion of the anchor frame subcomponent 1100 may pivot and compress about a location adjacent to the anchor frame subcomponent inflow end 1102, such as at the flared portion 1130, such that the anchor frame subcomponent 1100 may pivot or fold inwardly into the anchor frame subcomponent lumen 1110 and be drawn out of the anchor frame subcomponent lumen 1110 having been everted, as shown in FIG. 9B2. The anchor frame subcomponent 1100 is operable to compress to a smaller diameter to be received within the retrieval sheath lumen 1952 as shown in FIGS. 9A-9D.


It is appreciated that the anchor frame subcomponent 1100 may further comprises tissue engagement features 1118, as shown in FIGS. 1B1-1B3. In consideration of retrieval, the tissue engagement features 1118 are operable to minimize trauma as they are pulled from the tissue annulus 1930 during retrieval. In accordance with an embodiment, the tissue engagement features 1118 have a predetermined angle to the axis X such that when the anchor frame subcomponent 1100 is everted, the tissue anchors will radially extract from the tissue annulus.


Outflow Annular Groove Cover


FIG. 7D3 is a side view of an embodiment of a prosthetic valve 1000 in an expanded pre-deployed configuration. In various examples of the prosthetic valve 1000, when in the deployed configuration, an outflow annular groove is defined by the leaflet frame subcomponent 1200 and the connecting sheath, as shown in FIG. 7D1. FIG. 7D1 is a simplified side cross-sectional view along cut line 7D2 of the prosthetic valve 1000 of FIG. 7D3 in a deployed configuration as shown by way of example in FIG. 7C, but further comprising an outflow annular groove cover 1440. The outflow annular groove cover 1440 is an annular element that is coupled to and extends from a leaflet frame cover outflow edge 1233 of the leaflet frame subcomponent outflow end 1204 to the anchor frame subcomponent outflow end 1104 effectively covering the outflow annular groove 1706 formed between the connecting sheath 1300 and the leaflet frame subcomponent 1200 and closing the volume defined by the leaflet frame cover 1232 of the leaflet frame subcomponent 1200, the connecting sheath 1300, and the outflow groove cover 1432. In accordance with another embodiment, the outflow groove cover 1432 extends between the leaflet frame subcomponent outflow end 1204 and the anchor frame subcomponent outflow end 1104 such that fluid is prevented from entering into an outflow annular groove 1706.


It is desired to cover or seal off the outflow annular groove 1706 from blood flow for various reasons. In accordance with an embodiment, covering the outflow annular groove 1706 provides a smoother flow at the leaflet frame subcomponent outflow end 1204 of the leaflet frame subcomponent 1200 compared with flow that would otherwise flow antegrade into and retrograde out of the outflow annular groove 1706. Further, covering the outflow annular groove 1706 might prevent embolus that might be formed within the outflow annular groove 1706 from being dislodged and flow downstream of the prosthetic valve 1000.


In various embodiments, the outflow annular groove cover 1440 may assist with maintaining the relative positioning of the leaflet frame subcomponent 1200 within the anchor frame subcomponent 1100 when the prosthetic valve 1000 is fully deployed. For example, the outflow annular groove cover 1440 may be resiliently retractable and extendible, such that the outflow annular groove cover 1440 is able to be transitioned between extended and retracted configurations.


The outflow annular groove cover 1440 can present from the extended configuration to the retracted configuration during nesting and expansion of the leaflet frame subcomponent 1200 within the anchor frame subcomponent 1100 such that the outflow annular groove cover 1440 takes on relatively flatter shapes as the outflow annular groove cover 1440 contracts. For example, the outflow annular groove cover 1440 may have an angular wall that is defined as the outflow annular groove cover 1440 contracts and angulates as it transitions from a lower angle (shallower angle) relative to a longitudinal axis X of the prosthetic valve 1000 to a higher angle (steeper angle) relative to the longitudinal axis X of the prosthetic valve 1000. In some examples, the outflow annular groove cover 1440 extends approximately perpendicularly between the walls of the leaflet frame subcomponent 1200 and the anchor frame subcomponent 1100 in the retracted configuration. In some examples, the outflow annular groove cover first end 1444 can be coupled to the anchor frame subcomponent outflow end 1104 and the outflow annular groove cover second end 1442 can be coupled to the leaflet frame subcomponent outflow end 1204.


In the deployed, or retracted configuration, the outflow annular groove cover 1440 extends between the leaflet frame subcomponent outflow end 1204 and the anchor frame subcomponent outflow end 1104 with the outflow annular groove cover 1440 operable to cover and restrict fluid flow into, or out from, the outflow annular groove 1706. In various embodiments of the prosthetic valve 1000 that include flow enabling features 2350 as shown in FIGS. 5A-E, the outflow annular groove cover 1440 is required to be permeable to fluid when the prosthetic valve is in the pre-deployed configuration so at to allow fluid to pass through the flow enabling features. In accordance with an embodiment, the outflow annular groove cover 1440 is less permeable to blood (e.g., blood impermeable under physiologic conditions) when in the retracted configuration wherein the prosthetic valve 1000 is in the deployed configuration. The outflow annular groove cover 1440 may be configured to be blood permeable under physiologic conditions when in the extended configuration wherein the prosthetic valve 1000 is in the pre-deployed configuration. For example, after initiation, but prior to completion of transitioning the prosthetic valve 1000 to a fully deployed configuration the outflow annular groove cover 1440 is configured to be blood permeable.


In various examples, the outflow annular groove cover 1440 is a flexible elastic element that is operable to resiliently stow into a low radial profile in a delivery configuration and is operable to extend between the leaflet frame subcomponent 1200 and the anchor frame subcomponent 1100. The outflow annular groove cover 1440 can be implemented to inhibit flood flow into or out from between the anchor frame subcomponent 1100 and the leaflet frame subcomponent 1200.


In some examples, the outflow annular groove cover 1440 is under elastic bias when in a deployed position such that they are held relatively taught. Engagement of the outflow annular groove cover 1440 with the anchor frame subcomponent 1100 and the leaflet frame subcomponent 1200 may assist in maintaining the relative position of the leaflet frame subcomponent 1200 within an anchor frame subcomponent lumen 1140, according to some embodiments.


As shown in FIGS. 7D1-7D3, the outflow annular groove cover 1440 defines an outflow annular groove cover first end 1444 and an outflow annular groove cover second end 1442. The outflow annular groove cover first end 1444 is coupled to the anchor frame subcomponent outflow end 1104. The outflow annular groove cover second end 1442 is coupled to the leaflet frame subcomponent 1200 about the leaflet frame cover outflow edge 1233 of the leaflet frame cover 1232 adjacent to the leaflet frame subcomponent outflow end 1204. As shown in FIGS. 7D1-7D3, the outflow annular groove cover second end 1442 may be contiguously attached to the leaflet frame cover outflow edge 1233 of the leaflet frame cover 1232. For example, the outflow annular groove cover 1440 may be coupled to and circumferentially extend from adjacent the anchor frame subcomponent outflow end 1104 and a leaflet frame cover outflow edge 1233 of the leaflet frame cover 1232, to avoid blood flow through the leaflet frame 1220 into the space or volume corresponding to the outflow annular groove 1706. In some examples, the leaflet frame cover 1232 optionally couples to the anchor frame subcomponent outflow end 1104 and correspondingly, the outflow annular groove cover 1440 is coupled to the leaflet frame subcomponent outflow end 1204 wherein the leaflet frame cover 1232 extends thereto to define a closed volume with the connecting sheath 1300 and the leaflet frame subcomponent 1200. In such instances, it may be desirable for the leaflet frame cover 1232 to also extend to the leaflet frame subcomponent outflow end 1204 to avoid blood flow through the leaflet frame 1220 into the space corresponding to the outflow annular groove 1706.


The outflow annular groove cover 1440 is a tubular element that is operable to extend generally parallel to the longitudinal axis X of the prosthetic valve 1000 (or at a relatively small, or shallow angle relative to the longitudinal axis X), when in the pre-deployed/expanded configuration (e.g., FIG. 7D2) and operable to extend at an angle, and in some examples, in a generally lateral direction to the longitudinal axis X (or at a relatively large, or steep angle relative to the longitudinal axis X) when in the deployed/retracted configuration (e.g., FIG. 7D1). The outflow annular groove cover 1440 is operable to retract during the deployment process, as shown in FIG. 7D1 while the connecting sheath 1300 is operable to fold and evert within the anchor frame subcomponent lumen 1140 of the anchor frame subcomponent 1100 and lie between the leaflet frame subcomponent 1200 and the anchor frame subcomponent 1100 as shown in FIG. 7D1.


The outflow annular groove cover 1440 may be configured to facilitate delivery of the prosthetic valve 1000, and is operable to be elastically restrained to an extended tubular or conical configuration as shown in FIG. 7D2. In particular, the outflow annular groove cover 1440 may also be restrained to define a small tubular diameter in the constrained pre-deployment configuration, such as shown in FIG. 4, at relatively the same diameter as that of the constrained leaflet frame subcomponent 1200 and the constrained anchor frame subcomponent 1100 with the outflow annular groove cover 1440 extending within the anchor frame subcomponent 1100. For reference, as indicated above, in some embodiments, the delivery device 1500 is configured to longitudinally restrain the prosthetic valve 1000 in the un-nested configuration until the time in the delivery sequence at which the leaflet frame subcomponent 1200 is nested into the anchor frame subcomponent 1100.


In some embodiments, the outflow annular groove cover 1440 can help retain the relative position of the leaflet frame subcomponent 1200 and the anchor frame subcomponent 1100 by virtue of an elastic bias of the outflow annular groove cover 1440. For example, the outflow annular groove cover 1440 optionally resists forces in opposition to the outflow annular groove cover 1440 being biased to the retracted configuration.


If desired, the bias may be predetermined to assist with centering or other desirable positioning of the leaflet frame subcomponent 1200 within the anchor frame subcomponent 1100 under physiologic loading conditions. In other embodiments, the bias may be selected to permit some resilient deflection, or adjustment of the position of the leaflet frame subcomponent 1200 within the anchor frame subcomponent 1100 to accommodate physiologic loading, or potentially even better replicate natural physiologic action (e.g., to more closely match movement of a natural valve during a cardiac cycle). In different terms, the bias may be predetermined the such that fluid dynamic forces on the prosthetic valve 1000 are not sufficient to overcome the elastic bias needed to stretch/expand the outflow annular groove cover 1440 which would lead to the leaflet frame subcomponent 1200 moving an unacceptable distance axially or radially within the anchor frame subcomponent lumen 1140 and maintain a relative axial and/or radial position (or at least minimize relative axial or radial movement) between the anchor frame subcomponent 1100 and the leaflet frame subcomponent 1200.


In accordance with an embodiment, the outflow annular groove cover 1440 comprises a pleated, or folded configuration that has a continuous sinuous and/or zig-zag configuration. The pleated, or folded configuration may facilitate reduction of the outflow annular groove cover 1440 to a smaller diameter. The pleated configuration may have an elastic bias, or otherwise resiliently return to the contracted, or retracted configuration.


Although various features are described above, they are provided by way of example and additional or alternative features, associated advantages, and other inventive aspects are contemplated and will be apparent from the disclosure read as a whole.


Annular Groove Cover Materials


In some examples, the outflow annular groove cover 1440 is formed from a retracted microstructure membrane such as those described in U.S. Pat. No. 10,166,128, issued Jan. 1, 2019. Such retracted microstructures exhibit a high degree of recoverable elongation such that they can be extended and resilient retract. They may be formed of fluoropolymer membranes (e.g., porous synthetic fluoropolymer membranes) such that they exhibit high elongation while substantially retaining the strength properties associated with the fluoropolymer membrane. Such retracted microstructure membranes characteristically possess a microstructure of serpentine fibrils that curve or turn generally one way then generally another way. It is to be understood that the amplitude and/or frequency of the serpentine-like fibrils may vary. In some embodiments, the fluoropolymer membranes that go through a retraction process to provide a precursor retracted membrane are formed of expandable fluoropolymers. Non-limiting examples of expandable fluoropolymers include, but are not limited to, expanded PTFE, expanded modified PTFE, and expanded copolymers of PTFE.


The high elongation is facilitated by forming relatively straight fibrils into serpentine fibrils that substantially straighten upon the application of a force in a direction opposite to the compressed direction. The creation of the serpentine fibrils can be achieved through a thermally-induced controlled retraction of the expanded polytetrafluoroethylene (ePTFE), through wetting the article with a solvent, such as, but not limited to, isopropyl alcohol or Fluorinert® (a perfluorinated solvent commercially available from 3M, Inc., St. Paul, Minn.), or by a combination of these two techniques. The retraction of the article does not result in visible pleating, folding, or wrinkling of the ePTFE, unlike what occurs during mechanical compression. During the retraction process, the fibrils not only become serpentine in shape but also may also increase in width.


The retracted membranes described above can be imbibed with an elastomeric material prior, during, or subsequent to retraction to form a composite such that at least a portion of the pores of a porous material such as ePTFE or the like are filled. Suitable elastomeric materials may include, but are not limited to, PMVE-TFE (perfluoromethylvinyl ether-tetrafluoroethylene) copolymers, PAVE-TFE (perfluoro (alkyl vinyl ether)-tetrafluoroethylene) copolymers, silicones, polyurethanes, and the like. It is to be noted that PMVE-TFE and PAVE-TFE are fluoroelastomers. Other fluoroelastomers include suitable elastomeric materials as identified by those of skill in the art. The resultant retracted membrane composite possesses resilient elongation capability while substantially retaining the strength properties of the fluoropolymer membrane. Moreover, such retracted membranes have the ability to be free of creases, folds or wrinkles visible to the naked eye (i.e., on a gross scale) in both retracted and extended configurations.


In addition to or as an alternative to a membrane or other sheet-like component having elastic recovery (e.g., by coating or imbibing a membrane with elastomer), one or more elastomeric elements may otherwise be associated with a membrane or sheet-like member to provide desired properties. For example, one or more elastomeric bands, members, or other feature may be associated (e.g., bonded, adhered, or mechanically fastened) with a sheet-like member, such as a membrane or film, to provide resilient elongation capabilities to the annular groove cover(s).


In some examples, wherein the material of the outflow annular groove cover 1440 includes a porous elastic film that when in the extended configuration defines pores large enough to render the porous elastic film blood permeable under physiologic conditions and when in the retracted configuration the pores are small enough to render the porous elastic film low-permeability, such as blood impermeable under physiologic conditions.


The materials utilized for the outflow annular groove cover 1440 may also be configured for tissue ingrowth (i.e., to facilitate or promote tissue ingrowth or adhesion) or to resist tissue ingrowth. Moreover, one or more portions of the cover(s) may be configured for tissue ingrowth, whereas other portions are configured to resist tissue ingrowth.


Filler materials may also be utilized in addition to the inflow and outflow annular groove covers. Whether separately injectable (e.g., utilizing a syringe or other delivery mechanism) or associated with the annular groove cover(s) as a coating or other treatment, such filler materials may serve to help fill the inflow annular groove and inflow annular groove 1704 and/or the outflow annular groove 1706 as desired. Examples of such materials include biocompatible filler agents or bulking agents operable to fill a volume and may include at least one of hydrogel, alginate, foam, porous bulking material, collagen, hyaluronic acid, alginic salt, cellulose, chitosan, gelatin, agarose, glycosaminoglycans, polysaccharides, and combinations thereof, among others.


Tissue Engagement Features


In various examples, the one or more tissue engagement features 1118 project away from the anchor frame inner surface 1106 and/or the anchor frame outer surface 1108 of the anchor frame subcomponent 1100, radially outward from a longitudinal axis of the anchor frame subcomponent 1100, and toward the tissue surrounding the prosthetic valve 1000. Generally, the tissue engagement features 1118 are operable to project away from the anchor frame subcomponent 1100 when the anchor frame subcomponent 1100 is deployed (e.g., when a constraining member is withdrawn or otherwise removed). In some examples, with the anchor frame subcomponent 1100 in the deployed configuration, the tissue engagement features 1118 are operable to engage the tissue proximate the anchor frame subcomponent 1100 such that the tissue engagement features 1118 secure the anchor frame subcomponent 1100 to the surrounding tissue, as will be discussed in greater detail below.


In some examples, in a deployed configuration, the tissue engagement features project away from an exterior surface of the anchor frame subcomponent in a range of between thirty (30) and sixty (60) degrees. In some such examples, the tissue engagement features project away from an exterior surface of the anchor frame subcomponent at an angle of approximately forty five (45) degrees, though other configurations are contemplated and fall within the scope of the present application. Generally, any angle of projection is suitable provided that the tissue engagement features operate for their intended purpose of engaging the tissue surrounding the anchor frame subcomponent and causing the anchor frame subcomponent to be secured to the surrounding tissue. Though the tissue engagement features may include a variety of different lengths (depending on the angle from which they project from the anchor frame subcomponent), it will be appreciated that the tissue engagement features are of a length suitable for engaging tissue and securing the anchor frame subcomponent to the surrounding tissue, but not so long as to risk detrimental damage to the native valve orifice. One nonlimiting example configuration includes tissue engagement features projecting from the anchor frame subcomponent in a range of between thirty (30) and sixty (60) degrees and having a length of between fifty (50) micron and two hundred (200) micron.


Generally, the tissue engagement features 1118 are positioned along the anchor frame subcomponent 1100 such that they are operable to engage tissue proximate the anchor frame subcomponent 1100 when the anchor frame subcomponent 1100 is expanded in-situ. The tissue engagement features 1118 may be arranged in one or more rows along a longitudinal axis of the anchor frame subcomponent 1100. That is, in various examples, the anchor frame subcomponent 1100 may include a first set (or row) of anchors and a second set (or row) of anchors longitudinally offset relative to the first set of anchors. In one such example, the first set of anchors is more proximate the anchor frame subcomponent outflow end 1104 of the anchor frame subcomponent 1100 than is the second set of anchors.


In various embodiments, the one or more tissue engagement features 1118 are circumferentially arranged about the anchor frame subcomponent 1100. In some examples, the one or more tissue engagement features 1118 are evenly dispersed about the circumference of the anchor frame subcomponent. For example, the tissue engagement features 1118 are dispersed about the frame and are offset from one another by ninety (90) degrees depending on the number of anchors. Alternatively, the tissue engagement features 1118 may be dispersed about the frame and offset from one another by sixty (60) degrees depending on the number of anchors. Generally, the angular offset between the anchors is a function of the number of anchors dispersed about the anchor frame subcomponent 1100, as those of skill will appreciate. In some examples, the angular offset between the anchors is additionally or alternatively based on an arrangement or pattern of the frame members 1112.


In various examples, while the tissue engagement features 1118 project away from the anchor frame subcomponent 1100 when the anchor frame subcomponent 1100 is in the deployed configuration, the tissue engagement features 1118 are stowed or do not otherwise project away from the anchor frame subcomponent 1100 when the anchor frame subcomponent 1100 is compressed in the delivery configuration. Thus, in various examples, the tissue engagement features 1118 are stowable during delivery and are configured to transition to a deployed configuration where they project away from the anchor frame subcomponent 1100. In some examples, a constraining member disposed about the anchor frame subcomponent 1100 during delivery facilitates stowing of the tissue engagement features 1118. In some examples, the tissue engagement features 1118 are stowed in associated apertures or voids 1116 of the anchor frame subcomponent 1100.


In various embodiments, the tissue engagement features 1118 are integral to the anchor frame subcomponent 1100. For example, one or more of the tissue engagement features 1118 are formed in conjunction with and from the same material as the frame members 1112. In other examples, one or more of the tissue engagement features 1118 are separate components additionally or alternatively coupled or attached to the anchor frame subcomponent 1100. For instance, some non-limiting examples include crimping and/or welding one or more tissue engagement features to the anchor frame subcomponent 1100.


Leaflet Materials


For simplicity of discussion, when referring to materials from which leaflets 1230 are made, it is appreciated that the same material may also be used to make one or more portions or an entirety of a leaflet construct comprised of one or more leaflets. Therefore, in this context, the description of leaflet materials applies to options that may be employed for one or more individual leaflets, and also one or more portions of a leaflet construct, as well as for an entirety of the leaflet construct. In the examples that follow, the leaflets that are formed with the leaflet materials described are flexible and are comprised of flexible materials.


Suitable leaflet materials include natural materials (e.g., repurposed tissue, including bovine tissue, porcine tissue, or others), synthetic materials (e.g., biocompatible polymers), and combinations of natural and synthetic materials. Suitable leaflet forming processes include, but are not limited to, casting, molding, extruding, wrapping, coating, imbibing, laminating, combinations thereof and others.


Suitable synthetic leaflet materials include urethanes, silicones (e.g., organopolysiloxanes), copolymers of silicon-urethane, styrene/isobutylene copolymers, polyisobutylene, polyethylene, polyethylene-co-poly(vinyl acetate), polyester copolymers, nylon copolymers, fluorinated hydrocarbon polymers, fluoroelastomers (e.g., copolymers of tetrafluoroethylene and perfluoromethyl vinyl ether (TFE/PMVE copolymer) and (per)fluoroalkylvinylethers (PAVE)), and copolymers and/or mixtures of each of the foregoing and composite materials made therewith. Suitable biocompatible polymers, such as one or more of those described above, may exhibit the physical properties of an elastomer, elastomeric, or non-elastomeric material.


Leaflet materials may include composite materials. Suitable composite leaflet materials include, but are not limited to, one or more membranes combined with one or more polymers. In accordance with some examples, the composite material comprises a membrane material (e.g., porous synthetic polymer membrane) by weight in a range of about 10% to about 90%. The one or more polymers may be coatings or layers on the one or more membranes and/or may be imbibed into the one or more membranes (e.g., where the one or more membranes include a microporous structures), for example. Composite materials may include additional or alternative components, such as but not limited to, inorganic fillers, therapeutic agents, radiopaque markers, and others. In some examples, composite leaflet material includes at least one porous synthetic polymer membrane layer having a plurality of pores and/or spaces and a polymer that is an elastomer and/or an elastomeric material filling the pores and/or spaces. In other examples, the composite leaflet material further comprises a layer or coating of elastomer and/or elastomeric material and/or non-elastomeric material on one or both sides of the composite leaflet material.


Suitable membrane materials that is suitable for use in composite leaflet materials include, but are is not limited to, porous synthetic polymer membranes, such as microporous polyethylene and expanded fluoropolymer membranes such as expanded polytetrafluoroethylene (ePTFE). Such membranes can comprise PTFE homopolymer, blends of PTFE, expandable modified PTFE and/or expanded copolymers of PTFE. As referenced, the membranes may have a microporous structures (e.g., such as ePTFE membranes including a matrix of fibrils defining a plurality of spaces within the matrix).


Suitable polymers of composite leaflet materials include polymers that exhibit elastomer, elastomeric, and/or non-elastomeric material properties. Such polymers may include elastomers and elastomeric materials, such as fluoroelastomers. Examples of suitable polymers include TFE-PMVE copolymers, which may exhibit elastomer, elastomeric, and/or non-elastomeric material properties based on the wt % or mol % of the respective polymers. By way of example of a suitable elastomer, TFE/PMVE copolymer is an elastomer when comprising essentially of between 60 and 20 weight percent tetrafluoroethylene and respectively between 40 and 80 weight percent perfluoromethyl vinyl ether. By way of example of a suitable elastomeric material, TFE/PMVE copolymer is an elastomeric material when comprising essentially of between 67 and 61 weight percent tetrafluoroethylene and respectively between 33 and 39 weight percent perfluoromethyl vinyl ether. By way of example of a suitable non-elastomeric material, TFE/PMVE copolymer is a non-elastomeric material when comprising essentially of between 73 and 68 weight percent tetrafluoroethylene and respectively between 27 and 32 weight percent perfluoromethyl vinyl ether. In the foregoing examples, the TFE and PMVE components of the TFE-PMVE copolymer are presented in wt %. For reference, the wt % of PMVE of 40, 33-39, and 27-32 corresponds to a mol % of 29, 23-28, and 18-22, respectively.


In some examples, the composite leaflet material includes an expanded polytetrafluoroethylene (ePTFE) membrane having been imbibed with TFE-PMVE copolymer comprising from about 60 to about 20 weight percent tetrafluoroethylene and respectively from about 40 to about 80 weight percent perfluoromethyl vinyl ether, the leaflet further including a coating of TFE-PMVE copolymer comprising from about 73 to about 68 weight percent tetrafluoroethylene and respectively about 27 to about 32 weight percent perfluoromethyl vinyl ether on the blood-contacting surfaces. In other examples the leaflet is an ePTFE membrane having been imbibed with TFE-PMVE copolymer comprising from about 70 to about 61 weight percent tetrafluoroethylene and respectively from about 33 to about 39 weight percent perfluoromethyl vinyl ether, the leaflet further including a coating of TFE-PMVE copolymer comprising from about 73 to about 68 weight percent tetrafluoroethylene and respectively about 27 to about 32 weight percent perfluoromethyl vinyl ether on the blood-contacting surfaces.


Although some examples of suitable leaflet materials have been provided, the foregoing examples are not meant to be read in a limiting sense, and additional or alternative materials are contemplated.


In some examples, the leaflet frame cover 1232 and/or the anchor frame cover 1132 and/or connecting sheath 1300 and/or the outflow annular groove cover 1440 may comprise any of the leaflet materials as described above.


Delivery


With reference to FIGS. 10A-10M a non-limiting exemplary deployment sequence and nesting configuration of the prosthetic valve 1000 in-situ during a mitral valve (“W”) replacement procedure is shown, with a cross-section of a portion of the heart for illustrative purposes. In FIG. 10A, the left atrium (“LA”) is accessed transseptally by a delivery device 1500. In various examples, the delivery device 1500 delivered percutaneously and is coupled to a control system 1600 outside of the body. Accessing the left atrium transseptally can be done in accordance with techniques as known those of skilled in the art. Upon gaining access to the left atrium transseptally, the delivery device 1500 is positioned for deployment of the prosthetic valve 1000. For example, as shown in FIG. 10B, the delivery device 1500 is advanced through the mitral valve and into the left ventricle (“LV”). In some examples, advancement of the delivery device 1500 through the mitral valve causes the anterior leaflet (“AL”) and the posterior leaflet (“PL”) of the mitral valve to deflect into the left ventricle.



FIGS. 10A-10M show a cross-sectional view of a heart illustrating an exemplary medical device delivery procedure using a delivery device 1500 to implant a prosthetic valve 1000 into a mitral valve tissue annulus 1930, according to some embodiments. FIG. 10A shows the delivery device 1500 including a constraining sheath 1506 covering the prosthetic valve (1000, hidden from view). The constraining sheath 1506 is a tubular member that is operable to cover at least a portion of the prosthetic valve 1000 while constrained on the delivery device 1500. Covering a portion or all of the prosthetic valve 1000 with the constraining sheath 1506 presents, among other things, a smoother profile when traversing the anatomical structures and/or protection of the prosthetic valve 1000. The delivery device 1500 is entering the left atrium (LA) in a transseptal procedure to access the mitral valve (MV), in this example. The delivery device 1500 is steerable and flexible to traverse the anatomy. FIG. 10B shows the distal end of the delivery device 1500 being positioned through the mitral valve tissue annulus 1930. FIG. 10C shows the constraining sheath 1506 partially retracted to uncover the leaflet frame subcomponent 1200. FIG. 10D shows the constraining sheath 1506 further retracted to fully uncover the connecting sheath 1300 and partially uncover the anchor frame subcomponent 1100. As now seen, the prosthetic valve 1000 is mounted on a delivery catheter 1504 in a pre-deployed, un-nested configuration with the anchor frame subcomponent 1100 and the leaflet frame subcomponent 1200 being longitudinally offset from one another (also referred to as being delivered in series) and coupled together with the connecting sheath 1300 therebetween, which is also shown in FIG. 4. The retention element 1400 is hidden by the connecting sheath 1300.


As previously discussed and shown in FIG. 4, the leaflet frame subcomponent inflow end 1202 of the leaflet frame subcomponent 1200 is positioned distal to the anchor frame subcomponent outflow end 1104 of the anchor frame subcomponent 1100 with the connecting sheath 1300 coupled thereto and positioned therebetween coupling them together.



FIG. 10E shows the constraining sheath 1506 further retracted to fully uncover the anchor frame subcomponent 1100 which allows the flared portion 1130 to expand to a deployed configuration from the constrained configuration. In this example, the constraining sheath 1506 constrained the flared portion 1130, wherein in other examples other means of constraining may be used. The remaining portion of the anchor frame subcomponent 1100 and the leaflet frame subcomponent 1200 remain constrained to the delivery catheter 1504 by constraining elements 1716 as shown in FIG. 4. In various examples, withdrawal of a constraining sheath 1506 releases the flared portion 1130 as shown in FIG. 1B1 or flange element of FIG. 1150 as shown in FIGS. 1B2-1B3 which engages the tissue annulus 1390, as shown in FIGS. 10E-10G. The other portions of the prosthetic valve 1000 are restrained to the delivery catheter 1504 by use of constraining elements 1716 such as fiber loops shown in FIG. 4. The prosthetic valve 1000 may be positioned and oriented within the tissue annulus 1390 by advancing and withdrawing and otherwise manipulating the delivery catheter 1504 or delivery device 1500 as a whole, for a particular purpose, such as to ensure correct orientation and engagement with the anatomical structure of the tissue annulus 1390 and surrounding tissue.



FIG. 10F shows the flared portion 1130 advanced to and placed in contact with the tissue annulus 1390. The delivery catheter 1504 or delivery device 1500 as a whole may be manipulated such that the flared portion 1130 and thus the anchor frame subcomponent 1100 may be positioned and repositioned suitable for a particular purpose. FIG. 10G shows the anchor frame expanded to a larger diameter of the deployed configuration. Before disengagement of the constraining element 1716 that constrains the anchor frame subcomponent 1100 to the delivery catheter 1504, the position of the anchor frame subcomponent 1100 is verified, and if incorrect, the constraining element 1716 may be used, such as by instilling tension to the constraining element 1716 via a tether, for example, to re-constrain the anchor frame subcomponent 1100 back onto the delivery catheter 1504 for repositioning or removal.


In various examples wherein the anchor frame subcomponent 1100 includes tissue engagement features 1118, such as shown in FIGS. 1B1, the constraining element 1716 may constrain the deployment of the tissue engagement features 1118 so as to allow for repositioning or withdrawal of the anchor frame subcomponent 1100 from within the tissue annulus 1390. With the constraining element 1716 constraining the deployment of the tissue engagement features 1118, such as tissue anchors, re-constraining and repositioning of the anchor frame subcomponent 1100 may be done without trauma to the tissue.


In various examples, after the anchor frame subcomponent 1100 is expanded, the anchor frame subcomponent 1100 and the leaflet frame subcomponent 1200 are nested together. In various examples, nesting of the anchor frame subcomponent 1100 and the leaflet frame subcomponent 1200 in-situ involves proximally advancing the leaflet frame subcomponent 1200 relative to the anchor frame subcomponent 1100. FIG. 10H illustrates the leaflet frame subcomponent 1200 as it is proximally advanced relative to the anchor frame subcomponent 1100 as indicated by the arrow. FIG. 10H shows the delivery catheter 1504 being withdrawn from the anchor frame subcomponent 1100 which pulls the connecting sheath 1300 and a portion of the leaflet frame subcomponent within the anchor frame subcomponent 1100 with the connecting sheath 1300 in the process of being everted therebetween.


Alternatively, or in addition thereto, FIG. 10I shows the delivery catheter 1504 being further withdrawn from the anchor frame subcomponent 1100, and/or the pulling of tethers as discussed below, which pulls the connecting sheath 1300 and a portion of the leaflet frame subcomponent 1200 within the anchor frame subcomponent 1100 with the connecting sheath 1300 having been everted therebetween. As shown in FIG. 10I, one or more tether elements 1714 are coupled to the retention element 1400 as shown, and alternatively shown as a lasso or loop in FIG. 7A and discussed further below, which may be used to pull the retention element 1400 through the anchor frame subcomponent 1100, and therefore also pull the leaflet frame subcomponent 1200 therewith into the anchor frame subcomponent 1100.


As will be discussed below, if it is required to remove the prosthetic valve 1000 from the heart at this point in the deployment, the leaflet frame subcomponent 1200 may be recompressed by the tether elements 1714 and the tether elements 1714 may be used to pull the retention element 1400, and thus the leaflet frame subcomponent 1200 and subsequently the anchor frame subcomponent 1100 into the constraining sheath 1506 or a larger retrieval sheath 1950, shown in FIGS. 9A-9D, that had been advanced over the delivery device 1500. In this case, the anchor frame subcomponent 1100 is caused to evert initiating at the anchor frame subcomponent outflow end 1104 such that it is drawn, peeled or pulled away from the tissue annulus 1930, such as illustrated in FIGS. 9A-9D. Thus, this method provides a means for removing a prosthetic valve 1000 that is experiencing a failed deployment without the need for invasive surgical care.


In various examples, after the leaflet frame subcomponent 1200 is nested and expanded within the anchor frame subcomponent 1100, the tether elements 1714 are loosened allowing the retention element 1400 to expand and rotate downward from the leaflet frame subcomponent 1200 under spring bias as shown in FIG. 10J so as to fully deploy over the anchor frame subcomponent inflow end 1102 as shown in FIG. 10K. The delivery catheter 1504 may be withdrawn from the prosthetic valve 1000, as shown in FIG. 10L, so as to verify that the leaflets 1230 are properly functioning prior to releasing the tether elements 1714 from the retention element 1400. If the leaflets 1230 are not functioning properly, the delivery catheter 1504 may be advanced adjacent to or within the leaflet frame subcomponent 1200 and the prosthetic valve 1000 removed with the procedure discussed above.


Further, additional tethers may be coupled to the leaflet frame subcomponent inflow end 1202 operable to constrain and pull the leaflet frame subcomponent 1200 out of the anchor frame subcomponent 1100 as discussed before in reference to FIGS. 9A-9D.



FIG. 10L shows the prosthetic valve 1000 fully deployed within the tissue annulus 1390 of the mitral valve (MV). The prosthetic valve 1000 is in a fully deployed configuration wherein the anchor frame subcomponent 1100 and the leaflet frame subcomponent 1200 are nested. The prosthetic valve 1000 is fully deployed and operational upon the retention element 1400 engaging the anchor frame subcomponent inflow end 1102 which minimizes relative axial translation between the anchor frame subcomponent 1100 and the leaflet frame subcomponent 1200.


In various examples, the longitudinal separation or offset of the anchor frame subcomponent 1100 and the leaflet frame subcomponent 1200 provides for a low profile delivery configuration that can be easily tracked through the vasculature of the patient. For instance, by longitudinally offsetting the anchor frame subcomponent 1100 and the leaflet frame subcomponent 1200, a profile of the delivery system can be minimized because, unlike conventional designs, the anchor frame subcomponent 1100 and the leaflet frame subcomponent 1200 do not overlap one another during delivery. In some examples, a maximum profile of the delivery device 1500 including the prosthetic valve 1000 can be 8 mm or less.


Additionally, as shown in FIGS. 4 and 10D, a region 1502 of the delivery device 1500 positioned between the anchor frame subcomponent 1100 and the leaflet frame subcomponent 1200 and adjacent to the connecting sheath 1300 and retention element 1400 is operable to bend such that the anchor frame subcomponent 1100 and the leaflet frame subcomponent 1200 are temporarily misaligned with one another. In some examples, such a configuration is akin to rail cars navigating a curve. Such a configuration is beneficial in procedures where the prosthetic valve 1000 is delivered to a treatment region transseptally, which may require a delivery device to bend ninety (90) degrees or more within the left atrium of the heart.


Additionally, as shown in FIG. 1A, the tissue engagement features 1118 of the anchor frame subcomponent 1100 extend away from the anchor frame subcomponent 1100 and engage the tissue of the native valve orifice surrounding the prosthetic valve 1000. In some examples, the tissue engagement features 1118 are configured to penetrate the tissue or otherwise embed within the tissue. In various examples, this interaction of the tissue engagement features 1118 of the anchor frame subcomponent 1100 with the native tissue surrounding the prosthetic valve 1000 operates to secure the anchor frame subcomponent 1100 (and thus the leaflet frame subcomponent 1200) to the native tissue of the tissue annulus 1390.


The anchor frame subcomponent inflow end 1102 of the anchor frame subcomponent 1100 illustrated in FIGS. 10B-10M is flared radially outward and is situated adjacent to and in abutment with the native valve tissue annulus 1390, as shown. In some examples, such a configuration provides that the anchor frame subcomponent inflow end 1102 of the anchor frame subcomponent 1100 obstructs or otherwise limits the extent to which the anchor frame subcomponent 1100 is operable to extend through the native valve. For instance, in the case of a mitral valve replacement, such a flared anchor frame subcomponent inflow end 1102 limits the extent to which the anchor frame subcomponent 1100 can be advanced through the natural mitral valve orifice and into the left ventricle. In some examples, such flared anchor frame subcomponent inflow end 1102 additionally operates to minimize the potential for the anchor frame subcomponent 1100 to migrate distally.


While the embodiments and examples illustrated and described above pertain to trans-septal delivery, it should be appreciated that a variety of additional well-known delivery procedures can be utilized without departing from the spirit or scope of the present application. Additional non-limiting delivery procedures include trans-apical, left atriotomy, and trans-aortic. Generally, regardless of the particular delivery procedure, those of skill should appreciate that after deploying the prosthetic valve 1000, the leaflet frame subcomponent 1200 and the anchor frame subcomponent 1100 are nested by proximally advancing the leaflet frame subcomponent 1200 relative to the anchor frame subcomponent 1100.


Tissue Ingrowth Materials and Modifications


In various embodiments, one or more portions of the prosthetic valve 1000, such as the leaflets 1230, are constructed in a manner that promotes tissue ingrowth. In some embodiments, the leaflets 1230 and/or other portions of the valve 1000 may be constructed to encourage tissue ingrowth and proliferation across one or more discrete regions, portions, or sections of one or more of the materials forming the prosthetic valve 1000, or alternatively across an entirety of one or more of the materials forming the prosthetic valve 1000, such as the leaflets 1230. Tissue ingrowth and proliferation may be promoted on an outflow side or surface of such materials, and/or on an inflow side or surface of such materials, and/or within one or more such materials.


In various embodiments, materials configured to promote tissue ingrowth include a composite material combined with a tissue ingrowth curtain that may be incorporated into the composite material and/or coupled to the composite material.


In various embodiments, one or more portions of the leaflet frame subcomponent 1230 may be covered with material suitable for promoting tissue ingrowth. For example, the leaflet frame subcomponent 1230 can be wrapped with a material, suitable for promoting tissue ingrowth. In various examples, such tissue ingrowth promoting materials can be applied to the leaflet frame subcomponent 1230 entirely, or alternatively to less than all of the leaflet frame subcomponent 1230. For example, suitable materials for promoting tissue ingrowth could be coupled to the leaflet frame inner surface and the leaflet frame outer surface of the leaflet frame. Some nonlimiting examples of materials that can be applied to the leaflet frame subcomponent 1230 (or other portions of the prosthetic valve 1000) include expanded polytetrafluoroethylene (ePTFE), such as an ePTFE membrane, as well as fabric, film, or coating, and a polyethylene terephthalate fabric (e.g., Dacron fabric).


According to some examples, as will be discussed in greater detail below, this promotion of tissue ingrowth is facilitated by the coupling of one or more synthetic tissue ingrowth curtains to one or more composite materials such that tissue is encouraged to grow (or is not otherwise prevented or inhibited from growing) into and/or onto the one or more tissue ingrowth curtains. That is, in some examples, one or more layers configured to promote tissue ingrowth may be applied to the composite material. In some examples, as described herein, the underlying material may be configured to inhibit or prevent tissue ingrowth.


Additionally or alternatively, in some examples, this promotion of tissue ingrowth is facilitated by selectively imbibing, such as with one or more fluoroelastomers, one or more portions of the one or more materials forming the leaflet 1230 and/or other portions of the prosthetic valve 1000. Reference to “selectively imbibing” is referring to the act of imbibing a porous material with a filling material at selected portions of the porous material or to a lesser degree leaving a degree of porosity of the porous material.


That is, in some examples, in addition to or as an alternative to coupling one or more synthetic tissue ingrowth curtains to one or more composite materials, the composite material as discussed above regarding leaflet materials is configured to promote or accommodate tissue ingrowth. In some such examples, as discussed in greater detail below, the composite material is configured such that tissue is encouraged to grow (or is not otherwise prevented or inhibited from growing) into and/or onto one or more discrete or designated sections, portions, or regions of the composite material by way of selectively imbibing the membrane associated with those portions.


In various embodiments, the tissue ingrowth curtain generally includes an expanded fluoropolymer membrane which comprises a plurality of spaces within a matrix of fibrils that is suitable for promoting and supporting the ingrowth of tissue. Other nonlimiting example materials include other biocompatible porous materials such as knit PTFE. However, as mentioned above, and as discussed in greater detail below, in some examples the tissue ingrowth curtain(s) may be applied to the composite material in the form of one or more coatings.


In some examples, the tissue ingrowth curtain includes an expanded fluoropolymer made from a porous ePTFE membrane. However, it is appreciated that the tissue ingrowth curtain may be formed from a number of different types of membranes, including other fluoropolymer membranes, and other biocompatible porous materials such as porous polyethylene membrane and knit PTFE. For instance, the expandable fluoropolymer can comprise PTFE homopolymer. In some examples, the tissue ingrowth curtain can be formed from copolymers of hexafluoropropylene and tetrafluoroethylene, such as Fluorinated Ethylene Propylene (FEP). In some examples, blends of PTFE, expandable modified PTFE and/or expanded copolymers of PTFE can be used. It will thus be appreciated that the tissue ingrowth curtain may be formed from a variety of different polymeric materials provided they are biocompatible and possess or are modified to include a suitable microstructure suitable for promoting or supporting tissue ingrowth. In various examples, the tissue ingrowth curtains may range in thickness from between one micron and four hundred microns depending on the selected material.


In some examples, the polymeric material may include one or more naturally occurring and/or one or more artificially created pores, reliefs, channels, and/or predetermined surface topology, suitable for supporting tissue ingrowth. Other biocompatible materials which can be suitable for use in forming the tissue ingrowth curtain include but are not limited to the groups of urethanes, fluoropolymers, styrene/isobutylene copolymers, polyisobutylene, polyethylene-co-poly(vinyl acetate), polyester copolymers, nylon copolymers, fluorinated hydrocarbon polymers and copolymers or mixtures of each of the foregoing.


While the above-discussed tissue ingrowth curtains generally include membranes, films, knits, or other structures that are bonded, applied, or otherwise attached to the composite material, as mentioned above, in some examples the tissue ingrowth curtain(s) may be applied to the composite material in the form of one or more coatings. In some such example, a coherent irregular network is distributed or deposited onto one or more portions, regions, sections, areas, or zones of the composite material. In some examples, the coherent irregular network is applied to one or more portions of the composite material to create a surface texture suitable for supporting the ingrowth and proliferation of tissue, as those of skill will appreciate. For example, the coherent irregular network may be selectively applied to one or more discrete or designated sections, portions, or regions of the composite material. In some such examples, the coherent irregular network is applied to the designated areas by masking or otherwise covering those portions of the underlying leaflet, or other portion of the prosthetic valve 1000, where ingrowth of tissue is undesirable such that the cover or mask can be removed subsequent to the coherent irregular network application process to achieve a material having a first region including the coherent irregular network and a second region free of a coherent irregular network.


In some examples, one or more sacrificial sheets, such as one or more polyimide sheets (e.g., Kapton sheets), are arranged on the composite material and operate to mask or otherwise prevent the coherent irregular network from being applied to the masked or covered areas. Some nonlimiting examples of sacrificial sheet materials include polyester, polyetheretherketone (PEEK), PET, ePTFE/Kapton blends such as mapton, ePTFE, PTFE, silicones, and stainless steel, or other thin metal sheeting. In some examples, the one or more sacrificial sheets can be removed after the coherent irregular network application process to reveal a structure including one or more regions including the coherent irregular network and one or more regions free of the coherent irregular network (e.g., where the underlying composite material is exposed). Such a configuration provides for a construction that minimizes a possibility for delamination between bonded membrane layers.


As mentioned above, in some examples, in addition to or as an alternative to applying one or more tissue ingrowth curtains to the composite material, the composite material is configured to promote or accommodate tissue ingrowth. For instance, in some examples, the composite material is configured such that tissue is encouraged to grow (or is not otherwise prevented or inhibited from growing) into and/or onto one or more discrete or designated sections, portions, or regions of the composite material. For instance, as mentioned above, the composite material may include an elastomer and/or an elastomeric material such as a fluoroelastomer imbibed or otherwise incorporated into the expanded fluoropolymer membrane. In various examples, to achieve a composite material that promotes or otherwise accommodates the ingrowth and proliferation of tissue the expanded fluoropolymer membrane is selectively imbibed, such as with one or more fluoroelastomers, such that the expanded fluoropolymer membrane includes one or more discrete portions, regions, sections, zones, or areas that are free of or are not otherwise imbibed with the elastomeric filler material (or at least are not filled to the extent that the elastomeric filler material operates to prevent tissue ingrowth). Selectively imbibing the membrane material of the composite material may be done in accordance with techniques as known to those of skill in the art.


While the above discussed embodiments and examples include applying a tissue ingrowth curtain to one or more portions of one or more surfaces of the composite material, or selectively imbibing one or more portions of one or more sides of a membrane of the composite material with a filler material, it will be appreciated that, in various examples, a leaflet, and/or other features of the prosthetic valve 1000, may be constructed by both imbibing one or more portions of the membrane and applying a tissue ingrowth curtain to the selectively imbibed membrane.


In various examples, the membrane may be imbibed with a plurality of filler materials. That is, in some examples, a first portion, area, region, section, or zone of the membrane of composite material may be imbibed with a first filler material while a second portion, area, region, section, or zone of the membrane of the composite material is imbibed with a second filler material. For instance, in some examples, a first portion of the membrane of the composite material is imbibed with a first filler material such that the first portion of the membrane is resistant to or otherwise inhibits or prevents tissue ingrowth into and/or onto and/or across the first portion. However, in some examples, those portions of the membrane imbibed with the first filler may also be unsuitable for accommodating the bonding or coupling of a tissue ingrowth curtain. Accordingly, in examples where it is desirable bond or otherwise couple a tissue ingrowth material to a second portion of the membrane, the second portion may be imbibed with a second filler material such that the second portion of the membrane is suited to have a tissue ingrowth curtain bonded or otherwise coupled thereto. In some examples, the second filler material may additionally or alternatively encourage tissue ingrowth. That is, in some examples, one or more portions of the membrane may be imbibed with a filler material that encourages tissue ingrowth and proliferation. Alternatively, as mentioned above, the second portion may not be imbibed with any filler material at all, but may instead remain free of filler material.


In some examples, the method includes applying an adhesive to the membrane in addition to or as an alternative to applying the adhesive to the tissue ingrowth curtain, as discussed above. In some examples, an adhesive, such as FEP, is similarly wicked or imbibed into one or more portions of the membrane, after which the tissue ingrowth curtain and the membrane are pressed together and/or heat set according to known methods.


In some other examples, in addition to or as an alternative to applying adhesives to the tissue ingrowth curtain and the membrane separately or individually, the tissue ingrowth curtain (e.g., having a designated pattern) and the membrane are layered with one or more adhesives or adhesive layers therebetween, after which the layered construct is pressed and/or heat set according to known methods. The method further includes cutting the leaflet, and/or other feature of the prosthetic valve 1000, from the resulting construct according to known methods. In some examples, a final free edge cutting operation may be performed on the formed material to achieve a clean free edge according to known methods, as those of skill will appreciate.


Bio-Active Agents


Any of a variety of bio-active agents may be implemented with the materials of the prosthetic valve 1000. For example, any one or more of the leaflets 1230 and/or the leaflet frame cover 1232 and/or the anchor frame cover 1132 and/or connecting sheath 1300 and/or the outflow annular groove cover 1440 (including portions thereof) may comprise a bio-active agent. Bio-active agents can be coated onto one or more of the foregoing features for controlled release of the agents once the prosthetic valve 1000 is implanted. Such bio-active agents can include, but are not limited to, thrombogenic agents such as, but not limited to, heparin. Bio-active agents can also include, but are not limited to agents such as anti-proliferative/antimitotic agents including natural products such as vinca alkaloids (e.g., vinblastine, vincristine, and vinorelbine), paclitaxel, epidipodophyllotoxins (e.g., etoposide and teniposide), antibiotics (e.g., dactinomycin (actinomycin D), daunorubicin, doxorubicin, and idarubicin), anthracyclines, mitoxantrone, bleomycins, plicamycin (mithramycin) and mitomycin, enzymes (e.g., L-asparaginase which systemically metabolizes L-asparagine and deprives cells which do not have the capacity to synthesize their own asparagine); antiplatelet agents such as G(GP) IIb/IIIa inhibitors and vitronectin receptor antagonists; anti-proliferative/antimitotic alkylating agents such as nitrogen mustards (e.g., mechlorethamine, cyclophosphamide and analogs, melphalan, chlorambucil), ethylenimines and methylmelamines (e.g., hexamethylmelamine and thiotepa), alkyl sulfonates-busulfan, nitrosoureas (e.g., carmustine (BCNU) and analogs, streptozocin), trazenes-dacarbazinine (DTIC); anti-proliferative/antimitotic antimetabolites such as folic acid analogs (e.g., methotrexate), pyrimidine analogs (e.g., fluorouracil, floxuridine, and cytarabine), purine analogs and related inhibitors (e.g., mercaptopurine, thioguanine, pentostatin and 2-chlorodeoxyadenosine {cladribine}); platinum coordination complexes (e.g., cisplatin and carboplatin), procarbazine, hydroxyurea, mitotane, aminoglutethimide; hormones (e.g., estrogen); anti-coagulants (e.g., heparin, synthetic heparin salts and other inhibitors of thrombin); anti-platelet agents (e.g., aspirin, clopidogrel, prasugrel, and ticagrelor); vasodilators (e.g., heparin, aspirin); fibrinolytic agents (e.g., plasminogen activator, streptokinase, and urokinase), aspirin, dipyridamole, ticlopidine, clopidogrel, abciximab; antimigratory agents; antisecretory agents (e.g., breveldin); anti-inflammatory agents, such as adrenocortical steroids (e.g., cortisol, cortisone, fludrocortisone, prednisone, prednisolone, 6α-methylprednisolone, triamcinolone, betamethasone, and dexamethasone), non-steroidal agents (e.g., salicylic acid derivatives, such as aspirin); para-aminophenol derivatives (e.g., acetaminophen); indole and indene acetic acids (e.g., indomethacin, sulindac, and etodalac), heteroaryl acetic acids (e.g., tolmetin, diclofenac, and ketorolac), arylpropionic acids (e.g., ibuprofen and derivatives), anthranilic acids (e.g., mefenamic acid and meclofenamic acid), enolic acids (e.g., piroxicam, tenoxicam, phenylbutazone, and oxyphenthatrazone), nabumetone, gold compounds (e.g., auranofin, aurothioglucose, and gold sodium thiomalate); immunosuppressives (e.g., cyclosporine, tacrolimus (FK-506), sirolimus (rapamycin), azathioprine, and mycophenolate mofetil); angiogenic agents (e.g., vascular endothelial growth factor (VEGF)), fibroblast growth factor (FGF); angiotensin receptor blockers; nitric oxide donors; anti-sense oligonucleotides and combinations thereof; cell cycle inhibitors, mTOR inhibitors, growth factor receptor signal transduction kinase inhibitors; retinoids; cyclin/CDK inhibitors; HMG co-enzyme reductase inhibitors (statins); and protease inhibitors.


The scope of the concepts addressed in this disclosure has been described above both generically and with regard to specific examples. It will be apparent to those skilled in the art that various modifications and variations can be made in the examples without departing from the scope of the disclosure. Likewise, the various components discussed in the examples discussed herein are combinable. Thus, it is intended that the examples cover the modifications and variations of the scope.

Claims
  • 1. A prosthetic valve transitionable between a delivery configuration and a deployed, nested configuration in-situ, the prosthetic valve comprising: a leaflet frame subcomponent defining a tubular shape and having a leaflet frame subcomponent wall extending from a leaflet frame subcomponent inflow end and a leaflet frame subcomponent outflow end and the leaflet frame subcomponent defining a leaflet frame subcomponent lumen, the leaflet frame subcomponent including a one-way valve;an anchor frame subcomponent defining a tubular shape and having an anchor frame subcomponent inflow end and an anchor frame subcomponent outflow end, and the anchor frame subcomponent defining an anchor frame subcomponent lumen;a connecting sheath defining a tubular shape and having a connecting sheath inflow end coupled to the anchor frame subcomponent outflow end and a connecting sheath outflow end coupled to the leaflet frame subcomponent inflow end coupling the leaflet frame subcomponent to the anchor frame subcomponent, and the connecting sheath defining a connecting sheath lumen; anda retention element having a retention element first end and a retention element second end, the retention element second end being coupled to the connecting sheath outflow end, the retention element being pivotable about the retention element second end upon translation of the retention element within the anchor frame subcomponent lumen towards the anchor frame subcomponent inflow end, such that the retention element extends from the leaflet frame subcomponent inflow end to the anchor frame subcomponent inflow end;wherein when the prosthetic valve is in the delivery configuration, the leaflet frame subcomponent and the anchor frame subcomponent are longitudinally offset from one another such that the leaflet frame subcomponent inflow end is situated distal of the anchor frame subcomponent outflow end, wherein the retention element resides within the connecting sheath lumen and extends away from the leaflet frame subcomponent inflow end and substantially parallel with a longitudinal axis of the leaflet frame subcomponent and adjacent to the connecting sheath,wherein, when the prosthetic valve is in the deployed, nested configuration, the anchor frame subcomponent inflow end flares or tapers radially outward,wherein, when the prosthetic valve is in the deployed, nested configuration, the connecting sheath is everted and the leaflet frame subcomponent is at least partially nested within the anchor frame subcomponent lumen, the retention element has translated within the anchor frame subcomponent lumen towards the anchor frame subcomponent inflow end, and the retention element is biased outwardly against the anchor frame subcomponent with an outward bias such that the retention element extends from the leaflet frame subcomponent inflow end to the anchor frame subcomponent inflow end, andwherein the prosthetic valve is transitionable between the delivery configuration and a deployed, nested configuration via an expanded pre-deployed, un-nested configuration.
  • 2. The prosthetic valve of claim 1, wherein the leaflet frame subcomponent includes a leaflet frame defining a leaflet frame wall, one or more leaflets, and leaflet frame cover, the leaflet frame is generally tubular shaped defining a leaflet frame inflow end and a leaflet frame outflow end with a leaflet frame lumen therethrough.
  • 3. The prosthetic valve of claim 2, wherein the leaflet frame wall of the leaflet frame is at least partially covered with the leaflet frame cover configured to restrict fluid from passing through the covered portion of the leaflet frame wall.
  • 4. The prosthetic valve of claim 2, wherein the one or more leaflets are operable to open to allow flow from the leaflet frame subcomponent inflow end and to pass through the leaflet frame subcomponent outflow end in antegrade flow conditions, and are operable to close to restrict flow from flowing from the leaflet frame subcomponent outflow end through the leaflet frame subcomponent inflow end in retrograde flow conditions.
  • 5. The prosthetic valve of claim 2, wherein the leaflets comprise a composite material including a porous synthetic fluoropolymer membrane defining pores and an elastomer or elastomeric material filling the pores.
  • 6. The prosthetic valve of claim 1, wherein the anchor frame subcomponent includes an anchor frame and an anchor frame cover, the anchor frame defines a generally tubular shape extending between the anchor frame subcomponent inflow end and the anchor frame subcomponent outflow end, an anchor frame inner surface and an anchor frame outer surface defining an anchor frame wall, the anchor frame s at least partially covered with the anchor frame cover to restrict fluid from passing through the anchor frame wall.
  • 7. The prosthetic valve of claim 6, wherein, when the prosthetic valve is in the deployed, nested configuration, the anchor frame defines a flared portion at the anchor frame subcomponent inflow end that flares or tapers radially outward.
  • 8. The prosthetic valve of claim 6, wherein the connecting sheath is contiguous with the anchor frame cover and the leaflet frame cover.
  • 9. The prosthetic valve of claim 6, wherein the leaflet frame subcomponent includes a leaflet frame defining a leaflet frame wall, one or more leaflets, and leaflet frame cover, the leaflet frame is generally tubular shaped defining a leaflet frame inflow end and a leaflet frame outflow end with a leaflet frame lumen therethrough and, wherein the retention element is coupled to the connecting sheath between the leaflet frame and the anchor frame such that the retention element is operable to maintain the nested configuration of the anchor frame subcomponent and the leaflet frame subcomponent.
  • 10. The prosthetic valve of claim 1, wherein the prosthetic valve has a smaller diameter in the delivery configuration than in the deployed, nested configuration.
  • 11. The prosthetic valve of claim 1, wherein, in the deployed, nested configuration, the anchor frame subcomponent has an anchor frame subcomponent inner surface having a diameter at least slightly larger than a leaflet frame subcomponent outer surface of the leaflet frame subcomponent and the leaflet frame subcomponent is nested within the anchor frame subcomponent.
  • 12. The prosthetic valve of claim 1, wherein the connecting sheath is a thin-walled flexible tubular member having a connecting sheath inner surface that defines a connecting sheath lumen in fluid communication with the anchor frame subcomponent lumen and the leaflet frame subcomponent lumen, and wherein the connecting sheath is operable to fold and evert when the leaflet frame subcomponent is advanced from the pre-deployed, un-nested configuration to the deployed, nested configuration so as to lie between the leaflet frame subcomponent and the anchor frame subcomponent.
  • 13. The prosthetic valve of claim 1, wherein the connecting sheath comprises flow enabling features in a wall of the connecting sheath, the wall extending between the connecting sheath inflow end and the connecting sheath outflow end, wherein the flow enabling features are operable to allow antegrade fluid flow through the connecting sheath wall and restrict retrograde flow through the connecting sheath wall when the leaflet frame subassembly is not in the deployed, nested configuration.
  • 14. The prosthetic valve of claim 1, wherein the connecting sheath comprises an inner film layer and an outer film layer, the inner film layer and the outer film layer being coupled together at least at the anchor frame subcomponent outflow end, the inner film layer defining at least one inner aperture therethrough adjacent the anchor frame subcomponent outflow end, the inner film layer and the outer film layer being not coupled at least downstream of the at least one inner apertures so as to define a flow space therebetween operable to permit antegrade blood flow with the inner film layer separating from the outer film layer at the at least one inner aperture and so as to restrict retrograde flow therethrough with the inner film layer coming together and covering the at least one inner aperture when the leaflet frame subcomponent is not in the deployed, nested configuration in the anchor frame subcomponent, and is operable to restrict antegrade and retrograde flow when the leaflet frame subcomponent is in the deployed, nested configuration within the anchor frame subcomponent.
  • 15. The prosthetic valve of claim 1, wherein, when the prosthetic valve is in the deployed, nested configuration, the retention element is configured to cover an inflow annular groove formed between the anchor frame subcomponent, the everted connecting sheath, and the leaflet frame subcomponent.
  • 16. The prosthetic valve of claim 1, wherein the retention element is an elongated element that is operable to extend generally parallel to a central, longitudinal axis X of the prosthetic valve when in the pre-deployed configuration, and operable to extend at an angle to the axis X when in the deployed configuration.
  • 17. The prosthetic valve of claim 1, wherein the retention element is operable to translate through the anchor frame subcomponent during transition of the prosthetic valve between the delivery configuration and the deployed, nested configuration and the connecting sheath is operable to fold and evert within the anchor frame subcomponent lumen and lie between the leaflet frame subcomponent and the anchor frame subcomponent during transition of the prosthetic valve between the delivery configuration and the deployed, nested configuration.
  • 18. The prosthetic valve of claim 1, wherein the retention element has an outward bias towards a planar position and operable to retain a relative position of the leaflet frame subcomponent and the anchor frame subcomponent by virtue of the outward bias.
  • 19. The prosthetic valve of claim 1, wherein a length of the anchor frame subcomponent varies along its circumference wherein the anchor frame subcomponent outflow end has a tapered geometry operable such that, when the prosthetic valve is placed in a mitral valve annulus, the anchor frame subcomponent outflow end may extend further into a left ventricle adjacent to a posterior side of the left ventricle and extends less into a LVOT on an anterior side of the left ventricle.
  • 20. The prosthetic valve of claim 1, wherein a hoop strength of the anchor frame subcomponent is variable along a length and/or a circumference of the anchor frame subcomponent such that the anchor frame subcomponent has an anterior portion having a greater stiffness than posterior portion of the anchor frame subcomponent.
  • 21. The prosthetic valve of claim 1, wherein the anchor frame subcomponent is evertible such that the prosthetic valve may be removed from the tissue annulus.
  • 22. The prosthetic valve of claim 1, wherein the anchor frame subcomponent includes one or more tissue engagement features that project away from an anchor frame outer surface of the anchor frame subcomponent and are operable to engage a tissue annulus.
  • 23. The prosthetic valve of claim 1, further comprising an outflow annular groove cover extending from the anchor frame subcomponent outflow end and the leaflet frame subcomponent outflow end.
  • 24. The prosthetic valve of claim 23, wherein the outflow annular groove cover is configured to be blood permeable under physiologic conditions prior to the prosthetic valve being transitioned to the deployed, nested configuration.
  • 25. The prosthetic valve of claim 23, wherein the outflow annular groove cover is configured to be less permeable to blood under physiologic conditions when the prosthetic valve is in the deployed, nested configuration than when the prosthetic valve is not in the deployed, nested configuration.
  • 26. A prosthetic valve transitionable between a delivery configuration and a deployed, nested configuration in-situ, the prosthetic valve comprising: a leaflet frame subcomponent defining a tubular shape and having a leaflet frame subcomponent wall extending from a leaflet frame subcomponent inflow end and a leaflet frame subcomponent outflow end and the leaflet frame subcomponent defining a leaflet frame subcomponent lumen, the leaflet frame subcomponent including a one-way valve;an anchor frame subcomponent defining a tubular shape and having an anchor frame subcomponent inflow end and an anchor frame subcomponent outflow end, and the anchor frame subcomponent defining an anchor frame subcomponent lumen;a connecting sheath defining a tubular shape and having a connecting sheath inflow end coupled to the anchor frame subcomponent outflow end and a connecting sheath outflow end coupled to the leaflet frame subcomponent inflow end coupling the leaflet frame subcomponent to the anchor frame subcomponent, and the connecting sheath defining a connecting sheath lumen; anda retention element having a retention element first end and a retention element second end, the retention element second end being coupled to the connecting sheath outflow end,wherein when the prosthetic valve is in the delivery configuration, the leaflet frame subcomponent and the anchor frame subcomponent are longitudinally offset from one another such that the leaflet frame subcomponent inflow end is situated distal of the anchor frame subcomponent outflow end, wherein the retention element resides within the connecting sheath lumen and extends away from the leaflet frame subcomponent inflow end and substantially parallel with a longitudinal axis of the leaflet frame subcomponent and adjacent to the connecting sheath,wherein, when the prosthetic valve is in the deployed, nested configuration, the anchor frame subcomponent inflow end flares or tapers radially outward, wherein, when the prosthetic valve is in the deployed, nested configuration, the connecting sheath is everted and the leaflet frame subcomponent is at least partially nested within the anchor frame subcomponent lumen, the retention element has translated within the anchor frame subcomponent lumen towards the anchor frame subcomponent inflow end, and the retention element is biased outwardly against the anchor frame subcomponent with an outward bias such that the retention element extends from the leaflet frame subcomponent inflow end to the anchor frame subcomponent inflow end,wherein the leaflet frame subcomponent includes a leaflet frame defining a leaflet frame wall, one or more leaflets, and leaflet frame cover, the leaflet frame is generally tubular shaped defining a leaflet frame inflow end and a leaflet frame outflow end with a leaflet frame lumen therethrough, andwherein the retention element second end is not directly coupled to the leaflet frame at the leaflet frame subcomponent inflow end, there being a portion of the connecting sheath therebetween.
  • 27. A prosthetic valve transitionable between a delivery configuration and a deployed, nested configuration in-situ, the prosthetic valve comprising: a leaflet frame subcomponent defining a tubular shape and having a leaflet frame subcomponent wall extending from a leaflet frame subcomponent inflow end and a leaflet frame subcomponent outflow end and the leaflet frame subcomponent defining a leaflet frame subcomponent lumen, the leaflet frame subcomponent including a one-way valve;an anchor frame subcomponent defining a tubular shape and having an anchor frame subcomponent inflow end and an anchor frame subcomponent outflow end, and the anchor frame subcomponent defining an anchor frame subcomponent lumen;a connecting sheath defining a tubular shape and having a connecting sheath inflow end coupled to the anchor frame subcomponent outflow end and a connecting sheath outflow end coupled to the leaflet frame subcomponent inflow end coupling the leaflet frame subcomponent to the anchor frame subcomponent, and the connecting sheath defining a connecting sheath lumen; anda retention element having a retention element first end and a retention element second end, the retention element second end being coupled to the connecting sheath outflow end,wherein when the prosthetic valve is in the delivery configuration, the leaflet frame subcomponent and the anchor frame subcomponent are longitudinally offset from one another such that the leaflet frame subcomponent inflow end is situated distal of the anchor frame subcomponent outflow end, wherein the retention element resides within the connecting sheath lumen and extends away from the leaflet frame subcomponent inflow end and substantially parallel with a longitudinal axis of the leaflet frame subcomponent and adjacent to the connecting sheath,wherein, when the prosthetic valve is in the deployed, nested configuration, the anchor frame subcomponent inflow end flares or tapers radially outward, wherein, when the prosthetic valve is in the deployed, nested configuration, the connecting sheath is everted and the leaflet frame subcomponent is at least partially nested within the anchor frame subcomponent lumen, the retention element has translated within the anchor frame subcomponent lumen towards the anchor frame subcomponent inflow end, and the retention element is biased outwardly against the anchor frame subcomponent with an outward bias such that the retention element extends from the leaflet frame subcomponent inflow end to the anchor frame subcomponent inflow end, andwherein the connecting sheath comprises an inner film layer and an outer film layer, the inner film layer and the outer film layer being coupled together at least at the leaflet frame subcomponent inflow end and the anchor frame subcomponent outflow end, the inner film layer defining at least one inner aperture therethrough adjacent the anchor frame subcomponent outflow end and the outer film layer defines at least one outer aperture therethrough adjacent the leaflet frame subcomponent, the inner film layer and the outer film layer being not coupled at least between one of the inner apertures and one of the outer apertures so as to define a flow space therebetween operable to permit antegrade blood flow and restrict retrograde flow therethrough when the leaflet frame subcomponent is not in the deployed, nested configuration in the anchor frame subcomponent, and is operable to restrict antegrade and retrograde flow when the leaflet frame subcomponent is in the deployed, nested configuration within the anchor frame subcomponent.
  • 28. A prosthetic valve transitionable between a delivery configuration and a deployed, nested configuration in-situ, the prosthetic valve comprising: a leaflet frame subcomponent defining a tubular shape and having a leaflet frame subcomponent wall extending from a leaflet frame subcomponent inflow end and a leaflet frame subcomponent outflow end and the leaflet frame subcomponent defining a leaflet frame subcomponent lumen, the leaflet frame subcomponent including a one-way valve;an anchor frame subcomponent defining a tubular shape and having an anchor frame subcomponent inflow end and an anchor frame subcomponent outflow end, and the anchor frame subcomponent defining an anchor frame subcomponent lumen;a connecting sheath defining a tubular shape and having a connecting sheath inflow end coupled to the anchor frame subcomponent outflow end and a connecting sheath outflow end coupled to the leaflet frame subcomponent inflow end coupling the leaflet frame subcomponent to the anchor frame subcomponent, and the connecting sheath defining a connecting sheath lumen; anda retention element having a retention element first end and a retention element second end, the retention element second end being coupled to the connecting sheath outflow end,wherein when the prosthetic valve is in the delivery configuration, the leaflet frame subcomponent and the anchor frame subcomponent are longitudinally offset from one another such that the leaflet frame subcomponent inflow end is situated distal of the anchor frame subcomponent outflow end, wherein the retention element resides within the connecting sheath lumen and extends away from the leaflet frame subcomponent inflow end and substantially parallel with a longitudinal axis of the leaflet frame subcomponent and adjacent to the connecting sheath,wherein, when the prosthetic valve is in the deployed, nested configuration, the anchor frame subcomponent inflow end flares or tapers radially outward, wherein, when the prosthetic valve is in the deployed, nested configuration, the connecting sheath is everted and the leaflet frame subcomponent is at least partially nested within the anchor frame subcomponent lumen, the retention element has translated within the anchor frame subcomponent lumen towards the anchor frame subcomponent inflow end, and the retention element is biased outwardly against the anchor frame subcomponent with an outward bias such that the retention element extends from the leaflet frame subcomponent inflow end to the anchor frame subcomponent inflow end, andwherein the retention element further includes a non-permeable cover and wherein, when the prosthetic valve is in the deployed, nested configuration, an inflow annular groove is defined by the anchor frame subcomponent, the connecting sheath, and the leaflet frame subcomponent at an inflow end of the prosthetic valve, and wherein the retention element, including the non-permeable cover, is operable to cover and restrict fluid flow into the inflow annular groove.
  • 29. A prosthetic valve transitionable between a delivery configuration and a deployed, nested configuration in-situ, the prosthetic valve comprising: a leaflet frame subcomponent defining a tubular shape and having a leaflet frame subcomponent wall extending from a leaflet frame subcomponent inflow end and a leaflet frame subcomponent outflow end and the leaflet frame subcomponent defining a leaflet frame subcomponent lumen, the leaflet frame subcomponent including a one-way valve;an anchor frame subcomponent defining a tubular shape and having an anchor frame subcomponent inflow end and an anchor frame subcomponent outflow end, and the anchor frame subcomponent defining an anchor frame subcomponent lumen;a connecting sheath defining a tubular shape and having a connecting sheath inflow end coupled to the anchor frame subcomponent outflow end and a connecting sheath outflow end coupled to the leaflet frame subcomponent inflow end coupling the leaflet frame subcomponent to the anchor frame subcomponent, and the connecting sheath defining a connecting sheath lumen; anda retention element having a retention element first end and a retention element second end, the retention element second end being coupled to the connecting sheath outflow end,wherein when the prosthetic valve is in the delivery configuration, the leaflet frame subcomponent and the anchor frame subcomponent are longitudinally offset from one another such that the leaflet frame subcomponent inflow end is situated distal of the anchor frame subcomponent outflow end, wherein the retention element resides within the connecting sheath lumen and extends away from the leaflet frame subcomponent inflow end and substantially parallel with a longitudinal axis of the leaflet frame subcomponent and adjacent to the connecting sheath,wherein, when the prosthetic valve is in the deployed, nested configuration, the anchor frame subcomponent inflow end flares or tapers radially outward, wherein, when the prosthetic valve is in the deployed, nested configuration, the connecting sheath is everted and the leaflet frame subcomponent is at least partially nested within the anchor frame subcomponent lumen, the retention element has translated within the anchor frame subcomponent lumen towards the anchor frame subcomponent inflow end, and the retention element is biased outwardly against the anchor frame subcomponent with an outward bias such that the retention element extends from the leaflet frame subcomponent inflow end to the anchor frame subcomponent inflow end, andwherein the retention element comprises a continuous sinuous element configured to have an outward spring bias toward a planar star-shaped configuration defining elongated elements bending about apices, the elongated elements have an elongated element first end and an elongated element second end, when in the star-shaped configuration the elongated elements extend radially with the elongated element first ends and respective apices defining an inner circumference at a retention element first end and the elongated element second ends and respective apices defining an outer circumference at a retention element second end, the sinuous element is operable to be elastically restrained to a tubular configuration wherein the elongated elements are rotated about the apices at the elongated element first ends such that the elongated element second ends are rotated toward each other to define a tubular or conical configuration, with the sinuous element defining a first tubular diameter wherein the elongated elements extend laterally to a central, longitudinal axis X and along the connecting sheath and lateral with the anchor frame subcomponent and leaflet frame subcomponent.
  • 30. The prosthetic valve of claim 29, wherein a non-permeable cover extends from the apices at the elongated element first ends of the elongated elements to the apices at the elongated element second ends, wherein when the prosthetic valve is in the deployed, nested configuration, the non-permeable cover extends from the leaflet frame subcomponent inflow end to the anchor frame subcomponent inflow end covering an inflow annular groove formed between the anchor frame subcomponent, the connecting sheath and the leaflet frame subcomponent.
  • 31. The prosthetic valve of claim 29, further comprising a tether element coupled to the retention element, operable to be pulled by an operator to affect advancement of the retention element through the anchor frame subcomponent, the retention element second end of the retention element being held in a compressed state by a predetermined amount of tension on the tether element, wherein the tension of the tether element may be released and thus release the elongated element second end of the retention element so as to allow expansion and deployment of the retention element.
  • 32. A prosthetic valve transitionable between a delivery configuration and a deployed, nested configuration in-situ, the prosthetic valve comprising: a leaflet frame subcomponent defining a tubular shape and having a leaflet frame subcomponent wall extending from a leaflet frame subcomponent inflow end and a leaflet frame subcomponent outflow end and the leaflet frame subcomponent defining a leaflet frame subcomponent lumen, the leaflet frame subcomponent including a one-way valve;an anchor frame subcomponent defining a tubular shape and having an anchor frame subcomponent inflow end and an anchor frame subcomponent outflow end, and the anchor frame subcomponent defining an anchor frame subcomponent lumen;a connecting sheath defining a tubular shape and having a connecting sheath inflow end coupled to the anchor frame subcomponent outflow end and a connecting sheath outflow end coupled to the leaflet frame subcomponent inflow end coupling the leaflet frame subcomponent to the anchor frame subcomponent, and the connecting sheath defining a connecting sheath lumen; anda retention element having a retention element first end and a retention element second end, the retention element second end being coupled to the connecting sheath outflow end,wherein when the prosthetic valve is in the delivery configuration, the leaflet frame subcomponent and the anchor frame subcomponent are longitudinally offset from one another such that the leaflet frame subcomponent inflow end is situated distal of the anchor frame subcomponent outflow end, wherein the retention element resides within the connecting sheath lumen and extends away from the leaflet frame subcomponent inflow end and substantially parallel with a longitudinal axis of the leaflet frame subcomponent and adjacent to the connecting sheath,wherein, when the prosthetic valve is in the deployed, nested configuration, the anchor frame subcomponent inflow end flares or tapers radially outward, wherein, when the prosthetic valve is in the deployed, nested configuration, the connecting sheath is everted and the leaflet frame subcomponent is at least partially nested within the anchor frame subcomponent lumen, the retention element has translated within the anchor frame subcomponent lumen towards the anchor frame subcomponent inflow end, and the retention element is biased outwardly against the anchor frame subcomponent with an outward bias such that the retention element extends from the leaflet frame subcomponent inflow end to the anchor frame subcomponent inflow end, andwherein the anchor frame subcomponent defines an anchor frame subcomponent inner surface, wherein the connecting sheath is a thin-walled flexible tubular member having a connecting sheath inner surface, wherein one or more apices defined by the retention element at the retention element second end of the retention element may abut and slide along the connecting sheath inner surface and subsequently the anchor frame subcomponent inner surface while expanding under the outward bias until the apices at the retention element second end are fully expanded about the anchor frame subcomponent inflow end, wherein the outward bias produces sufficient force to advance the retention element through the connecting sheath and the anchor frame subcomponent inner surface toward the anchor frame subcomponent inflow end while pulling the leaflet frame subcomponent into the anchor frame subcomponent.
  • 33. A prosthetic valve transitionable from a delivery configuration to a deployed, nested configuration in-situ, the prosthetic valve comprising: a leaflet frame subcomponent including a one-way valve, the leaflet frame subcomponent having a leaflet frame subcomponent inflow end and a leaflet frame subcomponent outflow end;an anchor frame subcomponent having a lumen and an anchor frame subcomponent inflow end and an anchor frame subcomponent outflow end;a connecting sheath coupling the leaflet frame subcomponent to the anchor frame subcomponent; anda retention element coupled to the connecting sheath, the retention element having a first end and a second end and being configured to retain the prosthetic valve in the deployed, nested configuration, the retention element being pivotable about the retention element second end upon translation of the retention element within the anchor frame subcomponent lumen towards the anchor frame subcomponent inflow end, such that the retention element extends from the leaflet frame subcomponent inflow end to the anchor frame subcomponent inflow end;wherein in the delivery configuration the leaflet frame subcomponent and the anchor frame subcomponent are longitudinally offset relative to one another with the connecting sheath being unfolded and uneverted and in the deployed, nested configuration the leaflet frame subcomponent is nested with the anchor frame subcomponent and the connecting sheath is folded and everted so as to lie between the leaflet frame subcomponent and the anchor frame subcomponent, such that the retention element extends from the leaflet frame subcomponent inflow end to the anchor frame subcomponent inflow end.
  • 34. A method of replacing a native valve of a patient's anatomy comprising: advancing a prosthetic valve in a delivery configuration to a treatment site within a patient's anatomy, wherein in the delivery configuration a leaflet frame subcomponent and an anchor frame subcomponent of the prosthetic valve that are coupled by a connection sheath are longitudinally offset from one another such that a leaflet frame subcomponent inflow end of the leaflet frame subcomponent is situated distal of an anchor frame subcomponent inflow end of the anchor frame subcomponent;deploying the anchor frame within a tissue annulus;nesting the leaflet frame subcomponent within the anchor frame subcomponent by changing a relative position between the leaflet frame subcomponent and the anchor frame subcomponent; anddeploying a retention element coupled to the connecting sheath such that the retention element extends from the leaflet frame subcomponent inflow end to the anchor frame subcomponent inflow end, wherein the retention element further includes a non-permeable cover and wherein, when the prosthetic valve is in the deployed, nested configuration, an inflow annular groove is defined by the anchor frame subcomponent, the connecting sheath, and the leaflet frame subcomponent at an inflow end of the prosthetic valve, andwherein the retention element, including the non-permeable cover, is operable to cover and restrict fluid flow into the inflow annular groove.
CROSS-REFERENCE TO RELATED APPLICATION

This application claims the benefit of Provisional Application No. 62/812,782, filed Mar. 1, 2019, and also claims the benefit of Provisional Application No. 62/833,086, filed Apr. 12, 2019, both of which are incorporated herein by reference in their entireties for all purposes.

US Referenced Citations (540)
Number Name Date Kind
654799 Levett Jul 1900 A
3739402 Kahn et al. Jun 1973 A
3953566 Gore Apr 1976 A
4178639 Bokros Dec 1979 A
4187390 Gore Feb 1980 A
4222126 Boretos et al. Sep 1980 A
4265694 Boretos et al. May 1981 A
4332035 Mano Jun 1982 A
4340091 Skelton et al. Jul 1982 A
4477930 Totten et al. Oct 1984 A
4556996 Wallace Dec 1985 A
4626255 Reichart et al. Dec 1986 A
4759759 Walker et al. Jul 1988 A
4851000 Gupta Jul 1989 A
4877661 House et al. Oct 1989 A
4955899 Della et al. Sep 1990 A
5026513 House et al. Jun 1991 A
5064435 Porter Nov 1991 A
5071609 Tu et al. Dec 1991 A
5123918 Perrier et al. Jun 1992 A
5163955 Love et al. Nov 1992 A
5415667 Frater May 1995 A
5469868 Reger Nov 1995 A
5476589 Bacino Dec 1995 A
5489297 Duran Feb 1996 A
5534007 St et al. Jul 1996 A
5549663 Cottone, Jr. Aug 1996 A
5554183 Nazari Sep 1996 A
5554185 Block et al. Sep 1996 A
5562729 Purdy et al. Oct 1996 A
5628791 Bokros et al. May 1997 A
5673102 Suzuki et al. Sep 1997 A
5708044 Branca Jan 1998 A
5718973 Lewis et al. Feb 1998 A
5749852 Schwab et al. May 1998 A
5752934 Campbell et al. May 1998 A
5759192 Saunders Jun 1998 A
5769884 Solovay Jun 1998 A
5772884 Tanaka et al. Jun 1998 A
5788626 Thompson Aug 1998 A
5814405 Branca et al. Sep 1998 A
5824043 Cottone, Jr. Oct 1998 A
5843158 Lenker et al. Dec 1998 A
5843161 Solovay Dec 1998 A
5843171 Campbell et al. Dec 1998 A
5853419 Imran Dec 1998 A
5925061 Ogi et al. Jul 1999 A
5928281 Huynh et al. Jul 1999 A
5935162 Dang Aug 1999 A
5935163 Gabbay Aug 1999 A
5944654 Crawford Aug 1999 A
5957974 Thompson et al. Sep 1999 A
6010529 Herweck et al. Jan 2000 A
6013854 Moriuchi Jan 2000 A
6019785 Strecker Feb 2000 A
6042588 Munsinger et al. Mar 2000 A
6042605 Martin et al. Mar 2000 A
6042606 Frantzen Mar 2000 A
6086612 Jansen Jul 2000 A
6110198 Fogarty et al. Aug 2000 A
6117169 Moe Sep 2000 A
6129758 Love Oct 2000 A
6161399 Jayaraman Dec 2000 A
6165211 Thompson Dec 2000 A
6171335 Wheatley et al. Jan 2001 B1
6174329 Callol et al. Jan 2001 B1
6174331 Moe et al. Jan 2001 B1
6190406 Duerig et al. Feb 2001 B1
6197143 Bodnar Mar 2001 B1
6217609 Haverkost Apr 2001 B1
6245012 Kleshinski Jun 2001 B1
6261320 Tam et al. Jul 2001 B1
6261620 Leadbeater Jul 2001 B1
6283994 Moe et al. Sep 2001 B1
6283995 Moe et al. Sep 2001 B1
6287334 Moll et al. Sep 2001 B1
6328763 Love et al. Dec 2001 B1
6334873 Lane et al. Jan 2002 B1
6336937 Vonesh et al. Jan 2002 B1
6352552 Levinson et al. Mar 2002 B1
6379382 Yang Apr 2002 B1
6436132 Patel et al. Aug 2002 B1
6454798 Moe Sep 2002 B1
6454799 Schreck Sep 2002 B1
6461382 Cao Oct 2002 B1
6461665 Scholander Oct 2002 B1
6482228 Norred Nov 2002 B1
6488701 Nolting et al. Dec 2002 B1
6541589 Baillie Apr 2003 B1
6558418 Carpentier et al. May 2003 B2
6562069 Cai et al. May 2003 B2
6582464 Gabbay Jun 2003 B2
6613086 Moe et al. Sep 2003 B1
6620190 Colone Sep 2003 B1
6626939 Burnside et al. Sep 2003 B1
6645244 Shu et al. Nov 2003 B2
6666885 Moe Dec 2003 B2
6673102 Vonesh et al. Jan 2004 B1
6673107 Brandt et al. Jan 2004 B1
6726715 Sutherland Apr 2004 B2
6730118 Spenser et al. May 2004 B2
6730120 Berg et al. May 2004 B2
6755856 Fierens et al. Jun 2004 B2
6755857 Peterson et al. Jun 2004 B2
6758858 McCrea et al. Jul 2004 B2
6890350 Walak May 2005 B1
6893460 Spenser et al. May 2005 B2
6916338 Speziali Jul 2005 B2
6936067 Buchanan Aug 2005 B2
6953332 Kurk et al. Oct 2005 B1
7022132 Kocur Apr 2006 B2
7049380 Chang et al. May 2006 B1
7083642 Sirhan et al. Aug 2006 B2
7105018 Yip et al. Sep 2006 B1
7137184 Schreck Nov 2006 B2
7163556 Xie et al. Jan 2007 B2
7238200 Lee et al. Jul 2007 B2
7247167 Gabbay Jul 2007 B2
7306729 Bacino et al. Dec 2007 B2
7381218 Schreck Jun 2008 B2
7419678 Falotico Sep 2008 B2
7462675 Chang et al. Dec 2008 B2
7510575 Spenser et al. Mar 2009 B2
7513909 Lane et al. Apr 2009 B2
7531611 Sabol et al. May 2009 B2
7563277 Case et al. Jul 2009 B2
7708775 Rowe et al. May 2010 B2
7727274 Zilla et al. Jun 2010 B2
7758640 Vesely Jul 2010 B2
7780725 Haug et al. Aug 2010 B2
7789908 Sowinski et al. Sep 2010 B2
7803186 Li et al. Sep 2010 B1
7811314 Fierens et al. Oct 2010 B2
7815763 Fierens et al. Oct 2010 B2
7879085 Sowinski et al. Feb 2011 B2
7887562 Young et al. Feb 2011 B2
7914569 Nguyen et al. Mar 2011 B2
7927364 Fierens et al. Apr 2011 B2
7927365 Fierens et al. Apr 2011 B2
7935141 Randall et al. May 2011 B2
7967829 Gunderson et al. Jun 2011 B2
7967853 Eidenschink et al. Jun 2011 B2
7993394 Hariton et al. Aug 2011 B2
8048440 Chang et al. Nov 2011 B2
8062359 Marquez et al. Nov 2011 B2
8092523 Li et al. Jan 2012 B2
8167935 McGuckin et al. May 2012 B2
8226710 Nguyen et al. Jul 2012 B2
8246678 Salahieh et al. Aug 2012 B2
8252037 Styrc et al. Aug 2012 B2
8303647 Case Nov 2012 B2
8349000 Schreck Jan 2013 B2
8409274 Li et al. Apr 2013 B2
8475512 Hunt Jul 2013 B2
8545525 Surti et al. Oct 2013 B2
8568475 Nguyen et al. Oct 2013 B2
8585753 Scanlon et al. Nov 2013 B2
8585757 Agathos Nov 2013 B2
8628566 Eberhardt et al. Jan 2014 B2
8637144 Ford Jan 2014 B2
8709077 Schreck Apr 2014 B2
8722178 Ashmead et al. May 2014 B2
8728103 Surti et al. May 2014 B2
8728154 Alkhatib May 2014 B2
8784481 Alkhatib et al. Jul 2014 B2
8801774 Silverman Aug 2014 B2
8808848 Bacino Aug 2014 B2
8845709 Styrc et al. Sep 2014 B2
8845721 Braido et al. Sep 2014 B2
8852272 Gross et al. Oct 2014 B2
8870948 Erzberger et al. Oct 2014 B1
8936634 Irwin et al. Jan 2015 B2
8945212 Bruchman et al. Feb 2015 B2
8961599 Bruchman et al. Feb 2015 B2
8992608 Haug et al. Mar 2015 B2
9039757 McLean et al. May 2015 B2
9101469 Bruchman et al. Aug 2015 B2
9101696 Leontein et al. Aug 2015 B2
9107771 Wubbeling et al. Aug 2015 B2
9125740 Morriss et al. Sep 2015 B2
9139669 Xu et al. Sep 2015 B2
9144492 Bruchman et al. Sep 2015 B2
9168131 Yohanan et al. Oct 2015 B2
9198787 Kratzberg et al. Dec 2015 B2
9241695 Peavey et al. Jan 2016 B2
9283072 Bruchman et al. Mar 2016 B2
9295552 McLean et al. Mar 2016 B2
9314355 Styrc et al. Apr 2016 B2
9345601 Jantzen et al. May 2016 B2
9375308 Norris Jun 2016 B2
9393110 Levi et al. Jul 2016 B2
9398952 Bruchman et al. Jul 2016 B2
9399085 Cleek et al. Jul 2016 B2
9504565 Armstrong Nov 2016 B2
9554786 Carley et al. Jan 2017 B2
9554900 Bruchman et al. Jan 2017 B2
9597181 Christianson et al. Mar 2017 B2
9629718 Gloss et al. Apr 2017 B2
9681948 Levi et al. Jun 2017 B2
9737398 Bruchman et al. Aug 2017 B2
9737422 Armstrong et al. Aug 2017 B2
9743932 Amplatz et al. Aug 2017 B2
9795496 Armstrong et al. Oct 2017 B2
9801712 Bruchman et al. Oct 2017 B2
9827089 Bruchman et al. Nov 2017 B2
9827094 Bennett Nov 2017 B2
9839540 Armstrong et al. Dec 2017 B2
9855141 Dienno et al. Jan 2018 B2
9931193 Cully et al. Apr 2018 B2
9931204 Rothstein et al. Apr 2018 B2
9937037 Dienno et al. Apr 2018 B2
9968443 Bruchman et al. May 2018 B2
10039638 Bruchman et al. Aug 2018 B2
10166128 Armstrong et al. Jan 2019 B2
10279084 Goepfrich et al. May 2019 B2
10285808 Bruchman et al. May 2019 B2
10314697 Gassler Jun 2019 B2
10321986 Bruchman et al. Jun 2019 B2
10335298 Armstrong et al. Jul 2019 B2
10342659 Bennett Jul 2019 B2
10368984 Armstrong Aug 2019 B2
10376360 Bruchman et al. Aug 2019 B2
10441416 Oba et al. Oct 2019 B2
10463478 Bruchman et al. Nov 2019 B2
10507124 Armstrong et al. Dec 2019 B2
10639144 Bruchman et al. May 2020 B2
10660745 Bruchman et al. May 2020 B2
10881507 Bruchman et al. Jan 2021 B2
10980633 Dienno et al. Apr 2021 B2
11020221 Arcaro et al. Jun 2021 B2
11039917 Bruchman et al. Jun 2021 B2
D926322 Bennett et al. Jul 2021 S
11065112 Gassler Jul 2021 B2
11090153 Haarer et al. Aug 2021 B2
11109963 Dienno et al. Sep 2021 B2
11123183 Bennett et al. Sep 2021 B2
20010053929 Vonesh et al. Dec 2001 A1
20020045936 Moe Apr 2002 A1
20020055773 Campbell et al. May 2002 A1
20020076542 Kramer et al. Jun 2002 A1
20020082687 Moe Jun 2002 A1
20020133226 Marquez et al. Sep 2002 A1
20020183840 Lapeyre et al. Dec 2002 A1
20020198588 Armstrong et al. Dec 2002 A1
20020198594 Schreck Dec 2002 A1
20030014105 Cao Jan 2003 A1
20030027332 Lafrance et al. Feb 2003 A1
20030055494 Bezuidenhout et al. Mar 2003 A1
20030055496 Cai et al. Mar 2003 A1
20030060871 Hill et al. Mar 2003 A1
20030074052 Besselink Apr 2003 A1
20030097175 O'Connor et al. May 2003 A1
20030114913 Spenser et al. Jun 2003 A1
20030180488 Lim et al. Sep 2003 A1
20030209835 Chun et al. Nov 2003 A1
20030229394 Ogle et al. Dec 2003 A1
20040024442 Sowinski et al. Feb 2004 A1
20040024448 Chang et al. Feb 2004 A1
20040024451 Johnson et al. Feb 2004 A1
20040026245 Agarwal et al. Feb 2004 A1
20040039436 Spenser et al. Feb 2004 A1
20040044400 Cheng et al. Mar 2004 A1
20040044401 Bales et al. Mar 2004 A1
20040133266 Clerc et al. Jul 2004 A1
20040170782 Wang et al. Sep 2004 A1
20040176839 Huynh et al. Sep 2004 A1
20040224442 Grigg Nov 2004 A1
20040243222 Osborne et al. Dec 2004 A1
20040260277 Maguire Dec 2004 A1
20040260393 Rahdert et al. Dec 2004 A1
20050027348 Case et al. Feb 2005 A1
20050080476 Gunderson et al. Apr 2005 A1
20050119722 Styrc et al. Jun 2005 A1
20050137680 Ortiz et al. Jun 2005 A1
20050137682 Justino Jun 2005 A1
20050203614 Forster et al. Sep 2005 A1
20050261765 Liddicoat Nov 2005 A1
20050283224 King Dec 2005 A1
20060008497 Gabbay Jan 2006 A1
20060009835 Osborne et al. Jan 2006 A1
20060015171 Armstrong Jan 2006 A1
20060036311 Nakayama et al. Feb 2006 A1
20060041091 Chang et al. Feb 2006 A1
20060106337 Blankenship May 2006 A1
20060118236 House et al. Jun 2006 A1
20060122693 Biadillah et al. Jun 2006 A1
20060135985 Cox et al. Jun 2006 A1
20060154365 Ratcliffe et al. Jul 2006 A1
20060161241 Barbut et al. Jul 2006 A1
20060190070 Dieck et al. Aug 2006 A1
20060229718 Marquez Oct 2006 A1
20060229719 Marquez et al. Oct 2006 A1
20060259133 Sowinski et al. Nov 2006 A1
20060259136 Nguyen et al. Nov 2006 A1
20060265053 Hunt Nov 2006 A1
20060271091 Campbell et al. Nov 2006 A1
20060276813 Greenberg Dec 2006 A1
20060276883 Greenberg et al. Dec 2006 A1
20060276888 Lee et al. Dec 2006 A1
20060282162 Nguyen et al. Dec 2006 A1
20060287719 Rowe et al. Dec 2006 A1
20060290027 O'Connor et al. Dec 2006 A1
20070010876 Salahieh et al. Jan 2007 A1
20070012624 Bacino et al. Jan 2007 A1
20070021826 Case et al. Jan 2007 A1
20070060999 Randall et al. Mar 2007 A1
20070118210 Pinchuk May 2007 A1
20070129786 Beach et al. Jun 2007 A1
20070207186 Scanlon et al. Sep 2007 A1
20070207816 Spain, Jr. Sep 2007 A1
20070208421 Quigley Sep 2007 A1
20070213800 Fierens et al. Sep 2007 A1
20070244552 Salahieh et al. Oct 2007 A1
20070250146 Cully et al. Oct 2007 A1
20070250153 Cully et al. Oct 2007 A1
20070254012 Ludwig et al. Nov 2007 A1
20080009940 Cribier Jan 2008 A1
20080026190 King et al. Jan 2008 A1
20080039934 Styrc Feb 2008 A1
20080051876 Ta et al. Feb 2008 A1
20080065198 Quintessenza Mar 2008 A1
20080071369 Tuval et al. Mar 2008 A1
20080082154 Tseng et al. Apr 2008 A1
20080097301 Alpini et al. Apr 2008 A1
20080097401 Trapp et al. Apr 2008 A1
20080097579 Shanley et al. Apr 2008 A1
20080097582 Shanley et al. Apr 2008 A1
20080119943 Armstrong et al. May 2008 A1
20080133004 White Jun 2008 A1
20080140178 Rasmussen et al. Jun 2008 A1
20080195199 Kheradvar et al. Aug 2008 A1
20080208327 Rowe Aug 2008 A1
20080220041 Brito et al. Sep 2008 A1
20080228263 Ryan Sep 2008 A1
20080300678 Eidenschink et al. Dec 2008 A1
20080319531 Doran et al. Dec 2008 A1
20090005854 Huang et al. Jan 2009 A1
20090030499 Bebb et al. Jan 2009 A1
20090036976 Beach et al. Feb 2009 A1
20090043373 Arnault et al. Feb 2009 A1
20090104247 Pacetti Apr 2009 A1
20090117334 Sogard et al. May 2009 A1
20090138079 Tuval et al. May 2009 A1
20090157175 Benichou Jun 2009 A1
20090182413 Burkart et al. Jul 2009 A1
20090240320 Tuval et al. Sep 2009 A1
20090264997 Salahieh et al. Oct 2009 A1
20090276039 Meretei Nov 2009 A1
20090281609 Benichou et al. Nov 2009 A1
20090287305 Amalaha Nov 2009 A1
20090292350 Eberhardt et al. Nov 2009 A1
20090306762 McCullagh et al. Dec 2009 A1
20090306766 McDermott et al. Dec 2009 A1
20100016940 Shokoohi et al. Jan 2010 A1
20100023114 Chambers et al. Jan 2010 A1
20100036021 Lee et al. Feb 2010 A1
20100036484 Hariton et al. Feb 2010 A1
20100049294 Zukowski et al. Feb 2010 A1
20100082094 Quadri et al. Apr 2010 A1
20100094394 Beach et al. Apr 2010 A1
20100094405 Cottone Apr 2010 A1
20100106240 Duggal et al. Apr 2010 A1
20100131056 Lapeyre May 2010 A1
20100137998 Sobrino-Serrano et al. Jun 2010 A1
20100145438 Barone Jun 2010 A1
20100159171 Clough Jun 2010 A1
20100168839 Braido et al. Jul 2010 A1
20100185274 Moaddeb et al. Jul 2010 A1
20100185277 Braido et al. Jul 2010 A1
20100191320 Straubinger et al. Jul 2010 A1
20100204781 Alkhatib Aug 2010 A1
20100204785 Alkhatib Aug 2010 A1
20100211165 Schreck Aug 2010 A1
20100217382 Chau et al. Aug 2010 A1
20100248324 Xu et al. Sep 2010 A1
20100249923 Alkhatib et al. Sep 2010 A1
20100256738 Berglund Oct 2010 A1
20100262231 Tuval et al. Oct 2010 A1
20100286760 Beach et al. Nov 2010 A1
20100298931 Quadri et al. Nov 2010 A1
20100305682 Furst Dec 2010 A1
20110009953 Luk et al. Jan 2011 A1
20110040366 Goetz et al. Feb 2011 A1
20110054515 Bridgeman et al. Mar 2011 A1
20110064781 Cleek et al. Mar 2011 A1
20110087318 Daugherty et al. Apr 2011 A1
20110160836 Behan Jun 2011 A1
20110172784 Richter et al. Jul 2011 A1
20110208283 Rust Aug 2011 A1
20110218619 Benichou et al. Sep 2011 A1
20110251678 Eidenschink et al. Oct 2011 A1
20110257739 Corbett Oct 2011 A1
20110282439 Thill et al. Nov 2011 A1
20110295363 Girard et al. Dec 2011 A1
20120035722 Tuval Feb 2012 A1
20120078357 Conklin Mar 2012 A1
20120083839 Letac et al. Apr 2012 A1
20120089223 Nguyen et al. Apr 2012 A1
20120101567 Jansen Apr 2012 A1
20120101571 Thambar et al. Apr 2012 A1
20120116496 Chuter et al. May 2012 A1
20120116498 Chuter et al. May 2012 A1
20120123529 Levi et al. May 2012 A1
20120123530 Carpentier et al. May 2012 A1
20120130468 Khosravi et al. May 2012 A1
20120130471 Shoemaker et al. May 2012 A1
20120185038 Fish et al. Jul 2012 A1
20120215303 Quadri et al. Aug 2012 A1
20120253453 Bruchman et al. Oct 2012 A1
20120290082 Quint et al. Nov 2012 A1
20120323211 Ogle et al. Dec 2012 A1
20120323315 Bruchman et al. Dec 2012 A1
20130018456 Li et al. Jan 2013 A1
20130018458 Yohanan et al. Jan 2013 A1
20130079700 Ballard et al. Mar 2013 A1
20130110229 Bokeriya et al. May 2013 A1
20130116655 Bacino et al. May 2013 A1
20130131780 Armstrong et al. May 2013 A1
20130150956 Yohanan et al. Jun 2013 A1
20130158647 Norris et al. Jun 2013 A1
20130166021 Bruchman et al. Jun 2013 A1
20130183515 White Jul 2013 A1
20130184807 Kovach et al. Jul 2013 A1
20130197624 Armstrong et al. Aug 2013 A1
20130204347 Armstrong et al. Aug 2013 A1
20130204360 Gainor Aug 2013 A1
20130253466 Campbell et al. Sep 2013 A1
20130297003 Pinchuk Nov 2013 A1
20130338755 Goetz et al. Dec 2013 A1
20140005771 Braido et al. Jan 2014 A1
20140005773 Wheatley Jan 2014 A1
20140031924 Bruchman et al. Jan 2014 A1
20140031927 Bruchman et al. Jan 2014 A1
20140094898 Borck Apr 2014 A1
20140106951 Brandon Apr 2014 A1
20140135897 Cully et al. May 2014 A1
20140163671 Bruchman et al. Jun 2014 A1
20140163673 Bruchman et al. Jun 2014 A1
20140172066 Goepfrich et al. Jun 2014 A1
20140172069 Roeder et al. Jun 2014 A1
20140172077 Bruchman et al. Jun 2014 A1
20140172078 Bruchman et al. Jun 2014 A1
20140172079 Bruchman et al. Jun 2014 A1
20140172082 Bruchman et al. Jun 2014 A1
20140172083 Bruchman et al. Jun 2014 A1
20140180400 Bruchman et al. Jun 2014 A1
20140180402 Bruchman et al. Jun 2014 A1
20140194968 Zukowski Jul 2014 A1
20140222140 Schreck Aug 2014 A1
20140236289 Alkhatib Aug 2014 A1
20140277413 Richter et al. Sep 2014 A1
20140277418 Miller Sep 2014 A1
20140296969 Tegels et al. Oct 2014 A1
20140324160 Benichou et al. Oct 2014 A1
20140324164 Gross et al. Oct 2014 A1
20140330368 Gloss et al. Nov 2014 A1
20140343670 Bakis et al. Nov 2014 A1
20150005870 Kovach et al. Jan 2015 A1
20150018944 O'Connell et al. Jan 2015 A1
20150088250 Zeng et al. Mar 2015 A1
20150105856 Rowe et al. Apr 2015 A1
20150142100 Morriss et al. May 2015 A1
20150157456 Armstrong Jun 2015 A1
20150157770 Cully et al. Jun 2015 A1
20150224231 Bruchman et al. Aug 2015 A1
20150245910 Righini et al. Sep 2015 A1
20150313871 Li et al. Nov 2015 A1
20150366663 Bruchman et al. Dec 2015 A1
20150366664 Guttenberg et al. Dec 2015 A1
20160001469 Bacchereti et al. Jan 2016 A1
20160015422 De et al. Jan 2016 A1
20160074161 Bennett Mar 2016 A1
20160113699 Sverdlik et al. Apr 2016 A1
20160157998 Bruchman et al. Jun 2016 A1
20160175095 Dienno et al. Jun 2016 A1
20160175096 Dienno et al. Jun 2016 A1
20160206424 Al-Jilaihawi et al. Jul 2016 A1
20160213465 Girard et al. Jul 2016 A1
20160235525 Rothstein et al. Aug 2016 A1
20160310268 Oba Oct 2016 A1
20160317299 Alkhatib Nov 2016 A1
20170027727 Wuebbeling et al. Feb 2017 A1
20170042674 Armstrong Feb 2017 A1
20170056169 Johnson et al. Mar 2017 A1
20170065400 Armstrong et al. Mar 2017 A1
20170095330 Malewicz et al. Apr 2017 A1
20170095331 Spenser et al. Apr 2017 A1
20170100236 Robertson Apr 2017 A1
20170105854 Treacy et al. Apr 2017 A1
20170106176 Taft et al. Apr 2017 A1
20170128199 Gurovich et al. May 2017 A1
20170156859 Chang et al. Jun 2017 A1
20170165066 Rothstein Jun 2017 A1
20170165067 Barajas-Torres et al. Jun 2017 A1
20170216062 Armstrong et al. Aug 2017 A1
20170224481 Spenser et al. Aug 2017 A1
20170252153 Chau et al. Sep 2017 A1
20170348101 Vaughn et al. Dec 2017 A1
20180021128 Bruchman et al. Jan 2018 A1
20180021129 Peterson et al. Jan 2018 A1
20180125646 Bruchman et al. May 2018 A1
20180177583 Cully et al. Jun 2018 A1
20180221144 Bruchman et al. Aug 2018 A1
20180318070 Bruchman et al. Nov 2018 A1
20190076245 Arcaro et al. Mar 2019 A1
20190091014 Arcaro et al. Mar 2019 A1
20190091015 Dienno et al. Mar 2019 A1
20190110893 Haarer et al. Apr 2019 A1
20190125517 Cully et al. May 2019 A1
20190125528 Busalacchi et al. May 2019 A1
20190125530 Arcaro et al. May 2019 A1
20190125531 Bennett et al. May 2019 A1
20190125534 Arcaro et al. May 2019 A1
20190209292 Bruchman et al. Jul 2019 A1
20190209739 Goepfrich et al. Jul 2019 A1
20190216592 Cully et al. Jul 2019 A1
20190247185 Gassler Aug 2019 A1
20190254815 Bruchman et al. Aug 2019 A1
20190269505 Bruchman et al. Sep 2019 A1
20190314154 Armstrong Oct 2019 A1
20190328525 Noe et al. Oct 2019 A1
20190374339 Bennett Dec 2019 A1
20200000578 Bruchman et al. Jan 2020 A1
20200022828 Armstrong et al. Jan 2020 A1
20200179663 McDaniel et al. Jun 2020 A1
20200237497 Silverman et al. Jul 2020 A1
20200237505 Bruchman et al. Jul 2020 A1
20200246137 Bruchman et al. Aug 2020 A1
20200276014 Burkart et al. Sep 2020 A1
20210121289 Bruchman et al. Apr 2021 A1
20210177589 Arcaro et al. Jun 2021 A1
20210205074 Bruchman et al. Jul 2021 A1
20210307905 Arcaro et al. Oct 2021 A1
20210338422 Dienno et al. Nov 2021 A1
20210346156 Haarer et al. Nov 2021 A1
20210361420 Bennett et al. Nov 2021 A1
20210393399 Arcaro et al. Dec 2021 A1
20220000611 Arcaro et al. Jan 2022 A1
20220023032 Bruchman et al. Jan 2022 A1
20220183831 Burkart et al. Jun 2022 A1
Foreign Referenced Citations (214)
Number Date Country
2013363172 Jul 2015 AU
2017202405 Apr 2017 AU
2462509 Apr 2003 CA
2849030 Apr 2013 CA
2878691 Jan 2014 CA
2964546 Jan 2014 CA
2960034 Mar 2016 CA
101057796 Oct 2007 CN
101091675 Dec 2007 CN
101188985 May 2008 CN
101374477 Feb 2009 CN
101420913 Apr 2009 CN
101849863 Oct 2010 CN
101902989 Dec 2010 CN
101926699 Dec 2010 CN
201744060 Feb 2011 CN
102015009 Apr 2011 CN
102119013 Jul 2011 CN
102292053 Dec 2011 CN
102438546 May 2012 CN
102573703 Jul 2012 CN
102652694 Sep 2012 CN
102764169 Nov 2012 CN
102791223 Nov 2012 CN
102883684 Jan 2013 CN
103079498 May 2013 CN
103228232 Jul 2013 CN
103237524 Aug 2013 CN
103384505 Nov 2013 CN
103732183 Apr 2014 CN
103781439 May 2014 CN
103945796 Jul 2014 CN
104114127 Oct 2014 CN
104487023 Apr 2015 CN
104507417 Apr 2015 CN
104869948 Aug 2015 CN
105007955 Oct 2015 CN
105101911 Nov 2015 CN
105263445 Jan 2016 CN
105662651 Jun 2016 CN
105792780 Jul 2016 CN
106668949 May 2017 CN
106714733 May 2017 CN
106794065 May 2017 CN
107106294 Aug 2017 CN
107690323 Feb 2018 CN
108578016 Sep 2018 CN
212013000104 Nov 2014 DE
0293090 Nov 1988 EP
0313263 Apr 1989 EP
0582870 Feb 1994 EP
0775472 May 1997 EP
0815806 Jan 1998 EP
0893108 Jan 1999 EP
1666003 Jun 2006 EP
1318775 Nov 2006 EP
1395205 Jul 2008 EP
1235537 Dec 2008 EP
2193762 Jun 2010 EP
2255750 Dec 2010 EP
2400923 Jan 2012 EP
2359774 Jan 2013 EP
2591100 May 2013 EP
2109417 Nov 2013 EP
3142608 Mar 2017 EP
3797738 Mar 2021 EP
2591100 Jun 1987 FR
2312485 Oct 1997 GB
2513194 Oct 2014 GB
44-032400 Dec 1969 JP
1969-032400 Dec 1969 JP
02-000645 Jan 1990 JP
09-241412 Sep 1997 JP
10-507097 Jul 1998 JP
11-290448 Oct 1999 JP
11-512635 Nov 1999 JP
2000-511459 Sep 2000 JP
2000-513248 Oct 2000 JP
2001-508641 Jul 2001 JP
2001-508681 Jul 2001 JP
2001-509702 Jul 2001 JP
2001-511030 Aug 2001 JP
2002-525169 Aug 2002 JP
2002-541915 Dec 2002 JP
2004-510471 Apr 2004 JP
2005-500101 Jan 2005 JP
2005-512611 May 2005 JP
2007-525291 Sep 2007 JP
2007-526098 Sep 2007 JP
2007-536989 Dec 2007 JP
2008-506459 Mar 2008 JP
2008-535572 Sep 2008 JP
4335487 Sep 2009 JP
2010-500107 Jan 2010 JP
2010-504174 Feb 2010 JP
2010-517623 May 2010 JP
2010-528761 Aug 2010 JP
2010-188189 Sep 2010 JP
2010-535075 Nov 2010 JP
2010-536527 Dec 2010 JP
2012-504031 Feb 2012 JP
2012-152563 Aug 2012 JP
2013-543399 Dec 2013 JP
2014-513585 Jun 2014 JP
2014-517720 Jul 2014 JP
2016-501104 Jan 2016 JP
2016-518948 Jun 2016 JP
2017-527397 Sep 2017 JP
2018-079352 May 2018 JP
6392778 Sep 2018 JP
6802300 Dec 2020 JP
2124986 Jan 1999 RU
2434604 Nov 2011 RU
9413224 Jun 1994 WO
9416802 Aug 1994 WO
9505555 Feb 1995 WO
9509586 Apr 1995 WO
9602212 Feb 1996 WO
9607370 Mar 1996 WO
9640348 Dec 1996 WO
9710871 Mar 1997 WO
9926558 Jun 1999 WO
0018333 Apr 2000 WO
0041649 Jul 2000 WO
0047271 Aug 2000 WO
0062716 Oct 2000 WO
0128453 Apr 2001 WO
0141679 Jun 2001 WO
0164278 Sep 2001 WO
0174272 Oct 2001 WO
0207795 Jan 2002 WO
0224118 Mar 2002 WO
0224119 Mar 2002 WO
0245933 Jun 2002 WO
0247468 Jun 2002 WO
0260506 Aug 2002 WO
2002100301 Dec 2002 WO
0303946 Jan 2003 WO
0307795 Jan 2003 WO
0347468 Jun 2003 WO
0390834 Nov 2003 WO
2004000375 Dec 2003 WO
2005084595 Sep 2005 WO
2005112827 Dec 2005 WO
2006019626 Feb 2006 WO
2006058322 Jun 2006 WO
2006108090 Oct 2006 WO
2007016251 Feb 2007 WO
2008021002 Feb 2008 WO
2008028964 Mar 2008 WO
2008036870 Mar 2008 WO
2008049045 Apr 2008 WO
2008052421 May 2008 WO
2008091589 Jul 2008 WO
2008021006 Aug 2008 WO
2008097589 Aug 2008 WO
2008097592 Aug 2008 WO
2008150529 Dec 2008 WO
2009017827 Feb 2009 WO
2009029199 Mar 2009 WO
2009045332 Apr 2009 WO
2009100210 Aug 2009 WO
2009108355 Sep 2009 WO
2010006783 Jan 2010 WO
2010008570 Jan 2010 WO
2010030766 Mar 2010 WO
2010037141 Apr 2010 WO
2010057262 Jul 2010 WO
2010086460 Aug 2010 WO
2010132707 Nov 2010 WO
2010150208 Dec 2010 WO
2011098565 Aug 2011 WO
2011109450 Sep 2011 WO
2011109801 Sep 2011 WO
2011112706 Sep 2011 WO
2012004460 Jan 2012 WO
2012011261 Jan 2012 WO
2012040643 Mar 2012 WO
2012047644 Apr 2012 WO
2012065080 May 2012 WO
2012082952 Jun 2012 WO
2012099979 Jul 2012 WO
2012110767 Aug 2012 WO
2012116368 Aug 2012 WO
2012135603 Oct 2012 WO
2012158944 Nov 2012 WO
2012167131 Dec 2012 WO
2013074663 May 2013 WO
2013074990 May 2013 WO
2013096854 Jun 2013 WO
2013109337 Jul 2013 WO
2014018189 Jan 2014 WO
2014018432 Jan 2014 WO
2014099150 Jun 2014 WO
2014099163 Jun 2014 WO
2014099722 Jun 2014 WO
2014144937 Sep 2014 WO
2015045002 Apr 2015 WO
2015085138 Jun 2015 WO
2015171743 Nov 2015 WO
2015173794 Nov 2015 WO
2016028591 Feb 2016 WO
2016044223 Mar 2016 WO
2016100913 Jun 2016 WO
2016172349 Oct 2016 WO
2016186909 Nov 2016 WO
2017038145 Mar 2017 WO
2017096157 Jun 2017 WO
2019067219 Apr 2019 WO
2019067220 Apr 2019 WO
2019074607 Apr 2019 WO
2019074869 Apr 2019 WO
2019089138 May 2019 WO
2019246268 Dec 2019 WO
Non-Patent Literature Citations (15)
Entry
Certified Priority Document for U.S. Appl. No. 61/739,721, received by the International Bureau Jan. 3, 2014, 1 page.
Certified Application Data Sheet, Drawings, Specification, Claims, and Abstract filed under U.S. Appl. No. 13/843,196 on Mar. 15, 2013, 52 pages.
Clough, Norman E. Introducing a New Family of GORE ePTFE Fibers (2007), pp. 1-10.
English translation of RU2434604 (C1), filed Apr. 30, 2010, translation powered by EPO and Google, 8 pages.
Mano Thubrikar, “The Aortic Valve”, Chapter 1: Geometry of the Aortic Valve, CRC Press, Inc., Informa Healthcare, 2011, 40 pages.
Opposition from EP16196687.4, mailed on Dec. 12, 2019, 38 pages.
Opposition from EP17187595.8, filed Sep. 12, 2019, 50 pages.
International Search Report and Written Opinion received for PCT Application No. PCT/US2020/020550, dated Jun. 9, 2020, 12 pages.
Cardiac Surgery in the Adult, Third Edition, Chapter 2 2008.
EPO Form 1002 for EP16196687.4 Filed Dec. 28, 2016.
Forward citations for E12 obtained from: https://scholar google.com/scholar?cites=5981833429320176658&assdt=2005&sciodt=0,58hl= en.
Google Image Search Results, “S-Shaped”, accessed Nov. 1, 2013.
Nakayama, Yasuhide. Microporous Stent Achieves Brain Aneurysm Occlusion Without Disturbing Branching Flow. NeuroNews Nov. 2012; 8:1-2.
Nishi S, Nakayama Y, Ishibashi-Ueda FI, Okamoto Y, Yoshida M. Development of microporous self-expanding stent grafts for treating cerebral aneurysms: designing micropores to control intimal hyperplasia. J Artif Organs 2011; 14:348-356.
Norman E. Clough. Introducing a New Family of GORE (Trademark) ePTFE Fibers (2007).
Related Publications (1)
Number Date Country
20200276014 A1 Sep 2020 US
Provisional Applications (2)
Number Date Country
62833086 Apr 2019 US
62812782 Mar 2019 US